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VI SUMMARY 
Summary 
The development and clinical behavior of the two major inflammatory bowel diseases (IBD) 
subgroups Crohn’s disease (CD) and ulcerative colitis (UC), are determined by multiple 
underlying factors leading to an impaired antimicrobial barrier and chronic inflammation. 
Contributing environmental influences on the onset of the diseases such as the intestinal 
microbiota, antibiotics use, smoking, or nutrition have more and more entered the limelight of 
the field. The increasing incidence of IBD, the big variance in disease progression, and the 
discrepancy between monocygotic twins urgently impose the question how exactly 
environmental factors might impact on IBD risk and progression. The emerging field of 
epigenetics offers a mechanistic framework to dissect the present interplay between 
environment and genome in the context of IBD and will allow a better understanding of disease 
pathology. 
Histone deacetylases (HDACs) are important epigenetic factors implicated in intestinal 
tissue homeostasis. They deacetylate histones but also a vast number of non-histone proteins, 
e.g. the transcription factor NF-κB, thereby impacting on transcriptional regulation on different 
levels. A role for HDACs in the epigenetically-mediated modulation of hBDs has been 
demonstrated in a number of studies, underscoring a potential involvement of HDACs in the β-
defensin-related defects found in colonic IBD. In addition, inhibiting HDACs has been proposed 
as an IBD intervention, making more detailed studies on the role of HDACs in gut antimicrobial 
barrier function indespensible.  
Firstly, in this work, a systematic overview of class I HDAC mRNA intestinal expression 
has been performed in a large cohort of IBD patients. First insights on the expression pattern on 
the protein level are also given.  
Secondly, this study aimed to contribute to the small body of knowledge on HDAC-
mediated epigenetic control of antimicrobial peptide (AMP) expression; focusing on human β-
defensin 2 (hBD2). Herein, emphasis has been laid on the therapeutically relevant probiotic E. 
coli Nissle 1917 (EcN) as a potent hBD2-inducing factor in addition to the pro-inflammatory 
cytokine IL1β and the bacterial membrane component LPS. In vitro HDAC inhibition (HDACi) in 
colonic epithelial cells generated a strong, NF-κB-dependent enhancement of EcN- and LPS-
induced hBD2 expression, but also of the pro-inflammatory cytokine IL8. For IL1β-induced 
hBD2, the observed augmentation seems to be mediated by additional transducing factors and 
conditions depending on which HDACs are inhibited. In the case of IL1β, the enhancing effect of 
HDACi on hBD2 could be evinced in a second colonic epithelial cell line. 
In an effort to closer mimic the in vivo situation, an ex vivo human colonic biopsy culture 
has been established with almost identical culture conditions using IBD and healthy control 
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tissue. This was aimed to allow a comparison to the in vitro results, since it is of substantial 
importance to learn how a more complex, non-tumorous human tissue compound reacts to 
HDACi. Strikingly, in this context, an opposing impact of HDACi on EcN-stimulated hBD2 
expression was observed. Inhibiting HDAC function using pan-HDAC inhibitors hindered hBD2 
expression instead of enhancing it, but did not impede IL8 expression. Whether these contrary 
results could be due to the malignant nature of the in vitro cell lines was investigated using ex 
vivo treated human colorectal cancer tissue showing the same response as non-cancerous 
intestinal biopsies. In addition, first insights into the reactivity of a primary, non-transformed 
gingival epithelial cell line towards HDACi showed a comparable hBD2 response upon IL1β-
stimulation as did the cancerous intestinal cell lines. Furthermore, ex vivo fold induction levels of 
hBD2 in CD patients have been reduced hinting towards a disturbance in hBD2 inducibility in 
response to EcN. 
In this study, differential intestinal mRNA expression patterns have been unveiled for 
class I HDACs. Importantly, a strong regulatory influence of HDACs on the expression of hBD2 
could be demonstrated. The simultaneous upregulation of IL8 in epithelial cells and the missing 
downregulation of the same in biopsy culture under HDACi, advises caution in considering 
HDACi as therapeutic in IBD. Furthermore, a dependency of the HDACi-induced hBD2 
enhancement on NF-κB could be found. Utilizing different culture approaches, the obtained 
results argue for a cellular context-dependent modulation of the epigenetic regulation of hBD2 
expression by HDACs. Overall, this work promotes the understanding of epigenetics as the 
conjoining integrative mechanism between genome and environment, bridging the way to 
answering many yet elusive questions in the pathogenesis of IBD. 
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Zusammenfassung 
Der Pathogenese und der klinischen Präsentation der beiden chronisch entzündlichen 
Darmerkrankungen (CED), Morbus Crohn (MC) und Colitis Ulcerosa (CU) liegt eine Vielzahl 
bedingender Faktoren zu Grunde. Diese führen letztlich zu einer Beeinträchtigung der 
intestinalen, antimikrobiellen Abwehr und zu chronischer Entzündung. Diverse 
Umwelteinflüsse, wie zum Beispiel die intestinale Mikrobiota, die Einnahme von Antibiotika, 
Rauchen oder die Ernährung, sind maßgeblich an der Krankheitsentwicklung von CED beteiligt. 
Die stiegende Inzidenz von CED, die große Variabilität im Krankheitsverlauf und die Diskordanz 
zwischen eineiigen Zwillingen drängt die Frage danach auf, wie genau verschiedene 
Umweltfaktoren auf das Erkrankungsrisiko und den Krankheitsverlauf wirken. Das wachsende 
Forschungsfeld der Epigenetik kann dabei helfen diese Frage zu klären und aufzeigen, wie genau 
sich Umweltfaktoren auf die Interpretation der Gene im Kontext von CED auswirken und somit 
zu einem besseren Verständnis dieser Erkrankungen beitragen. 
Histon-Deacetylasen (HDACs) sind wichtige epigenetisch wirkende Enzyme, die unter 
Anderem eine Rolle in der Aufrechterhaltung der intestinalen Homöostase spielen. Sie 
deacetylieren Histone, aber auch eine Reihe von nicht-Histon-Proteinen wie beispielsweise den 
Transkriptionsfaktor NF-κB, und beeinflussen so die Regulation der Transkription auf 
verschiedenen Ebenen. Eine Reihe von Studien beschreibt eine Rolle für HDACs in der 
epigenetisch-vermittelten Modulation der humanen β-Defensin-Expression. Sie unterstreichen 
somit eine mögliche Beteiligung dieser Enzyme an den Defekten in der β-Defensin-Expression, 
die bei Morbus Crohn des Dickdarms gefunden wurden. HDACs in ihrer Wirkweise zu inhibieren 
wurde zudem als mögliche therapeutische Intervention für CED vorgeschlagen. Vor diesem 
Hintergrund ist es unverzichtbar die genaue Rolle, welche HDACs für die Funktion der 
antimikrobiellen Darmbarriere spielen, detaillierter zu untersuchen.  
In dieser Arbeit wurde daher zum einen ein systematischer Überblick über die mRNA-
Expression von Klasse I HDACs in einer großen Kohorte von CED Patienten erstellt. Des 
Weiteren gibt sie Einblicke in die HDAC Expression auf Proteinebene. 
Zum anderen sollte mit dieser Studie die epigenetische, HDAC-vermittelte Regulation der 
Expression antimikrobieller Peptide (AMPs) genauer untersucht werden; im Speziellen die des 
humanen β-Defensin 2 (hBD2), da dessen Induzierbarkeit bei MC des Dickdarms beinträchtigt 
ist. Besonderes Augenmerk wurde bei den Untersuchungen auf das therapeutisch relevante 
Probiotikum E. coli Nissle 1917 (EcN) gelegt, von dem gezeigt wurde, dass es hBD2 in 
Dickdarmepithelzellen induziert. Des Weiteren wurden das pro-inflammatorische Zytokin IL1β 
und der bakterielle Zellmembranbestandteil LPS als hBD2 stimulierende Faktoren mit 
einbezogen. Die Inhibition von HDACs in vitro führte in Kolon-Epithelzellen zu einer enormen, 
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NF-κB-anhängigen Verstärkung der EcN- und LPS-induzierten hBD2 Expression und der des 
pro-inflammatorischen Zytokins IL8. Bei IL1β-induziertem hBD2 scheint der Verstärkungseffekt 
durch zusätzliche Transduktionsmoleküle vermittelt zu werden, zudem abhängig davon, welche 
spezifischen HDACs inhibiert werden. Der durch HDACi verursachte Verstärkungseffekt konnte 
für IL1β-induziertes hBD2 in einer zweiten Kolon-Epithelzelllinie gezeigt werden. 
Um die in vivo Situation genauer nachbilden zu können, wurde ein ex vivo Ansatz 
etabliert, in dem Dickdarmbiopsien von Gesunden sowie von CED-Patienten unter nahezu 
identischen Kultur-Bedingungen behandelt werden können, um einen möglichst guten Vergleich 
zu den in vitro Ergebnissen ziehen zu können. Diese ex vivo Kultur ermöglicht die Untersuchung 
der Effekte von HDACi in einem komplexeren, nicht-tumorösen menschlichen Gewebeverband. 
Bemerkenswert ist, dass in diesem Kontext ein völlig gegensätzlicher Effekt von HDACi auf die 
EcN-vermittelte hBD2 Induktion beobachtet wurde. Bei Verwendung von Pan-HDACi wurde die 
Expression von hBD2 vollständig verhindert anstatt sie zu verstärken. Jedoch wurde die IL8-
Expression nicht reduziert. Ob diese, zu den in vitro Ergebnissen gegensätzlichen Effekte, auf 
den tumorösen Charakter der Zelllinien zurückzuführen sind, wurde mit Hilfe der Verwendung 
kolorektaler Tumorbiopsien untersucht. Diese zeigten jedoch dieselbe Reaktion, wie die nicht-
malignen Kolonbiospien. Zudem wurde in einem ersten Pilotexperiment mit nicht-
transformierten primären humanen Mundschleimhaut-Epithelzellen, eine ähnliche Verstärkung 
der IL1β-induzierten hBD2-Expression beobachtet. Des Weiteren wurde in den ex vivo hBD2-
Stimulationsexperimenten mit EcN beobachtet, dass Proben von MC-Patienten niedrigere 
Induktionslevel für hBD2 aufwiesen, was eine Störung der hBD2-Induzierbarkeit in MC 
Patienten bestätigt. 
In dieser Arbeit wurden unterschiedliche mRNA-Expressionsmuster von Klasse I HDACs 
zwischen Gesunden und Patienten mit CED aufgedeckt. Außerdem wurde ein starker 
regulatorischer Einfluss von HDACs auf die Expression von hBD2 gezeigt. Die simultane 
Hochregulation von IL8 in vitro und fehlende Herunterregulation desselben ex vivo verlangt 
nach Vorsicht bei der Evaluation von HDACi als Therapeutikum in CED. Darüber hinaus wurde in 
Teilen eine NF-κB-Abhängigkeit für die Verstärkung der hBD2 Induktion unter HDACi gezeigt. 
Die Ergebnisse aus dem Vergleich unterschiedlicher Kulturansätze erlaubt die Spekulation, dass 
die HDAC-vermittelte epigenetische Regulation von hBD2, Zell-Kontext-anhängig zu sein scheint. 
Zusammenfassend fördert diese Studie das Verständnis von integrativen, epigenetischen 
Mechanismen zwischen Umwelt und Genom und die Beantwortung vieler noch ungelöster 
Fragen in Bezug auf die Pathogenese von CED. 
  
  
1 INTRODUCTION 
1 Introduction 
 Epigenetics – bridging genes and environment 
There is more to our story than our genes can tell. Our genes are not solely responsible for who 
and how we are. They also do not on their own define our susceptibility to disease and whether 
or not and when we might sicken. If the nucleotide sequences of our genes, of our DNA, are the 
words our story is written in, something else resembling grammar and punctuation rules must 
exist to enable differential interpretation of those plain words. Those rules convey the different 
and individual meanings in particular situations and contexts by ensuring the right words are 
used and read with the right emphasis and accentuation. This becomes especially obvious when 
we look at monozygotic twins. They are natural clones in respect to their DNA sequence- their 
words are the same. Yet monozygotic twins can still be quite different individuals. They do not 
exactly look alike and they can be discordant in respect to the diseases they might develop. 
Similar observations have been made in cloned animals. Despite carrying identical donor DNA, 
their phenotypes differ from one another and from their donor (Rideout III, 2001). Classic 
genetics does not fully explain these phenomena. So, there must be more to the story. 
In 1942, Conrad H. Waddington coined the term epigenetics for studies on the 
mechanisms and processes at work during development from genotype to phenotype 
(Waddington 1942). Since then, the definition of the term epigenetics has changed and quite 
substantial research has been undertaken in the field. Especially within the last two decades, it 
has picked up tremendous speed. Even though, a great deal of exciting discoveries is still to be 
made, the current knowledge carves the following definition. Epigenetics describes the study of 
mechanisms leading to mitotically but also potentially meiotically heritable changes in gene 
expression and associated changes in phenotypes. Such changes do not include alterations in the 
primary DNA sequence (Berger et al., 2009; Dupont et al., 2009; Portela and Esteller, 2010). 
Epigenetics describes how chemical marks are assigned to DNA and chromatin, but also to a 
wide range of non-histone proteins, and how these impact on gene transcription and the 
functionality of the genome in general (Esteller, 2008). Altogether, genome-wide molecular 
modifications that are functionally relevant make up the epigenome of an organism (Fofanova et 
al., 2016). 
Epigenetic mechanisms have been shown to act in a developing organism and during 
cellular differentiation (Li, 2002), when cells start to run different sets of genes departing from 
the toti- or pluripotent state. While those different sets of genes originate from the same 
genome, epigenetic mechanisms silence or activate them. This reprograming of the genome in 
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embryogenesis and for tissue-specific gene expression leads to different cellular functionalities 
and identities (Boland et al., 2014; Salts and Meshorer, 2016). Stability of differentiated cellular 
phenotypes is supported by an ‘epigenetic memory’ that is passed on through cell divisions 
(Nashun et al., 2015; Shipony et al., 2014). Thereby, epigenetics helps answering questions like, 
how stem cells differentiate but also how an epithelial cell gives rise to new epithelial daughter 
cells. 
Besides the modulation of cell type-specific transcriptional profiles, epigenetics also 
plays an important role in X-chromosome inactivation (Heard et al., 2004), genomic imprinting 
(Ferguson-Smith, 2011), or chromatin-organization by regulating histone modifications 
(Gardner et al., 2011; Henikoff and Shilatifard, 2011). Unsurprisingly, the importance of the 
correct function of epigenetic features becomes obvious in many diseases. The best studied 
example is cancer, where globally occurring perturbations in DNA methylation and histone 
marks but also changes in the expression profiles of chromatin remodeling enzymes have been 
reported, leaving cancer cells with an extensively disturbed epigenome (Esteller, 2007; Portela 
and Esteller, 2010). Among other conditions, autoimmune disorders (Javierre et al., 2010) and 
inflammatory conditions, such as inflammatory bowel diseases (IBD) have been associated with 
changes epigenetic landscaping (Bayarsaihan, 2011; Scarpa and Stylianou, 2012; Shanmugam 
and Sethi, 2013). 
A common feature of these diseases is the epigenetic contribution to disease onset, 
penetrance and progression (Portela and Esteller, 2010; Scarpa and Stylianou, 2012). During an 
individual’s lifetime, exogenous impact on epigenetic variation naturally increases, as epigenetic 
modifications occur as cellular responses to environmental stimuli. This epigenetic adaptation to 
an individual’s environment can be witnessed very impressively in monozygotic twins whose 
epigenetic drift increases by age and life style differences (Esteller, 2008). Most strikingly, 
diseases with an underlying genetic susceptibility, such as IBD, have shown to be strongly 
influenced by environmental cues via epigenetic mechanisms which impact on disease 
susceptibility and presentation (Esteller, 2008; Scarpa and Stylianou, 2012). 
Taken together, epigenetics may be considered as a bridge between genome and 
environment - internal as well as external, that can help explain complex phenotypes, 
phenotypic discordance in monozygotic twins, disease variabilities and sporadic incidence 
(Petronis, 2010; Scarpa and Stylianou, 2012). 
1.1.1. Epigenetic mechanisms and their molecular tools 
There are several distinct epigenetic mechanisms that integrate intrinsic signals and also allow 
the embedding of external environmental cues into genetic interpretation. They operate 
interconnectedly on diverse levels and can conceptually be grouped into the following 
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categories: DNA methylation, histone modification, nucleosome positioning and RNA 
interference. 
1.1.1.1. DNA methylation 
DNA methylation is an intensely studied epigenetic mechanism regulating gene transcription. It 
describes the covalent addition of methyl groups to cytosines (Hotchkiss, 1948; Sinsheimer, 
1955) in the relatively sparsely occurring (only about 1% in the genome) cytosine-guanine 
dinucleotides (CpG) but also of cytosines in non-CpG sequences (Ramsahoye et al., 2000; Ratel et 
al., 2006; Woodcock et al., 1987). Those concentrate in certain areas of the genome called “CpG 
islands”. These islands are defined as sequences of 200 bases of DNA containing more than 50% 
CpG dinucleotides and an observed-to-expected CpG ratio greater than 0.6 (Portela and Esteller, 
2010). CpG islands are mainly found near transcriptional start sites and within promotor 
regions of genes (Saxonov et al., 2006). The borders of these islands are termed “CpG shores”, 
contain less CpG dinucleotides and make up about 2 kb upstream of CpG islands. Both, 
methylation of CpG islands as well as CpG shores are associated with gene silencing or 
transcriptional inactivation either e.g. via preclusion of transcription factor binding or the 
recruitment of histone modifiers and chromatin-remodeling complexes (Portela and Esteller, 
2010). Tissue-specific methylation patterns seem to mostly occur in CpG shores (Doi et al., 
2009). The case of DNA methylation of gene bodies, on the other side, has been found to 
facilitate transcription and correlates positively with gene expression (Hellman and Chess, 2007; 
Laurent et al., 2010). 
The addition of methyl groups from S-adenosyl methionine to DNA is catalyzed by the 
family of DNA methyltransferases (DNMTs), which in mammals consists of 5 known members- 
DNMT1, DNMT2, DNMT3a, DNMT3b and DNMT3L. However, only DNMT1, 2a and 3b possess 
methyltransferase activity (Jeltsch, 2006). The de novo DNMTs (DNMT3a and 3b) are abundant 
in embryonic stem cells and seem responsible for the establishment of the DNA methylation 
pattern during embryonic development, but are reduced in differentiated cells. The maintenance 
DNMT1 has a strong preference for hemi-methylated DNA and is especially active during DNA 
replication and cell division, but also has been shown to have de novo activity (Portela and 
Esteller, 2010). Furthermore, DNMTs are coordinated and controlled on several levels, via 
different pathways and a great number of posttranslational modifications (PTM) (Denis et al., 
2011). 
A big question of the field is how and when the DNA methylation machinery is guided to 
its target sequences. Many reports suggest interactions of DNMTs with other epigenetic marks 
and factors, including non-coding RNAs (Jeong et al., 2009; Portela and Esteller, 2010; Zhao et al., 
2009). Moreover, it is under discussion whether DNA methylation rather has to be considered a 
secondary event to gene silencing via other mechanisms, leading to stably silenced genes (Bird, 
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2002; Clark and Melki, 2002). DNA methylation processes have been found to be crucial in 
regulating cellular differentiation, organ development, and cell type-specific gene expression. 
DNA Methylation is a key player, for example, in genetic imprinting (Ferguson-Smith, 2011; 
Kacem and Feil, 2009) and for X chromosome inactivation in females (Reik and Lewis, 2005). 
Furthermore, aberrations in DNA methylation resulting in decreased DNA methylation or 
hypermethylation of certain gene promotors that are normally unmethylated have been 
associated with a range of diseases (Robertson, 2005) such as IBD and cancer (Esteller, 2007; 
Heyn et al., 2016; Karatzas et al., 2014; Sandoval and Esteller, 2012; Scarpa and Stylianou, 2012; 
Ventham et al., 2013). 
1.1.1.2. Histone modifications 
Histones are alkaline predominantly globular proteins present in all eukaryotic cell nuclei. There 
they act as scaffolding for chromatin, organizing DNA into its basic structural units called 
nucleosomes. These are made up of two of each of the four core histones (H2A, H2B, H3 and H4) 
forming an octamer which is wrapped round by a 147 base pair (bp) containing DNA segment. 
The unstructured N terminal tails of the core histones which extend from the surface of the 
nucleosomes, are decorated with a great number of different PTMs, including acetylation, 
methylation, phosphorylation, ubiquitination, SUMOylation and more than 50 others (Tan et al., 
2011) but also the globular domains can be modified (Kouzarides, 2007). Histone modifications 
play an important role in transcriptional regulation but also in many other cellular processes 
such as DNA repair (Huertas et al., 2009), the regulation of alternative splicing (Luco et al., 
2010), or chromatin condensation (Kouzarides, 2007). In general, histone PTMs lead to changes 
in chromatin structure via alterations in the electrostatic charge of the histone proteins thereby 
affecting DNA accessibility but also acting as recruitment platforms for transcription factors 
(TFs) and transcriptional co-regulators (Gardner et al., 2011). A wide range different patterns of 
histone modifications can occur at different sites simultaneously that have been shown to be 
potentially interdependent and in constant cross-talk (Rando, 2012; Suganuma and Workman, 
2011; Wang et al., 2008). Whether or not different patterns of histone modifications constitute a 
“histone code” that might be fully capable of predicting downstream biological effects, as does 
the genetic code, is a highly and controversially debated issue (Henikoff and Shilatifard, 2011; 
Jenuwein and Allis, 2001; Rando, 2012). 
Condensed chromatin, where DNA is tightly wrapped around nucleosomes and packed 
into a higher order-chromatin structure, is termed heterochromatin and transcriptionally 
inactive. Euchromatin, on the other side, is more relaxed and open and can be actively 
transcribed. Low levels of histone acetylation and methylation of specific residues are, for 
example, associated with heterochromatin whereas high levels of trimethylation of other sites 
and highly acetylated histone tails are characteristic for euchromatin (Li et al., 2007; Portela and 
Esteller, 2010). Additionally, different levels of histone modifications have been found to be 
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predictive for gene expression (Karlić et al., 2010). Histone PTMs do furthermore interact with 
other epigenetic factors, such as DNMTs, directing de novo DNA methylation to specific sites 
(Ooi et al., 2007) – and vice versa, DNA methylation can orchestrate histone modifications to 
specific sequences (Fuks et al., 2003). 
Overall, multiple histone-modifying enzyme families have been described that are 
responsible for the establishment or removal of their designated histone PTMs (Bhaumik et al., 
2007; Dillon et al., 2005; Kouzarides, 2007; Marmorstein and Roth, 2001; Selvi et al., 2010; Seto 
and Yoshida, 2014). Interestingly, while histone methyltransferases, demethylases and kinases 
are relatively specific to certain histone subunits and residues (Chi et al., 2010; Kouzarides, 
2007), histone acetyltransferases (HATs) or histone deacetylases (HDACs) are rather unspecific 
targeting several residues (Portela and Esteller, 2010). However, histone substrate specificity of 
HAT enzymes is being discussed (Marmorstein and Zhou, 2014) . Taken together, histone 
modifications represent a diverse epigenetic toolbox allowing the complex and dynamic changes 
in the landscape of DNA accessibility necessary to enable cellular reactivity to internal as well as 
external environmental cues (Klemm et al., 2019). 
Histone deacetylation and inhibitors of histone deacetylases 
An evolutionary very old protein modification is the acetylation of lysine residues as it has even 
been described in bacteria (Gardner et al., 2006). In 1969, histones have been the first substrates 
to be described for lysine deacetylases (KDACs) (Inoue and Fujimoto, 1969), the enzymes 
responsible for removing acetyl groups from proteins, leading to the term histone deacetylases 
(HDACs) in eukaryotes (Yang and Seto, 2008) even though a large number of non-histone 
protein targets has been identified in the meantime (Seto and Yoshida 2014). Histone or protein 
acetylation at the ε-amino group of lysine residues is mediated by histone/lysine 
acetyltransferase enzymes (HATs) (Marmorstein and Zhou, 2014) and can be reversed by 
HDACs/KDACs. For convenience, as from now the term HDAC will be used when talking about 
histone/lysine deacetylases. HDACs are amidohydrolases and comprise an ancient enzyme 
family that exists in mammals, plants, fungi and bacteria. The first mammalian HDAC enzyme, 
HDAC1, was isolated in 1996 by Taunton and colleagues, and after that the field of histone 
deacetylation has rapidly expanded (Taunton et al., 1996). In humans, HDACs are grouped into 
four classes (class I, II, III, also called sirtuins and IV), based on their sequence homology to 
corresponding enzymes in yeast and their sequence similarities among each other. Homologues 
to reduced potassium dependency 3 (Rpd3) in yeast constitute class I HDACs (HDAC1, 2, 3 and 
8), class II HDACs (class IIa: HDAC4, 5, 7 and 9; class IIb: HDAC6 and 10) are homologues to 
yeast histone deacetylase-A 1 (hda1), class III (SIRT1-7) corresponds to yeast silent regulator 2 
(Sir2) and the single HDAC constituting class IV (HDAC11) is much less homologous to either 
Rpd2 or hda1 enzymes (Yang and Seto, 2008). Class I, II and IV HDACs are also called classical 
   
6 INTRODUCTION 
HDACs and their enzymatic activity is dependent on a Zn2+ ion as a cofactor, whereas Sirtuins are 
NAD+-dependent (de Ruijter et al., 2003). Concerning their subcellular localization, class I HDACs 
have long been described as located in the nucleus, but can also be found in the cytoplasm and 
certain organelles of the cell. Class II HDACs have all to some extend been described as located to 
the cytoplasm, but also stimulus-dependent shuttling between nucleus and cytoplasm has been 
observed (Chawla et al., 2003). 
As posttranslational modifiers of histones but also of a vast number of non-histone 
protein substrates, such as transcription factors, signaling molecules, DNA binding and repair 
molecules, or chaperone proteins, HDACs function as regulators and modulators of a large 
number of vital cellular processes, most notably, cell cycle and transcriptional regulation (Chen 
et al., 2002; Glozak et al., 2005; Luo et al., 2000; Seto and Yoshida, 2014; Yang and Seto, 2003). 
More than 3600 acetylation sites have been found on more than 1700 proteins, many of which 
have been shown to be affected by HDACs (Choudhary et al., 2009). Via deacetylating histones, 
HDACs unmask the positive electrostatic charges of the core histones that have been neutralized 
by the acetyl-groups, leading to an increased affinity of the negatively charged backbone of the 
DNA to the histones and thereby to more condensed chromatin. Consequently, transcription is 
sterically hindered (Figure 1). Therefore, HDACs are referred to as epigenetically acting 
transcriptional (co-)repressors.  
 
 
Figure 1: Schematic of histone (de)acetylation and the effects on chromatin structure 
 
HDAC enzymes themselves are regulated by several mechanisms at transcriptional, translational 
and posttranslational levels (Segré and Chiocca, 2011), but also via subcellular localization 
(Schlumm et al., 2013) and protein-protein interactions (Zhang et al., 2005). Furthermore, class I 
HDACs have been found to be part of and form large multi-subunit protein complexes to exert 
their transcriptional regulation. Class I HDACs have been shown to be integral parts of 
corepressor complexes. HDAC1 and 2, when isolated show low enzymatic activity, interact with 
each other and are found together as the catalytic core in the Sin3, the nucleosome remodeling 
deacetylase (NuRD), and the co-repressor of REST (repressor element 1 silencing transcription 
factor (CoREST)) complexes (Ahringer, 2000; Ayer, 1999; Denslow and Wade, 2007), whereas 
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HDAC3 has been found as the only class I HDAC as a component of endogenous nuclear receptor 
co-repressor (NCoR)/ silencing mediator of retinoic acid and thyroid hormone receptors 
(SMRT) complexes (Kao et al., 2000; Li et al., 2000). Interaction of HDAC3 with the NCoR/SMRT 
complex has been shown to be necessary for HDAC3 catalytic activity (Emmett and Lazar, 2018; 
Guenther et al., 2001). 
A large number of naturally occurring (Bassett and Barnett, 2014) and synthetic 
compounds capable of inhibiting HDAC function have been characterized and can be categorized 
upon their chemical properties as hydroxamic acid derivates (e.g. Trichostatin A (TSA) or SAHA), 
benzamides (e.g. MS-275), short-chain fatty acids (e.g. butyrate and valproate) cyclic peptides 
(e.g. depsipeptide) (Miller et al., 2003; Minucci and Pelicci, 2006). Most histone deacetylase 
inhibitors (HDACi) bind to the Zn2+ ion in the catalytic pocket of HDACs and have been shown to 
induce cell cycle arrest and differentiation in transformed cells (Johnstone, 2002). Besides the 
investigation of pan-HDACi, such as TSA or SAHA, more selective inhibitors are being developed 
(Bantscheff et al., 2011; Olzscha et al., 2016). This is important, since inhibiting HDAC function 
does not only result in an overall, “global” reduction of the deacetylation status of core histones 
of nucleosomes which affects chromatin structure in general, but also has an effect on non-
histone protein acetylation (Olzscha et al., 2016; Seto and Yoshida, 2014). Since HDACs display 
aberrant activity and are overexpressed in many cancers, HDACi are promising anticancer drugs 
(Li and Seto, 2016; Ropero and Esteller, 2007), but are also being discussed for the treatment of 
many other conditions related to epigenetic abnormalities including inflammatory diseases such 
as IBD (Felice et al., 2014; Glauben and Siegmund, 2011). 
1.1.1.3. Nucleosomes and chromatin remodeling 
The positioning of nucleosomes and chromatin structure is dynamically regulated and 
continuously remodeled by diverse mechanisms such as the aforementioned histone 
modification and the process of nucleosome positioning. The packaging of DNA into 
nucleosomes presents a barrier for the transcription machinery and is therefore a crucial mean 
of epigenetic regulation of gene expression (Längst and Manelyte, 2015; Li et al., 2007). 
Specialized multiprotein chromatin remodeling complexes are diverse and highly abundant in 
the cell and ATP-dependently slide, rotate, or eject nucleosomes around and from gene 
regulatory sequences (Rippe et al., 2007). They have also been shown to exchange canonical 
histones with histone variants that can alter the properties of the affected nucleosome and 
chromatin (Papamichos-Chronakis et al., 2011). Chromatin remodelers recognize different 
histone modifications (Wysocka et al., 2006), DNA sequences or RNA signals (Yoo et al., 2009) 
which target them to specific genes. The known chromatin remodeling complexes can be 
grouped into four enzyme families (SWI/SNF, ISWI,CHD and INO80) that hydrolyze ATP to 
induce protein conformational changes in order to regulate nucleosome positioning as an 
epigenetic mechanism of gene expression regulation (Längst and Manelyte, 2015). 
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1.1.1.4. microRNAs 
Lastly, non-coding RNAs (ncRNAs) play an important role as epigenetic regulators of gene 
expression. They emanate from intergenic transcription and comprise for example small non-
coding RNAs, mid-size RNAs, and long non-coding RNAs (Cech and Steitz, 2014). Small RNAs 
loom large at RNA degradation, translational repression, chromatin modification and the 
regulation of gene expression via RNA interference (RNAi) (Holoch and Moazed, 2015). 
MicroRNAs (miRNAs) are about 22 nucleotide long RNAs that post-transcriptionally 
downregulate the translation of mRNAs (Bartel, 2018) by targeting the partially complementary 
3’ untranslated region of mRNAs leading to gene silencing. Hundreds of miRNAs have been 
identified in the human genome that seem to target and regulate the majority of the human 
genes (Friedman et al., 2009). Furthermore, there is substantial crosstalk between ncRNAs and 
the afore described epigenetic mechanisms of DNA methylation, histone modification and 
chromatin formation (Mochizuki et al., 2002; Parodi et al., 2016; Taguchi, 2015; Volpe et al., 
2002). Unsurprisingly, the disruption of non-coding RNAs is relevant in many diseases (Esteller, 
2011).  
1.1.2. Environmental influences on the intestine 
Throughout our whole life, we are exposed to a multitude of environmental stimuli influencing 
the homeostasis of our cells and our whole organism. Besides the skin, the gastrointestinal tract 
also represents an organ system with a very large surface of about 32 m2 (Helander and 
Fändriks, 2014) that is under constant internal and external influences. Right after birth it is 
gradually being colonized by an enormous number of microorganisms (Dominguez-Bello et al., 
2010; Huang et al., 2013), while it is simultaneously exposed to a myriad of nutrients, 
breakdown products thereof and bacterial metabolites, but also to potentially toxic compounds 
such as pharmaceuticals. Infections but also stress and other psychological factors also impact 
on the balanced physiology of the intestinal surface (Legaki and Gazouli, 2016). Especially, the 
single cell layer of the intestinal epithelium is in constant, close contact to the external 
environment (Zilbauer and Kraiczy, 2017). The epigenetic toolbox represents an important 
mean enabling intestinal microbiota and other environmental cues to leave their signature on 
epithelial gene expression (Alenghat et al., 2013; Dai and Wang, 2014; Kelly et al., 2018) which is 
why epigenetic mechanisms are increasingly recognized as key contributors of pathologies of 
the intestines such as IBD (Fofanova et al., 2016; Legaki and Gazouli, 2016; Zilbauer and Kraiczy, 
2017).  
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 The human gastrointestinal tract 
The digestive or gastrointestinal (GI) tract comprises an interconnected organ system of about 
nine meters in length (Hounnou et al., 2002) consisting of mouth, esophagus, stomach, followed 
by the small and large intestines or small and large bowels, and rectum and anus. Its purpose is 
to digest food that has been taken in, absorb nutrients and energy and excrete the solid leftover 
waste as feces. An immense number of microbes is constantly living inside the lower intestinal 
tract (small and large intestines) that are summarized as the commensal intestinal microbiota. 
This symbiotic relationship between host and resident microbiota starts right after birth 
(Dominguez-Bello et al., 2010) and affects a multitude of processes in the host starting from a 
healthy development of the Gi tract, the development of the immune system and immune 
tolerance towards microbiota but also food-derived proteins (Chistiakov et al., 2015; Hooper et 
al., 2012), up to metabolism and the shaping of the epigenetic landscape (Kelly et al., 2018). 
Needless to say, however, microorganisms always also represent a potential threat that needs to 
be balanced and held under tight control by the host immune system. Owed to its task to digest 
food and absorb nutrients, the small intestine represents the largest part of the GI tract in terms 
of surface area (Helander and Fändriks, 2014). In the subjacent following large bowel, water is 
reabsorbed and remaining feces are stored before defecation. The general histology of the GI 
tract comprises four concentric layers combining into the gastrointestinal wall (Paxton et al., 
2003). The outermost layer consists of connective tissue and is called serosa or adventitia. 
Subjacent lies a layer of smooth muscles, the muscularis propria. This is followed by the 
submucosa, a layer of loose connective tissue traversed by large blood vessels, lymphatics and 
nerves and serves to support the mucosa. The innermost layer of the GI tract, the tunica mucosa, 
is composed of an underlying muscle layer (lamina muscularis mucosae), followed by the lamina 
propria mucosae, a layer of loose connective tissue containing nerves and small blood and lymph 
vessels, and the top luminal layer of epithelial cells, the lamina epithelialis mucosae. The single 
cell layer of the intestinal epithelium is responsible for nutrition uptake and for building up a 
physical and biological border to restrict harmful substances and microorganisms from entering. 
About every four days, it is completely renewing itself via cell division, differentiation and 
migration and shedding of cells. 
1.2.1. The small and large intestine 
Between the stomach and the large intestine lies the tubular structure of the small intestine. It 
begins with the duodenum followed by the jejunum and ends with the ileum and the ileocecal 
valve, the sphincter muscle separating the terminal ileum from the colon. Adapted to its function 
of digestion and nutrition and mineral uptake, the mucosal surface area is strongly enlarged to 
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approximately 30 m2 (Helander and Fändriks, 2014). This is realized via in- and evaginations of 
the mucosa called crypts of Lieberkühn (Glandulae intestinalis) and villi, respectively, and even 
more increased by the protrusions of the cellular membranes of the enterocytes called 
microvilli. Partly digested food enters the duodenum coming from the stomach. The duodenum 
further receives pancreatic and hepatic juice to promote digestion, breaking down proteins and 
other macromolecules and emulsifying fats. Along the way to the terminal ileum, epithelial 
enterocytes are responsible for the resorption of the products of digestion. With increasing 
distance from the stomach, specialized cells residing at the bottom of the crypts, so called Paneth 
cells, are increasing in number (Sekirov et al., 2010). They produce and secrete different 
antimicrobial compounds making them important players in antimicrobial host-defense and 
immunity. 
The demarcation of the small intestine from the large intestine is provided by the 
ileocecal valve. The large intestine, also referred to as colon, is about 1.5 m long (Hounnou et al., 
2002) and has a much smaller mucosal surface area of about 2 m2 than the small intestine, also 
owed to the fact, that while there are crypts there are no villi in the colon. There are also no 
Paneth cells in the colonic mucosa, but the number of goblet cells for the production of a thick 
protective mucus layer covering the epithelium, is much higher than in the small intestine. This 
mucus layer serves as a physical barrier against the invasion of microbiota into the mucosa and 
also stores antimicrobial peptides (Dupont et al., 2014). The large intestine can be subdivided 
into the cecum with the attached appendix, which is a small finger-like pouch, that possibly 
serves as a storage place for normal, healthy gut bacteria and has a potential immune function in 
diarrheal illness (Laurin et al., 2011). The cecum is then followed by the ascending, transverse, 
descending and sigmoid colon, rectum, and anus. 
The colon mainly functions in reabsorbing salt and water from the chyme and solid 
waste of the digestive process. It furthermore represents a reservoir for the highest density of 
bacteria and the bacteria-assisted fermentation of unused carbohydrates and protein and 
indigestible dietary fiber (Blaut and Clavel, 2007; Edwards and Rowland, 1992). The large 
number of bacteria residing within the colonic lumen is also reflected by the fact that about 60% 
of the fecal dry mass are made up by bacteria (Guarner and Malagelada, 2003). 
1.2.2. Microbiota of the intestines 
The number of microbial cells in the gut has been reported to be higher than the total amount of 
human cells in the body of the host (Sender et al., 2016) and comprising a biomass of up to 2 kg. 
The intestinal microbiota represent an extremely diverse ecosystem (Eckburg et al., 2005), 
which supports an optimal nourishment of the host, but is also essential for the development of 
the GI tract and the enteric immune system (Hooper et al., 2012; Huang et al., 2013). It can 
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furthermore, mainly via microbial metabolites, even influence remote organs, such as the 
cardiovascular system or the brain, and adipose tissue (Koeth et al., 2013; Lee et al., 2006; 
Schroeder and Bäckhed, 2016; Stilling et al., 2014). On the other hand, an individual’s genetic 
background, age, lifestyle, usage of antibiotics, geographical location and especially dietary 
habits influence on the dynamic and diverse composition of the intestinal microbiome of each 
individual (Voreades et al., 2014; Yatsunenko et al., 2012). Furthermore, niche competition 
between different bacterial species for nutrients and habitat but has an impact, also in terms of 
protection against potentially pathogenic bacteria (Fukuda et al., 2011). However, despite of all 
these strong influencers, the individual microbiota in adults is relatively stable and changes 
occur rather in the abundances of different species and not so much in species composition itself 
(Lozupone et al., 2012; Rajilić-Stojanović et al., 2013). 
The microbial density gradually increases from the proximal to the distal segments of the 
intestine and the local microbial composition differs among the different segments, mostly due 
to distinct physiologic conditions within the compartments (Human Microbiome Project 
Consortium, 2012). The passage through the acidic environment of the stomach is deadly for 
most of the ingested bacteria and therefore the stomach and the following duodenum are barely 
populated. The highest microbial density and diversity is found in the colon. There are five 
prevalent phyla present in the intestine- Bacteroidetes, Firmicutes, Actinobacteria, 
Proteobacteria and Verrucomicrobia, however single species can vary considerably (Forster et 
al., 2019; Schroeder and Bäckhed, 2016). For the characterization of the microbiota of the 
different intestinal segments, and depending on whether luminal or mucus-adherent bacteria 
are subject to the investigation, different sampling procedures are required, making it generally 
difficult to create a detailed description of a healthy microbiota. In general, the luminal content 
of the distal colon is easily accessible via stool sampling, whereas small intestinal microbiota has 
to be accessed via more invasive procedures such as colonoscopy and biopsy sampling. 
Intestinal tissue data revealed that the mucosal microbiota of the ileum is especially abundant in 
Bacteroidetes and Firmicutes (Bacillus and Clostridiales species), as opposed to the colon where 
Bacillus species are strongly diminished and mainly Bacteroidetes and Firmicutes/Clostridiales 
are prevalent (Peterson et al., 2008). Alterations in composition of the gut microbiota are 
associated with a range of diseases affecting all kinds of different organs (Schroeder and 
Bäckhed, 2016; Sekirov et al., 2010). Conditions as diverse as obesity, type 2 diabetes, 
arteriosclerosis, autism spectrum disorders and especially IBD have been linked to dysbiosis, an 
imbalance or maladaptation of the intestinal microbiome (Bäckhed et al., 2004; Koeth et al., 
2013; Matsuoka and Kanai, 2015; Morgan et al., 2012; Perry et al., 2016; Schroeder and Bäckhed, 
2016; Wang et al., 2012). Study design, sampling method and analysis strategy are however 
pivotal factors for the reliability of the deduced associations between the microbial effector and 
the disease (Hanage, 2014; Walters et al., 2014). The reported associations for IBD, where 
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mainly a generally reduced diversity accompanied with a reduction in Firmicutes and an 
elevation of Proteobacteria and Actinobacteria were found, have however been consistent 
across several studies together with a high effect size (Frank et al., 2007; Gophna et al., 2006; 
Papa et al., 2012; Peterson et al., 2008; Walker et al., 2011; Walters et al., 2014). 
1.2.3. Immunity – the intestinal barrier 
While the immense surface of the intestine constitutes an optimization for the resorption of 
nutrients, at the same time, it represents an interface for microbial-mucosal contact and a 
potential attack surface. Therefore, an arsenal of defense mechanisms is needed for the 
protection of the host against invasion by microorganisms but also to shape the composition of 
the microbiota. An effective intestinal antimicrobial barrier consists of two basic defense lines – 
the physical or mechanical barrier composed of the epithelium and the overlaying mucus, and 
the second defense line, a biochemical barrier, involving antimicrobial peptides (AMPs) and the 
gut associated lymphatic tissue (GALT). 
1.2.3.1. Physical barrier – epithelium and mucus 
A single cell layer, the epithelium, is lining the intestines towards/from the lumen. Adjacent 
epithelial cells are connected via tight junctions, forming a continuous, sealed cellular barrier 
(Peterson and Artis, 2014). Specialized epithelial cells, the mucus-producing goblet cells, secrete 
highly glycosylated mucins into the lumen. The main component is mucin 2 (Rousseau et al., 
2004), which is also essential for the two-layered organization of the mucus in the colon 
(Johansson et al., 2011).  
 
Figure 2: Composition of the small intestinal barrier 
Figure was kindly provided by Dr. Lioba Courth 
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While in the small intestine the mucous layer is only loosely attached to the epithelium 
(Figure 2), and can be transported onward by the peristalsis of the gut, mucus is double-layered 
in the large intestine. The inner layer is rather compact and impenetrable for bacteria. The outer 
layer is assumed to emerge from the inner layer through degradation and is only loosely layered 
above building the habitat for commensal bacteria (Johansson et al., 2011). The tight structure of 
the epithelium together with the mucus layer, which furthermore serves as a reservoir for 
antimicrobial peptides secreted from epithelial cells, represent a strong mechanical barrier 
against bacterial invasion (Johansson et al., 2013; McGuckin et al., 2011; Sansonetti, 2004). 
1.2.3.2. Biological barrier – Innate immune factors of the intestines 
The biological component of the innate intestinal antimicrobial barrier is provided by immune 
cells like dendritic cells and macrophages and the production and secretion of an arsenal of 
antimicrobial peptides by the intestinal epithelium. Cells of the adaptive immune system present 
in the lamina propria of intestine will be discussed in Chapter 1.2.3.3 Adaptive immunity in the 
intestine. 
Antimicrobial peptides 
Many epithelial cells, immune cells and a number of specialized cells in the human body produce 
diverse small AMPs (Ostaff et al., 2013) with an amphipathic character, containing cationic and 
hydrophobic residues (Cederlund et al., 2011; Zasloff, 2002). These peptides are conserved from 
plants to humans and present in all eukaryotes (Zasloff, 2002). Concerning their modes of 
antimicrobial action, different mechanisms have been reported for different types of AMPs. 
Many AMPs target structures of the bacterial cell wall, as e.g. lysozyme enzymatically degrades 
bacterial peptidoglycan (Ganz, 2003), or the secreted phospholipase sPLA2, which invades the 
cell wall and also hydrolyses phospholipids of cellular membranes (Koprivnjak and Peschel, 
2011). Others build up pores in the bacterial surface disrupting the membrane potential (Hill et 
al., 1991; Kagan et al., 1990; Mukherjee et al., 2014). Human α-defensin 6 (HD6) has been 
reported to form nanonets in vivo, thereby entrapping bacteria (Chu et al., 2012). Furthermore, 
immuno-chemotactic properties have been shown for AMPs, e.g. human α-defensin 5 (HD5) or 
human β-defensin 2 (hBD2) (Grigat et al., 2007; Röhrl et al., 2010). 
The Paneth cell of the small intestine is a specialized secretory epithelial cell residing in 
the stem cell niche at the bottom of the crypts, providing large amounts of AMPs, thereby 
contributing on a big scale to the intestinal antimicrobial barrier. It expresses lysozyme, the 
lectin Reg-3γ, the secreted phospholipase sPLA2 and the α-defensins HD5 and HD6 (Bevins and 
Salzman, 2011), which are among the most abundant AMPs in the small intestine(Kübler et al., 
2009). Further AMPs, such as the cathelecidin LL-37 or β-defensins, are produced by other 
epithelial cells of the intestine (Pazgier et al., 2006). An important human group of AMPs are 
defensins. Structural characteristics of defensins are richness in β-sheets and the occurrence of 
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three disulfide bridges between six cysteine residues (Ganz, 2003; White et al., 1995). 
Depending on the arrangement of these disulfide bridges, defensins are classified into α-, β-, or 
θ-defensins, the latter of which, the cyclic defensins, are only found in Rhesus monkeys (Ganz, 
2003; Mukherjee et al., 2008). Interestingly, most genes encoding human defensins are clustered 
on chromosome 8p23 (Harder et al., 1997a; Linzmeier et al., 1999; Sparkes et al., 1989). 
Furthermore, the antimicrobial spectrum of defensins includes all types of microorganism 
(bacteria, fungi, viruses and protozoa) (Selsted and Ouellette, 2005; Wilson et al., 2013; Zasloff, 
2002). 
α-defensins 
So far, in humans, six distinct α-defensins have been identified. The α-defensins 1-4, the Human 
Neutrophil Peptides 1-4 (HNPs), have first been described in neutrophils but they are also 
expressed in monocytes and natural killer cells (Selsted and Ouellette, 2005). HD5 and HD6 are 
only expressed by Paneth cells of the small intestine, presumably constitutively. The regulatory 
elements of HD5 and HD6 genes display great similarities, e.g. both contain Wnt-response 
elements (Andreu et al., 2005; Wehkamp et al., 2007). Accordingly, the Wnt pathway has been 
shown to be a regulator of HD5 and HD6 expression via the Wnt transcription factors TCF-1 and 
TCF-4 (Beisner et al., 2014; Wehkamp et al., 2007). However, many further influencers and 
activators of Paneth cell HD5 and HD6 expression remain elusive. Recently, more light has been 
shed on their expressional regulation. Courth et al could show that the peripheral blood 
mononuclear cells (PBMC) secretome, more precisely the Wnt ligands therein, was able to 
induce HD5 and HD6 in ex vivo stimulated ileal biopsies. However, PBMC supernatants derived 
from Crohn’s Disease (CD) patients, displayed an impaired induction capacity likely due to 
reduced levels of Wnt ligands (Courth et al., 2015). 
HD5 and HD6 are being stored intracellularly as propeptides within vesicles and their 
content is secreted upon stimulation such as the detection of bacterial at the cell surface. 
Thereafter, the tryptic cleavage of the propetide into the active form of 32 aminoacids in length 
takes place in the crypt lumen (Ghosh et al., 2002). There, high concentrations these AMPs can 
be reached (Ghosh et al., 2002), ensuring the crypt environment to stay sterile (Ericksen et al., 
2005; Ouellette and Bevins, 2001). The study by Erickson et al found partially diverting 
antimicrobial activities for all α-defensins, except for HD6 (Ericksen et al., 2005). They are active 
against bacteria, fungi and viruses (Porter et al., 1997; Wilson et al., 2013). The mechanism of 
action for both, HD5 and HD6, has however been under intense investigation. HD5 has been 
reported to form dimers (Szyk et al., 2006) and to disturb cell division in gram-negative bacteria 
by provoking the formation of membrane vesicles termed blebs (Chileveru et al., 2015). 
Furthermore, HD5 seems to hold the ability to detoxicate bacterial toxins (Kudryashova et al., 
2014). In a mouse gain-of-function model transgenic for HD5, it presented activity against 
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Salmonella typhimurium and lead to a change in the microbiota composition (Salzman et al., 
2003, 2010). Experts were long baffled by the seemingly missing antimicrobial activity of HD6 
(Bevins, 2013; Ericksen et al., 2005). But within the last several years, even two distinct 
antimicrobial mechanisms have been reported to be inherent in HD6. It has been shown to form 
extracellular, bacteria-trapping nanonet structures in vivo (Chu et al., 2012) and been found to 
develop a direct antimicrobial killing activity against specific bacteria under reducing conditions 
like they are found in the intestine (Schroeder et al., 2014). Together, HD5 and HD6 build a 
broad defense arsenal for the maintenance of the gut innate antimicrobial barrier. 
ß-Defensins 
The evolutionary older family of β-defensins is the largest defensin family and members have 
been found in about all vertebrates studied so far (Zhu and Gao, 2013). Extensive gene 
duplications have led to about 30 β-defensin genes in humans (Rodríguez-Jiménez et al., 2003; 
Schutte et al., 2002) but so far mainly human β-defensins 1, 2,and 3 have been studied in greater 
detail (Pazgier et al., 2006). They are mainly expressed in many different epithelia, such as of the 
genitourinary and respiratory tract, the corneal epithelium (McDermott et al., 2003), gingival 
epithelial cells, the epidermis of the skin (Harder et al., 1997b, 2000; Schröder and Harder, 
1999), and epithelial cells of the intestine (Bals et al., 1998; O’Neil et al., 1999), but can also be 
found in immune cells (Duits et al., 2002; Wah et al., 2006; Yin et al., 2010). Not much is known, 
however, about the intracellular storage mode of β-defensins. In keratinocytes of the skin, hBD2 
is for example stored in lamellar bodies (Oren et al., 2003). Depending on the anatomical site of 
expression, β-defensins are either constitutively expressed or inducible (Selsted and Ouellette 
2005). HBD1 is mostly constitutively expressed but its expression can be modulated (Duits et al 
2002), hBD2 and hBD3 are differentially expressed and often inducible in a Toll-like receptor 
(TLR)- or inflammation dependent manner via pro-inflammatory cytokines (García et al., 2001; 
Liu et al., 1998; Selsted and Ouellette, 2005; Wehkamp et al., 2002). Among the manifold 
stimulants capable of inducing β-defensins at the transcriptional level are also different 
probiotic and pathogenic bacteria (Birchler et al., 2001; Harder et al., 2001; O’Neil et al., 1999; 
Schlee et al., 2007, 2008). Concerning their antimicrobial spectrum, β-defensins have been 
shown to be mainly effective against Gram-negative bacteria and fungi but have also been found 
to be active against Gram-positive bacteria and viruses ((Wehkamp et al., 2002, 2005a) Harder 
et al., 2001; Weinberg et al., 2012). Furthermore, immune-modulatory functions have been 
reported for β-defensins (Lai and Gallo, 2009), where, in different settings, they showed to be 
capable of recruiting immune cells (Yang et al., 1999), breaking self-DNA tolerance (Lande et al., 
2015) or reducing the expression of pro-inflammatory cytokines (Donnarumma et al., 2007). 
Interestingly, in the case of hBD1, the antimicrobial potential was long thought to be 
small. However, in 2011, it could be demonstrated that the environmental conditions are crucial 
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for hBD1 to unfold its antimicrobial activity (Schroeder et al., 2011). Reducing testing conditions 
mimicking the in vivo situation in the gut lead to the reduction of the intramolecular disulfide-
bridges in hBD1 conferring it with a potent antimicrobial activity against commensals and fungi 
(Jaeger et al., 2013), but also against pathogenic bacteria (Raschig et al., 2017; Wendler et al., 
2018). In vivo, the reduction of hBD1 can occur via the thioredoxin system (Jaeger et al., 2013). 
Alterations in the inducibility of β-defensins has furthermore been found in specimens of colonic 
CD and of ulcerative colitis (UC), highlighting their important contribution to an efficient 
antimicrobial defense system (Wehkamp et al., 2002, 2003, 2005a). 
1.2.3.3. Adaptive immunity in the intestine 
GALT is the part of the lymphatic system associated with the intestine. Along the whole 
gastrointestinal tract, diffuse aggregates of lymphocytes but also organized lymphoid follicles 
and mesenteric lymph nodes (MLNs) can be found in the mucosa and submucosa of the small 
and large intestine. If necessary, these effector sites function in the initiation of adaptive immune 
responses. In the small intestinal wall, especially the ileum, so called Peyer’s patches can be 
found which are large aggregates of up to 50 lymphoid follicles, containing a great number of B 
and T cells (Mowat, 2003). Right above the Peyer’s patches, specialized enterocytes, microfold 
cells (M cells), are scattered into the epithelium besides infiltrated B cells, T cells, dendritic cells 
(DCs) and macrophages (Mowat, 2003). M cells serve as detectors of invasive pathogens and 
other antigens and transcytose them across the epithelium. Thereafter, antigen presenting cells 
process and forward the information leading to activation of adaptive immunity. This includes 
not only the maturation and differentiation of residing naïve lymphocytes but also the 
recruitment of further immune cells from the blood stream into affected tissue sites (Mowat, 
2003). 
1.2.3.4. Recognition of bacterial components in the intestine 
The intestinal epithelium, as the first defense line, is equipped with pattern recognition 
receptors (PRRs) enabling epithelial cells to keep track of the composition of the resident 
microbiota. These PRRs recognize highly conserved pathogen-associated or microbe-associated 
molecular patterns (PAMPs or MAMPs) (Didierlaurent et al., 2002). The term MAMP is more 
general since there are many PAMPs that can also be found in non-pathogenic commensals. 
Abundant PRRs include TLRs, which are located on the surface membrane of epithelial cells and 
intracellular PRRs such as Nucleotide-binding oligomerization domain containing molecules 
(NODs) in NOD-like receptors (NLRs). Upon activation by respective ligands, pro-inflammatory 
pathways involving distinct signaling components are triggered, e.g. Myeloid differentiation 
primary response gene (MyD) 88, mitogen-activated protein kinases (MAPK) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) with the goal to quickly eliminate the 
intruders or if necessary induce adaptive immune responses (Cario, 2005; Takeda and Akira, 
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2004). In general, TLRs and their associated signaling cascades are involved in many processes 
affecting the well-functioning of the intestinal barrier, such as proliferation of epithelial cells, the 
integrity of tight junctions and AMP production (Abreu, 2010; Santaolalla et al., 2011). One 
mechanism to maintain a tolerant immune microenvironment towards the abundant microbiota 
in the intestine is the selective spatial expression of PRRs in the epithelia, limiting specific TLRs 
to be localized in low levels mostly to the basolateral membrane but to be inducible upon 
demand in macrophages (Abreu, 2010; Cario, 2010; Hausmann et al., 2002). Furthermore, the 
intracellular receptor for muramyldipeptide NOD2 is for example mainly expressed in Paneth 
cells of small intestinal crypts (Lala et al., 2003). Last but not least, the aforementioned overlying 
mucus layer provides a first shield against the attachment and invasion of microbes. 
 Inflammatory bowel diseases and the impaired 
antimicrobial barrier 
There are two major entities in IBD, CD and UC, which are both characterized by a chronic 
relapsing intestinal inflammation and infiltrating mono- and lymphocytes into the intestinal wall 
(Podolsky, 2002). IBD pathology is currently incompletely understood and thought to be caused 
by a myriad of genetic susceptibilities (Halfvarson et al., 2006; McGovern et al., 2015; Schreiber 
et al., 2005; Van Limbergen et al., 2014) together with environmental influences driving 
intestinal inflammation into a chronically activated status. Genetically and environmentally 
caused predispositions which seem to eventually result in a loss of mucosal tolerance towards 
resident microbiota and bacterial invasion leading to a continuous adaptive immune reaction 
and chronic inflammation (Figure 3) (Beisner et al., 2010; Ostaff et al., 2013; Wehkamp and 
Stange, 2010).  
 
 
Figure 3: Proposed model for development of IBD. 
Graphic from Ostaff et al., 2013, published in EMBO Mol Med 2013;5:1465-1483 
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Great environmental influence seems to be exerted by the bacterial communities living in the 
intestine, individual life styles, antibiotics use, smoking, and dietary habits (Legaki and Gazouli, 
2016; Sartor, 2008). In the proposed model depicted in Figure 3, these environmental effectors 
act upon an initially impaired barrier, which is e.g. weakened due to reduced mucus and AMP 
production, within a genetically predisposed host. The resulting loss in host-microbe-
homeostasis is herein thought to be primary to the consequence of an overshooting adaptive 
immune response (Ostaff et al., 2013; Wehkamp and Stange, 2010). 
The division into the two major IBD subgroups, CD and UC, is mainly determined by 
differing clinical behavior. CD can affect all sites of the whole GI tract displaying a rather patchy, 
over time often transmural inflammation pattern. UC, on the other side is characterized by a 
continuous mucosal inflammation beginning in the rectum which can gradually wander up to 
proximal colonic segments but stays restricted to the colon. Furthermore, CD and UC differ in 
terms of many molecular mechanisms contributing to disease onset, progression, or severity. In 
total, more than 200 genetic susceptibility loci have been identified for IBD, but only a fraction 
are shared by CD and UC (Anderson et al., 2011; Franke et al., 2010; Jostins et al., 2012; Khor et 
al., 2011; de Lange et al., 2017) affecting innate and adaptive immunity pathways, including the 
expression of pro-inflammatory and regulatory cytokines, endoplasmatic reticulum (ER) stress, 
or autophagy, among others. Furthermore, non-genetic factors are thought to play a bigger role 
in UC than in CD, since monozygotic twins display a concordance rate of only about 15% in UC 
but of about 35%-50% in CD, additionally emphasizing the role of the environment in those 
diseases (Khor et al., 2011; Loddo and Romano, 2015; Spehlmann et al., 2008) The divergence 
between CD and UC is also reflected by partially differing response to therapeutical approaches. 
For example, the probiotic bacterium E. coli Nissle 1917 is effective in maintaining remission in 
UC patients (Mack, 2011), possibly via the induction of hBD2 in colonic mucosa (Möndel et al., 
2009; Wehkamp et al., 2004a), whereas CD patients are lacking a probiotic benefit. No cure has 
been found so far, wherefore most therapies only treat the symptoms. Upregulated pro-
inflammatory cytokines in IBD, e.g. TNF-α, IL-17, or IL-23 mark them as targets for 
immunosuppressive approaches. Blocking TNF-α with anti-TNF antibodies is effective in many 
patients and can strongly ameliorate symptoms (Chudy-Onwugaje et al., 2018; Dahlén et al., 
2015), however, targeting IL-17 lead to severe disease exacerbations (Neurath, 2014). Hence, 
more research is needed on the interplay of all disease influencers and the affected signaling 
pathways, including their interconnected crosstalks, to find a more causal therapeutic approach. 
1.3.1. Crohn’s Disease 
Depending on the localization of the disease, which stays quite stable once it is established in a 
patient, CD is classified into further subdivisions according to the Vienna classification. L1 
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patients show ileal involvement only, L2 only colonic involvement, and L3 patients have both 
ileal and colonic tissue affected. If also the upper GI tract is involved the description “+L4” is 
added to the label. Relating to some extend to disease localization, distinct molecular 
mechanisms regarding defective AMP expression could be observed, reflecting their importance 
in a healthy functioning antimicrobial barrier.  
Patients with CD localized to the small intestine, have for example a deficit in the AMP 
human alpha-defensin 5 and 6 (HD 5/6) due to multi-layered defects in Paneth cells (Courth et 
al., 2015; Koslowski et al., 2009, 2012; Wehkamp et al., 2005b, 2007, 2008). This reduced 
expression of HD5 and HD6, which is independent of the inflammatory status (Bevins et al., 
2009), renders patients with decreased antimicrobial activity (Wehkamp et al., 2005b). 
Underlying defects in the expressional regulation could be uncovered. The HD5 and HD6 
controlling Wnt pathway transcription factors TCF-1 and TCF-4 have been found to be 
diminished in small intestinal CD (Beisner et al., 2014; Perminow et al., 2010; Wehkamp et al., 
2007). Furthermore, ileal CD could be associated with mutations in the gene regulatory 
sequence of TCF-4 (Koslowski et al., 2009). Concerning the age of disease onset, a variant of the 
Wnt ligand co-receptor LRP6 has been found to be linked to an early onset (Koslowski et al., 
2009). Another interesting discovery concerning the induction of HD5 and HD6 could recently 
be made. It has been found that the secretome of stimulated PBMCs contains Wnt ligands and is 
capable of inducing the two α-defensins in ileal biopsies ex vivo. However, in contrast to PBMC 
supernatant from healthy individuals, CD derived PBMCs failed to do so which was concomitant 
with a lower expression of Wnt ligands in patient PBMCs (Courth et al., 2015). Further genetic 
defects affecting Paneth cell physiology have been reported. A single-nucleotide polymorphism 
(SNP) in the calcium-activated potassium channel protein (KCNN4) has been associated with 
ileal CD (Simms et al., 2010). This channel is involved in the process of granule secretion, 
thereby potentially affecting the availability of HD5 and HD5 in the intestinal lumen (Bevins and 
Salzman, 2011). In addition, genetic variants of the PRR NOD2, which is abundantly expressed in 
Paneth cells (Lala et al., 2003) have been identified as a strong risk factor for small intestinal CD 
(Economou et al., 2004; Hugot et al., 2001; Ogura et al., 2001) and could furthermore also be 
linked to reduced HD5 and HD6 expression (Wehkamp et al., 2004b, 2005b). So far, this 
correlation lacks profound causal connection, it still delivers a further conjunction between the 
sensing microbes and antimicrobial defensins in CD. Other susceptibility genes for ileal CD are 
the gene encoding a component of the ER stress response, XBP1, which has been reported to 
lead to an augmentation in Paneth cell apoptosis (Adolph et al., 2013; Kaser et al., 2008) and 
ATG16L1, an autophagy protein involved in the exocytosis of granules (Cadwell et al., 2008; 
Hampe et al., 2007). All the above described defects in Paneth cells unequivocally make these 
cells gain center stage not only for the upkeeping of the mucosal antimicrobial barrier as well in 
the pathogenesis of ileal CD. 
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Patients with colonic CD on the other hand, but also UC (which will be discussed in the next 
chapter), produce a reduced amount of the constitutively expressed hBD1 in their large bowel 
epithelia (Wehkamp et al., 2003) and are furthermore impaired in their redox-activation of the 
same peptide (Jaeger et al., 2013). Furthermore, colonic CD is associated with an attenuated 
upregulation of the hBD2, but also hBD3 and hBD4 and other AMPs like Elafin and LL37 are 
diminished (Fahlgren et al., 2004; Schmid et al., 2007; Wehkamp et al., 2003, 2008), 
accompanied by reduced mucosal antimicrobial activity (Nuding et al., 2007). HBD2 has been 
shown to be upregulated in colonic mucosa in response to probiotic bacteria (Möndel et al., 
2009; Schlee et al., 2008; Wehkamp et al., 2004a), possibly underlying the beneficial effect of 
probiotics on intestinal barrier function. The impaired inducibility of this important defense 
molecule in colonic CD under inflammatory or infectious conditions may, however, help explain 
why these patients are more susceptible to a bacterially induced chronic inflammation; and 
furthermore why probiotics show no efficiency in prolonging colonic CD remission (Mack, 
2011). Underlying causes of the defects in AMP expression have, however, so far only been 
scarcely investigated and are not yet fully understood. While predisposing genetic factors have 
been reported in the context of reduced Paneth cell mediated epithelial defense in the small 
intestine (Wehkamp and Stange, 2010), not much has been reported regarding the genetics of 
epithelial antimicrobial immunity in colonic CD. Data on hBD2 copy number variations have 
been inconclusive (Aldhous et al., 2009; Fellermann et al., 2006; Groth et al., 2010; Hollox, 2010) 
and so far only limited data exists on a hBD1 promoter SNP association with colonic CD (Lakatos 
et al., 2008). 
1.3.2. Ulcerative colitis 
In the colonic mucus layer of UC, adherent bacteria has been found (Swidsinski et al., 2002). 
Likewise to the situation in colonic CD, these patients also show diminished levels of hBD1 
expression and functional redox-activation thereof also seems to be impaired (Jaeger et al., 
2013; Schroeder et al., 2011; Wehkamp et al., 2003). UC is additionally also characterized by a 
defective goblet cell maturation and a thinned mucus layer on the surface of the colon, especially 
during inflammation (Gersemann et al., 2009; Johansson et al., 2013; Pullan et al., 1994; Strugala 
et al., 2008). These defects indicate that an impairment in the antimicrobial barrier is a key 
factor in this disorder aswell. Although other β-defensins, such as hBD2, hBD3 and hBD4 are 
readily upregulated in colonic mucosal epithelium of UC (Fahlgren et al., 2003, 2004; Wehkamp 
et al., 2003), this potentially compensatory effort to repair the antimicrobial defense likely 
hazards the consequences of an increase in inflammation caused by the pro-inflammatory and 
immunomodulatory effects of these AMPs (Lai and Gallo, 2009; Niyonsaba et al., 2005, 2007; 
Yang et al., 1999). An additional negative influence on disease progression might be, that the 
  
21 INTRODUCTION 
defective mucus layer is also less effective in binding the secreted AMPs and keeping them in 
close proximity to the epithelium where they could exert their antimicrobial killing activity 
(Ostaff et al., 2013). Hints for this have been obtained in a number of mouse models, including 
models of dextran sulfate sodium (DSS)-induced colitis (Fu et al., 2011; Petersson et al., 2011). 
Overall, however, the causal mechanisms for the dysregulations in AMP expression remain 
largely elusive at this point. 
1.3.3. Epigenetics in IBD 
The development and clinical behavior of CD and UC is determined by multiple underlying 
factors as has been described above. Among the most well studied ones are a growing number of 
genetic susceptibility loci (Halfvarson et al., 2006; McGovern et al., 2015; Schreiber et al., 2005; 
Van Limbergen et al., 2014) but also contributing environmental influences such as antibiotics 
use, smoking, or nutrition have found their way into the fields’ focus (Legaki and Gazouli, 2016). 
The increasing incidence of IBD (Molodecky et al., 2012), the big variance in disease progression, 
localization, severity, the age of onset, and the discrepancy between monozygotic twins (Loddo 
and Romano, 2015; Spehlmann et al., 2008) however urgently impose the question how exactly 
environmental factors might impact on IBD risk and progression. The rapidly growing field of 
epigenetics could help to further dissect how environmentally induced changes occur in the 
epigenome affecting the interpretation of different genes in an individual in the context of IBD to 
allow a more wholistic understanding of disease pathology (Scarpa and Stylianou, 2012; 
Aleksandrova et al., 2017; Fogel et al., 2017; Wawrzyniak and Scharl, 2018; Zilbauer and Kraiczy, 
2017; Fofanova et al., 2016). 
Gloria and colleagues were among the first to investigate epigenetic features in IBD, who 
found global DNA hypomethylation in UC rectal mucosa while exploring the role in associated 
cancer development (Glória et al., 1996). Later on, IBD pathogenesis was linked to mutations in 
the DNA methylation enzyme DNMT3a (Franke et al., 2010). Furthermore, for ileal CD, 
methylation changes in proximity to susceptibility loci including NOD2 have been identified 
(Nimmo et al., 2012). Others have investigated differences between the methylation profiles of 
inflamed and non-inflamed tissue in IBD and in comparison to healthy individuals (Cooke et al., 
2012; Häsler et al., 2012). Despite these and further interesting findings affecting the methylome 
in IBD and considering the plausible rationale to investigate epigenetics in these disorders, 
detailed mechanistic studies remain relatively scarce. Also still sparsely examined are changes in 
histone modifications in the field of IBD (Wawrzyniak and Scharl, 2018). However, there are 
several elegant mouse studies, closer describing the role of HDACs and histone methylation in 
the context of intestinal homeostasis and inflammation. Murine models of colitis have 
demonstrated the efficacy on inhibiting HDACs (Glauben et al., 2006; Turgeon et al., 2014). 
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Furthermore, Turgeon and colleagues have shown recently, that a double knockout of HDAC1 
and HDAC2 in intestinal epithelial cells lead to a more severe DSS colitis and to higher 
inflammatory gene expression. However, single depletion of HDAC2 protected against DSS colitis 
and resulted in  increase in colonic antimicrobial expression (Turgeon et al., 2013). Another very 
interesting finding has been made, where HDAC3 has been found to act as an integrator of 
signals derived from intestinal commensal microbiota for the correct regulation of the host-
microbe relationship (Alenghat et al., 2013). In a very recent report, Kelly et al further report 
potential mechanism linking genetic suscepitbility and environment in mice and IBD patients. 
They describe how the microbiome-host interplay might effect on the epigenetic histone 
methylation landscape potentially priming the epithelium into future inflammation (Kelly et al., 
2018)). In general, the question how microbiome and especially diet influence on epigenetics in 
IBD is gaining more and more center stage in the field (Aleksandrova et al., 2017). Not least 
because a large number of HDACi have been identified to occur as natural food components or 
emerge from bacterial metabolism, e.g. short chain fatty acids (Bassett and Barnett, 2014; Bhat 
and Kapila, 2017; Furusawa et al., 2013). 
Concerning the impaired AMP expression in IBD, while genetic studies are still 
insufficient in explaining the changes in colonic defensin expression, some first insights on 
potential involvement of epigenetics in hBD regulation have been gained in non IBD related 
studies. One epigenetically mediated mechanism might be exerted by HDACs. Recently, Yin and 
Chung found HDACs to be important regulators of the TLR-dependent induction of the 
antimicrobial peptide hBD2 in gingival epithelial cells (Yin and Chung, 2011). HDAC1 has been 
shwon to be involved in the transcriptional regulation of hBD1 in human lung epithelial cells 
(Kallsen et al., 2012). Besides these interesting reports, in vitro experiments could also show that 
treatment with a dietary HDACi of histone deacetylation leads to an upregulation of hBD2 
expression in intestinal epithelial cell lines (Schwab et al., 2008). A further study by Fischer and 
colleagues, that has been conducted in parallel to this one, investigated colonic epithelial cells 
and colonic organoids, also highlighting HDACs as regulators of hBD2 (Fischer et al., 2016). 
Overall, these findings sharply point towards the importance of HDACs in β-defensin regulation 
and consequently in antimicrobial defense. 
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 Aim of the study  
In IBD, the innate antimicrobial barrier has been shown to be severely compromised – for a big 
part due to different defensin deficiencies. Data on the genetics of epithelial antimicrobial 
immunity concerning colonic CD but also UC remain scarce. Especially the underlying 
mechanisms of the attenuated inducibility of hBD2 in colonic CD (Wehkamp et al., 2003) are 
largely unknown so far. On the contrary, UC patients show strongly increased levels of hBD2 
expression, especially in inflamed tissue (Fahlgren et al., 2003; Wehkamp et al., 2003). Despite 
the large number of identified genetic susceptibility loci in IBD (Khor et al., 2011; de Lange et al., 
2017), the discordance found in monozygotic twin studies emphasizes the role of environmental 
factors as crucial contributors to and modulators of these diseases (Loddo and Romano, 2015). 
Therefore, a feasible rationale for the investigation of epigenetic mechanisms in the context of 
IBD is given since it could help to gain more insight into the crosstalk between environment, 
epigenome and genome (Aleksandrova et al., 2017; Fofanova et al., 2016; Scarpa and Stylianou, 
2012). A role for HDACs in the epigenetically-mediated modulation of hBDs has been 
demonstrated in a number studies (Fischer et al., 2016; Kallsen et al., 2012; Schwab et al., 2008; 
Yin and Chung, 2011) underscoring a potential involvement of HDACs in the β-defensin related 
defects found in colonic IBD.  
Prompted by these findings, I aimed at studying HDAC expression in the epithelium of 
IBD patients by determining the mRNA and protein levels of class I HDACs in a large cohort 
including healthy controls and individuals with active as well as inactive ileal and/or colonic CD 
or UC via RT-PCR and western blotting. Furthermore, immunohistochemistry for those HDACs 
were performed on intestinal biopsy sections. The strategic analysis should allow first insights 
into the overall deacetylation capacity of the intestinal tissue in IBD based on the inflammatory 
status, as well as in comparison to overall healthy tissue and open up promising new research 
avenues regarding epigenetic involvement in disease pathology and could pinpoint potential 
new targets for therapeutic intervention. 
While HDACi have been proposed as therapeutics in IBD (Felice et al., 2014; Glauben and 
Siegmund, 2011), their at most safe appliance demands a profound understanding of the exact 
role of HDACs in intestinal antimicrobial barrier function and inflammatory processes. Thus, it is 
vital to extend the existing body of knowledge on HDAC-mediated epigenetic regulation of the 
inducible hBD2, an IBD-associated, important player in both gut barrier function and 
inflammation. I therefore planned on studying the effects of HDACi on hBD2 expressional 
regulation in colonic epithelial cells in vitro, focusing on the therapeutically relevant probiotic 
EcN as a potent hBD2-inducing factor (Möndel et al., 2009) in addition to IL1β and LPS. Since our 
working group could recently successfully study small intestinal innate immune regulation in an 
ex vivo ileal biopsy culture (Courth et al., 2015), I established a human colonic biopsy culture 
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surviving in a culture medium almost identical to that used for the in vitro experiments 
presented herein to potentially better mimic and refelct the in vivo situation and to integrate the 
more complex tissue context. A substantial cohort was assembled, including IBD-derived and 
healthy control biopsies as well as several originating from colorectal cancer tissue. The latter 
served to examine and dissect the potential impact of the cancer nature inevitably present in 
transformed cell lines on the observed effects in vitro.  
Finally, mechanistic investigations had to be focused on in vitro settings, due to the rare 
and valuable nature of human biopsy material. Since hBD2 has been shown to be, at least in part, 
regulated NF-κB-dependently (Wehkamp et al., 2004a) and NF-κB has been reported to be a 
non-histone protein target of HDACs (Ashburner et al., 2001; Chen et al., 2001; Singh et al., 
2010), I aimed to investigate the potential role of NF-κB in HDAC-mediated hBD2 expressional 
modulation using pharmacological inhibition of NF-κB in addition to employing differentially 
mutated reporter gene constructs of the hBD2 promotor region. 
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2  Material and Methods 
 Material 
Non-listed equipment, consumable items, plastics, or chemicals were conform of 
laboratory standards. 
2.1.1. Equipment 
Equipment Manufacturer 
ABI Prism™310 Sequencer  Applied Biosystems, Germany 
Agilent 2100 bioanalyzer Agilent, USA 
BX63 microscope Olympus, Germany 
DP80 camera Olympus, Germany 
cellSens Dimension imaging software Olympus, Germany 
Enspire® Multimode Plate reader PerkinElmer, USA 
LightCycler® 480 Roche, Germany 
NanoDrop 2000 Spectrophotometer Thermo Scientific, USA 
ChemiDoc™ MP Bio-Rad, USA 
2.1.2. Software 
Program Manufacturer 
EnSpire software PerkinElmer, USA 
Geneious Pro 5.1.7 Biomatter Ltd., New Zeeland 
GraphPad Prism Version 7.03 GraphPad Software, Inc., USA 
Leica SCN400 software Leica, Germany 
LightCycler Software V. 3.5 Roche, Germany 
Image Lab Software 5.1 Bio-Rad, USA 
2.1.3. Consumables 
Item Manufacturer 
LightCycler® 480 Multiwell Plate 96 Roche, Germany 
OptiPlate™ 96 (for Enspire) PerkinElmer, USA 
Columbia Agar plates with 5% Sheep Blood Becton Dickinson, USA 
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2.1.4. Chemicals, kits and antibodies 
2.1.4.1. Chemicals 
Chemical / Reagent Manufacturer 
100bp DNA Ladder Invitrogen, USA 
1kb Plus DNA Ladder Invitrogen, USA 
Asparagine Merck Millipore, Germany 
CnT-Prime (CnT-PR) CELLnTEC, Switzerland 
CnT-Prime-D (CnT-PR-D) CELLnTEC, Switzerland 
CaCl2 Sigma-Aldrich, Germany 
DMEM Life Technologies, USA 
EcoRI NEB, USA 
Eosin Sigma-Aldrich, Germany 
FCS Life Technologies, USA 
Hepes Buffer, 1M Invitrogen, USA 
Helenalin Enzo Life Sciences, Switzerland 
Hematoxylin Merck, Germany 
HotStar Taq DNA-Ploymerase Qiagen, Germany 
Human IL-1ß PeproTech, Germany 
Human TNF-α Sigma-Aldrich, Germany 
L-Lactat Dehydrogenase Roche, Germany 
LPS E. coli serotype O111:B4 Sigma-Aldrich, Germany 
MS-275 (Entinostat) Selleckchem, USA 
Non-Essential Amino Acids Solution 100x  Life Technologies, USA 
Passive lysis buffer Promega, USA 
Penicillin/Streptomycin (Pen/Strep) Life Technologies, USA 
PIC complete Ultra Tablets, EDTA-free Roche, Switzerland 
RNAlater Qiagen, Germany 
Sodium-butyrate Sigma-Aldrich, Germany 
Sodium-pyruvate (100 nM) Life Technologies, USA 
Suberoylanilide hydroxamid acid (SAHA; Vorinostat) InvivoGen, USA 
Triton X Sigma-Aldrich, Germany 
TRIzol Life Technologies, USA 
Trypsin-EDTA Roth, Germany 
Tryptic Soy Broth media (TSB) Becton Dickinson, USA 
TurboFect Transfection Reagent Thermo Fisher Scientific, USA 
 
2.1.4.2. Kits and antibodies 
Kit / Antibody Manufacturer 
AMV Reverse Transcription System  Promega, USA 
Anti-HDAC1 antibody (ab109411) Abcam, UK 
Anti-HDAC2 antibody (ab12169) Abcam, UK 
Anti-HDAC3 antibody (ab7030) Abcam, UK 
Anti-HDAC8 antibody (HPA048560) AtlasAntibodies, Sweden 
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Big Dye Terminator V.1.1 Cycle Sequencing Kit Applied Biosystems, USA 
Cytotoxicity Detection Kit (LDH) Roche, Germany 
Dako REAL™ EnVision™ Detection System Dako, Denmark 
Direct-zol RNA Miniprep Kit ZymoResearch, USA 
Dual-Luciferase® Reporter Assay System Promega, USA 
HotStar Taq DNA-Polymerase Qiagen, Germany 
Human Beta-Defensin2 (hBD2) ELISA Kit Phoenix Pharmaceuticals, USA 
iScript™ cDNA Synthesis Kit Bio-Rad, USA 
LightCycler®480 SYBR Green I Master Kit Roche, Switzerland 
MTT Sigma-Aldrich, Germany 
QIAprep Spin Miniprep Kit Qiagen, Germany 
QIAquik PCR Purification Kit Qiagen, Germany 
Quick RNA Miniprep Kit ZymoResearch, USA 
RNA 6000 Nano Assay Agilent, USA 
RNeasy Kit Qiagen, Germany 
RNeasy Mini Kit Qiagen, Germany 
TOPO TA Cloning Kit Invitrogen, USA 
2.1.5. Media and buffer 
2.1.5.1. Cell culture 
CaCo2/HCT116 cultivation 
media 
 Hgep cultivation media 
DMEM 435 ml  CnT-PR  
FCS 50 ml  CnT-PR-D (+/-Ca2+)  
Sodium Pyruvate 5 ml  Ca2+ 1.2 mM 
NEAA 5 ml    
Pen/Strep 5 ml    
     
Colonic biopsy cultivation media    
DMEM 430 ml    
FCS 50 ml    
Sodium Pyruvate 5 ml    
NEAA 5 ml    
Pen/Strep 10 ml 
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2.1.5.2. Other 
TAE Buffer (50x)   Protein lysis buffer/PIC 
Tris 242 g  50 mM Tris-HCl 3,94 g 
Acetic acid 57,1 ml  0,25 mM NaCl 7,30 g 
0,5M EDTA pH 8,0 100 ml  0,1 TritonX 100 500 µl 
H2O up to 1 l  5 mM EDTA  0,73 g 
   Add 1 PIC (Roche) tablet to 25 ml lysis buffer  
TBS (10x)     
NaCl 400 g    
KCl  10 g    
Tris-Base 150 g    
HCl  set to pH 7,4  1% Agarose gel  
H2O up to 5 l  Agarose 1 g 
   10x FA Gel-buffer 10 ml 
TBS-T   H2O 1.86 g 
TBS 1x in H2O  HCl/NaOH set to pH 7 
Tween20 1%  H2O, RNAse-free 87 ml 
   boil and cool down to 50 °C 
FA Gel-buffer (10x)   Formaldehyde (37%) 3 ml 
MOPS 41.85 g    
Sodium acetate 4.1 g    
EDTA 1.86 g    
HCl/NaOH set to pH 7    
H2O, RNAse-free up to 1l    
2.1.6. Plasmids and sequences 
Oligonucleotides were purchased from MWG Biotech (Ebersberg, Germany), High Purity Salt 
Free purified. 
Table 1: Primer for real-time PCR 
TARGET  SENSE (5'-3') ANTISENSE (5'-3') 
   
Human   
hBD2 ATC AGC CAT CAG GGT CTT GT GAG ACC ACA GGT GCC AAT TT 
hBD1 GGC CTC AGG TGG TAA CTT TCT TTC TTC TGG TCA CTC CCA GC 
IL8 ATG ACT TCC AAG CTG GCC GTG GC TCT CAG CCC TCT TCA AAA ACT TC 
Ki67 GAG AAG AAC CTC TGC TCC CCA TTT GCT GCA TTC TGT GCA CTG 
β-Actin GCC AAC CGC GAG AAG ATG A CAT CAC GAT GCC AGT GGT A 
HDAC1 CCA AGT ACC ACA GCG ATG AC TGG ACA GTC CTC ACC AAC G 
HDAC2 TGA AGG AGA AGG AGG TCG AA GGA TTT ATC TTC TTC CTT AAC GTC 
TG 
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HDAC3 GAG TGG CCG CTA CTA CTG TC ATT CAA CGC ATT CCC CAT GC 
HDAC8 GCT GGT CCC GGT TTA TAT CT TGC AGT GCA TAT GCT TCA ATC 
   
 
Table 2: Plasmids 
Name Description Source 
hBD2-2338-
luc 
Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector 
Prof. Jürgen Harder, Kiel; 
(Harder et al., 2000; 
Wehkamp et al., 2004a) 
NF-κB-mut1-
luc 
Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector, NF-κB-binding site mutated at 
position -205 to -186; see Figure 31 
 Prof. Jürgen Harder, 
Kiel; (Harder et al., 2000; 
Wehkamp et al., 2004a) 
NF-κB-mut2-
luc 
Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector, NF-κB-binding site mutated at 
position -596 to -572; see Figure 31 
Prof. Jürgen Harder, Kiel; 
(Harder et al., 2000; 
Wehkamp et al., 2004a) 
NF-κB-
mut1+2-luc 
Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector, both NF-κB-binding sites 
mutated; see Figure 31 
Prof. Jürgen Harder, Kiel; 
(Harder et al., 2000; 
Wehkamp et al., 2004a) 
AP1-mut-luc Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector, AP1-binding site mutated at 
position -127 to -121; see Figure 31 
Prof. Jürgen Harder, Kiel; 
(Harder et al., 2000; 
Wehkamp et al., 2004a) 
NF-κB-
mut1+2+AP1-
luc 
Luciferase Reporter: 2,3kB of hBD2 promoter region 
in pGL3-Basic vector, both NF-κB-binding sites and 
the AP1-binding site mutated; see Figure 31 
Prof. Jürgen Harder, Kiel; 
(Harder et al., 2000; 
Wehkamp et al., 2004a) 
pNF-κB-luc Luciferase Reporter: tandemly repeated NF-κB 
binding sites in pGL3-Basic vector 
Clontech BD 
Biosciences, USA 
pAP1-luc Luciferase Reporter: tandemly repeated AP1 binding 
sites in pGL3-Basic vector 
Clontech BD 
Biosciences, USA 
pGL3 Basic Luciferase Reporter vector: includes Luciferase gene 
without vector 
Promega, USA 
Renilla CMV Renilla reporter gene with CMV-promoter Promega, USA 
2.1.7. Cell lines and bacteria 
2.1.7.1. Cell lines 
The majority of experiments has been conducted with the human colonic epithelial 
adenocarcinoma cell line CaCo2 subclone TC7 (Chantret et al., 1994; Sambuy et al., 2005) which 
were received from Oliver Burk, IKP Stuttgart, Germany. In general, CaCo2 cells undergo 
spontaneous enterocytic differentiation (Chantret et al., 1988). The TC7 subclone has been 
isolated from the parental line at a late passage (Fogh et al., 1977) and represents a more 
homogenic and faster growing subculture with specific characteristics in terms of sucrase-
isomaltase expression, transport function, and differentiation (Chantret et al., 1994). In our 
experiments, cells were used at an internal early passage of about 25 - 40. 
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Additionally, HCT116 cells (Brattain et al., 1981) have been used as an additional 
colorectal carcinoma cell line with an epithelial morphology. They have been kindly provided by 
Heiko van der Kuip, IKP Stuttgart, Germany.  
Furthermore, human primary gingival epithelial cells (hgeps; CELLnTEC, Switzerland) 
have been utilized in a pilot experiment to study the observed effects from cancerous cell lines in 
a normal epithelial setup. 
2.1.7.2. Bacteria 
Table 3: Bacteria used  
Species Serotype Characteristics Source 
E. coli Nissle 1917 (DSM6601) O6:K5:H1 Apathogen, 
pharmaceutical strain 
ACS 
ACS:  Ardeypharm Collection of Strains, Herdecke, Germany 
2.1.8. Patients 
All patients and controls included in this study gave their written and informed consent after 
they were informed about the study purpose, sample procedure, and potential adjunctive risks 
before being endoscoped because of diagnostic reasons. The study protocol was previously 
approved by the ethical committee of the University Hospital Tübingen, Germany and all 
experiments were conducted in accordance with the relevant guidelines and regulations. All 
tissue samples used for mRNA analysis were part of the Stuttgart cohort which has been 
continuously collected at the Robert-Bosch Hospital, Stuttgart, Germany, since 2001. Diagnosis 
was performed according to standard criteria including clinical, radiological, endoscopic, and 
histopathological results. The standard Vienna classification based on the disease localization in 
Crohn’s disease patients was applied to subgroup them into L1 (ileal involvement), L2 (colonic 
involvement), and L3 (ileal and colonic involvement). Further subgrouping of included patients 
into inflamed or non-inflamed was done based upon clinical phenotype data. Samples for 
western blot and immunohistochemical analyses were obtained in the same way as for the 
mRNA experiments. Biopsies for ex vivo culture studies were sampled from the sigmoidal colon 
of healthy controls, patients with Crohn’s disease, and patients with ulcerative colitis during 
routine colonoscopy at the Robert-Bosch Hospital, Stuttgart, Germany and the University 
Hospital Tübingen, Germany. Biopsies from colorectal tumors were obtained within 90 minutes 
after resection of the tumors at the Marienhospital, Stuttgart, or at the University Hospital 
Tübingen, Germany and were treated right away. The detailed numbers of patient biopsies used 
for different experiments are specified in the according figure legends and under 2.1.8.1 and the 
following (Stebe-Frick et al., 2018). 
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2.1.8.1. Ex vivo biopsy cohort 
Group 
N         
[total] 
Gender            Age                
[mean±SEM] f m 
L1 Patients 15 47 % 55 % 47.4 ± 3.34 
L3 Patients 14 29 % 71 % 38.29 ± 2.93 
UC Patients 14 36 % 64 % 39.92 ± 2.7 
Controls 13 53 % 47 % 53.69 ± 3.4 
Colonic 
carcinoma 
4 25 % 75 % 66.33 ± 9.5 
 
2.1.8.2. In vivo ileal biopsy cohort (numbers taken from the HDAC2 mRNA 
measurement) 
 
2.1.8.3. In vivo colonic biopsy cohort (numbers taken from the HDAC2 mRNA 
measurement) 
Group 
N         
[total] 
Gender            Age                
[mean±SEM] 
Localization Inflammation (UC) 
f m L2 L3 UC + - 
Patients 100 53 % 47 % 37  ± 1.2 22% 33% 45% 40% 60% 
Controls 24 58 % 42 % 46  ± 4.2    
 
 
2.1.8.4. Patient samples for western blotting and immunohistochemistry 
For western blot analysis of ileal tissue, five ileal specimens of healthy controls and five ileal 
specimens of uninflamed L3 CD patients were analyzed. For western blot analysis of colonic 
tissue, five colonic specimens of healthy controls and uninflamed L3 CD patients, as well as 4 
uninflamed UC specimens were used for HDAC1 and 2 detection. Five further samples of all 
three groups (healthy controls, L3 and UC) have been used for HDAC3 analysis. All patients were 
between 18 and 73 years old and female and male numbers were relatively equal in distribution. 
Group 
N         
[total] 
Gender            Age                
[mean±SEM] 
Localisation     
f m L1 L3 
Patients 60 52 % 45 % 40 ± 1.7 47 % 53 % 
Controls 25 56 % 44 % 51 ± 4   
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Sampling has been conducted in the same way as for all the other intestinal biopsies used in this 
study. Exemplarily shown immunohistochemical stainings from intestinal tissue slices and those 
used for the semiquantitative analysis of HDAC1 in the human ileum (cf. Figure 10) had been 
sampled from patients that were mostly also included in the ex vivo biopsy cohort (see Chapter 
2.1.8.1) and therefore fit into the same age range and gender distribution.  
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 Methods 
2.2.1. Cell culture methods 
2.2.1.1. Cell line cultivation 
CaCo2/TC7 and HCT116 cells were cultured in CaCo2/HCT116 cultivation media in a humidified 
atmosphere at 37°C with 5% CO2. For maintenance, cells were passaged every 3-4 days. Both cell 
lines were used for a maximum of 40 passages. Experiments were performed in FCS- and 
Pen/Strep-free medium in 12-well-plates on cellular monolayers at about 80-90 % confluency. 
After a total treatment duration of 20 hrs mRNA and protein was subsequently analyzed (Stebe-
Frick et al., 2018).  
Hgep cells were first cultured in CnT-PR media until they nearly reached confluency. 
Then they were switched to CnT-PR-D medium containing 1.2 mM Ca2+ to stimulate 
differentiation for either 48 or 72 hrs. Cells were then treated as depicted in 2.2.1.3 Treatment of 
cells and biopsies. 
2.2.1.2. Ex vivo biopsy cultivation 
Freshly collected colonic biopsies were utilized to study the expression of hBD2 in a more 
complex ex vivo tissue context as compared to mono-layered cell culture. After receiving the 
specimen, they were immediately washed several times with ice-cold PBS containing 10% (v/v) 
Pen/Strep, transferred into wells of a 24-well-plate with 1 ml of designated media consisting of 
DMEM containing 2% (v/v) Pen/Strep to minimize bacterial overgrowth and incubated at 37°C 
with 5% CO2 for a total treatment duration of 20 hrs. Thereafter, biopsies were put into 
RNAlater until RNA isolation and the supernatant was collected for subsequent quality control. 
The integrity of total RNA was controlled using the RNA 6000 Nano Assay. The viability of the 
samples was tested via the supernatants using LDH-ELISA (Stebe-Frick et al., 2018). 
For the hematoxylin and eosin staining of biopsy sections, biopsies were either directly 
fixed with 4% formalin or after 20 hrs of treatment (Stebe-Frick et al., 2018).  
Biopsies which were used for immunohistochemcial analysis of class I HDAC protein 
expression were put into 4% formalin. After incubation overnight, the biopsies were fixed in 
paraffin. Slides with a thickness of 7 µm were prepared and used for immunohistochemistry 
(Stebe-Frick et al., 2018). 
2.2.1.3. Treatment of cells and biopsies 
Cells or biopsies were pretreated with suberoylanilide hydroxamid acid (SAHA; Vorinostat), 
Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl] carbamate (MS-275; 
Entinostat) (both dissolved in Dimethyl sulfoxide (DMSO)), or sodium-butyrate (SB) (dissolved 
in H2O) for 2 hrs prior to the start of the stimulation with either heat-inactivated E. coli Nissle 
1917, Interleukin 1β (IL1β), or lipopolysaccharide (LPS) from E. coli serotype O111:B4 which 
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took place in parallel to HDAC inhibition for additional 18 hrs adding up to a total of 20 hrs of 
treatment. Treatment with the NF-κB inhibitor Helenalin took place for 1h right at the beginning 
of the 20 hrs and was then removed to avoid cytotoxic effects (Stebe-Frick et al., 2018). 
The non-toxic character of the treatment reagents was confirmed via MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-tests which are based on reduction of 
the tetrazolium salt (Berridge and Tan, 1993; Mosmann, 1983) performed by a technician and by 
stratifying for DMSO effects on cells with concentrations of up to 1% DMSO which showed to 
have no effects on target of interest mRNA expression. 
2.2.1.4. Transient transfection, luciferase assay and promoter activity 
CaCo2/TC7 cells seeded in 24 well plates were transfected with 500 ng DNA using 1 µl Turbofect 
transfection reagent according to manufacturer’s protocol at about 70% confluency. HBD2 
reporter plasmids used in this work (hBD2-2338-luc, NF-κB-mut1-luc, NF-κB-mut2-luc, NF-κB-
mut1+2-luc, NF-κB-mut1+2+AP1-luc, AP1-mut-luc) have been described previously (Harder et 
al. 2000, Wehkamp et al. 2004) and are specified in Table 2. Briefly, these plasmids carry 
differentially mutated 2338 bp of the wildtype hBD2 promoter affecting positions in NF-κB or 
AP1 transcription factor binding sites. CMV-Renilla plasmid was used as an internal standard to 
which firefly luciferase activity was normalized. Promoterless pGL3basic firefly luciferase vector 
(Promega, USA) being the backbone of the aforementioned hBD2 reporters, was used as control. 
Used cultivation media was the above described DMEM used for cell culture but without FCS and 
Pen/Strep. 24 hrs post transfection, treatment with indicated media or agents was started as 
described above in “treatment of cells and biopsies”. After 20 hrs of treatment cells were lysed 
for measurement of luciferase activity with the Dual Luciferase Reporter Assay- adding 20 µl of 
firefly luciferase reagent (LARII) and after measuring the luminescence adding 20µl of Stop and 
Glow reagent to quench the firefly luciferase reaction and initiate Renilla reaction. 
Bioluminescences was measured using an Enspire PlateReader. Firefly luciferase signals were 
normalized to Renilla activities, the latter representing the transfection efficiency. Each 
transfection was performed in triplicates in three or more independent experiments (Stebe-
Frick et al., 2018). 
2.2.2. Bacterial methods 
Cultivation and inactivation of bacterial cultures 
E. coli Nissle 1917 (EcN) has been heat-inactivated for all experiments as has been described 
before (Wehkamp et al., 2004a). Heat-inactivated bacteria have been used, since it has been 
shown that they show the same effect as living EcN (Wehkamp et al., 2004a). EcN has been 
grown overnight in trypticase soy broth (TSB) medium at 37°C under constant shaking. 
Anaerobic bacteria (Bifidobacteria) were first cultured on blood agar, on the next day 
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transferred to TSB media and then grown in anaerobic jars for additional 24 hrs. The next 
morning, 100 µl of the bacterial suspension were diluted in 10 ml of TSB medium to keep 
bacteria in a linear growth phase and grown under shaking conditions at 37°C. After about 3 hrs, 
EcN were heat killed in a water bath at 65°C for 45 min and then diluted to a concentration of 3 × 
108 cells/ml in FCS-free and Pen/Strep-free DMEM cell culture medium (Stebe-Frick et al., 
2018). 
2.2.3. Nucleic acid methods 
2.2.3.1. RNA isolation and cDNA synthesis 
RNA isolation from biopsies- cohort and ex vivo 
Acidic phenol/chloroform partitioning of RNA into an aqueous supernatant was carried out to 
isolate RNA from cohort biopsies. For this, TRIzol reagent was used according to the 
manufacturer’s protocol (Life technologies). Frozen biopsies were pestled and TRIzol, containing 
protein denaturating (including RNAses) guanidinthiocyanate, was added. The acidic phenol 
dissolves DNA and protein.. In the next step, chlorophorm was added to create different layers. 
The uppermost aqueous phase containing the RNA was carefully removed into a fresh tube and 
precipitated with isopropanol. Ethanol washing steps were followed by RNA dissolution in 
DEPC-H2O and storage at -80°C. 
From ex vivo treated biopsies RNA was isolated using the Direct-zol RNA Miniprep Kit 
(ZymoResearch) according to the manufacturer’s protocol. The method is based on the same 
principles using TRIzol reagent as described above. 
RNA isolation from cell culture experiments was done using the RNeasy Mini Kit 
(QIAgen) or the Quick RNA Miniprep Kit (ZymoResearch) based on the company’s protocols. The 
gained pellet was resolved in 25-50 µl DEPC-H2O and stored at -80°C. 
RNA quantification and quality control 
RNA quantity was determined by a NanoDrop spectrophotometer. UV light (λ=260 nm) 
stimulation of RNA samples leads to some absorption of the light by the nucleic acids, 
proportional to their quantity which is shown in OD. Furthermore, possible contamination can 
be detected due to the fact that proteins, phenol and other components absorb λ=280 nm. To 
determine contaminations the ratio of 260/280 nm for RNA is calculated, which should be 
around 2.0 for RNA.  
To ensure good RNA quality for real-time PCR, it was evaluated using the Agilent RNA 
600 nano kit and the Agilent 2100 bioanalyzer (Agilent) according to the manual. 18S and 28S 
ribosomal RNA bands were analysed to assure that the RNA was not degraded. Samples with 
degraded RNA were excluded from the study. 
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Reverse transcription – cDNA synthesis 
Since DNA is necessary as a template for real-time PCR, RNA had to be reversely transcribed into 
cDNA. For biopsy cohort RNA samples, this was performed using the AMV reverse transcriptase 
kit with oligo-dT primers to provide amplification only of mRNA by using the polyA+-tail as 
template. For cell culture and ex vivo treated biopsies RNA the iScript™ cDNA Synthesis Kit (Bio-
Rad) was utilized following manufacturer instructions. A final concentration of 10 ng/µl RNA 
was used as template in each experimental setup. 
2.2.3.2. Cloning (TA cloning, primer design) 
Real-time PCR analyses (based on SYBR Green) were performed in absolute quantification. 
Specific primers targeting the desired DNA sequence and plasmids had to be generated. Primers 
were designed using Geneious software and NCBI Primer Blast to ensure there were no off-
target sequences and to receive primer locations spanning exons and about 20 bp leading to an 
amplification of a product of between 80 and 250 bp. All primers were double checked and their 
sequences are specified in Table 1. 
Construction of plasmid standards for absolute mRNA quantification of specific products 
was achieved using the TA cloning technique according to TOPO TA Cloning Kit procedures. 
Therefore, designed primers were utilized in a PCR reaction amplifying cDNA from human 
intestinal tissue. Achieved amplicons with TA-overhangs created by the HotStarTaq DNA 
polymerase were separated by an agarose gel, purified with the QIAquick PCR purification kit 
and ligated into an open pCR 2.1-TOPO-Vector, which has thymidine (T’) and adenine (A’) 
overhangs for simple ligation. The ligated product was transformed into competent Top10 E. coli 
by a 45 second heat-shock and plated on an agar plate coated with ampicillin and X-Gal. Bacteria 
containing the plasmid plus the insert exhibit a white phenotype and were picked for further 
cultivation in LB-media. Purification of plasmids was carried out using the QIAprep spin 
Miniprep Kit and verification was achieved by a control digestion using the EcoRI restriction 
enzyme. All plasmids were then controlled by sequencing using the Big Dye terminator 3.1 kit 
based on the the chain-terminator method according to Sanger (Sanger et al., 1977) in an ABI 
3500 DX sequencer according to manufacturer’s protocol. 
2.2.3.3. Real-time PCR 
The achieved plasmid standards described above were used for quantitative real-time PCR 
measurements. Quantification of specific DNA molecules is achieved by adding the fluorescent 
dye SYBR Green that can intercalate with double-stranded DNA and the measurement of the 
melting curves. In each PCR cycle, emitted fluorescence is determined which rises with the  
increasing amount newly synthesized amplicons creating a direct proportionality between 
fluorescence and the amount of target in the samples. Standard DNA plasmid samples whose 
concentration was determined at a NanoDrop spectrophotometer with the appropriate insert 
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were used for absolute quantification, as they allowed the generation of a calibration curve. For 
this, plasmid standards were diluted from 1ng in a 1:10 manner till a concentration of 10-7ng 
was achieved. Real-time PCR was performed using indicated primers specified in Table 1 and 
measured in a Roche Light Cycler 480 as given in the manufacturer’s protocol. Thereby the 
SYBR® Green master mix contains all PCR components plus the SYBR Green dye. In general, the 
PCR started with a first denaturation step and subsequently 40 amplification cycles. The 
annealing temperature was specific for each assay and PCR details are specified in Table 4. Each 
run was analyzed for efficiency and quality using the Light Cycler software.  
Table 4: Real-Time PCR program 
Target Denaturation Amplification Melting curve 
IL-8; Ki67; 96°C – 5 min. 96°C – 10 s 
62°C – 5 s 
72°C – 10 s 
95°C – 1 s 
60°C – 15 s 
95°C – ∞ 
hBD2 96°C – 5 min. 95°C – 10 s 
60°C – 5 s 
72°C – 10 s 
95°C – 1 s 
58°C – 15 s 
95°C – ∞ 
HDAC1, HDAC3, HDAC8; hBD1 97°C – 5 min. 96°C – 10 s 
62°C – 5 s 
72°C – 10 s 
95°C – 1 s 
60°C – 15 s 
99°C – ∞ 
HDAC2 96°C – 5 min. 96°C – 10 s 
60°C – 5 s 
72°C – 10 s 
95°C – 1 s 
58°C – 15 s 
95°C – ∞ 
ß-Actin 95°C – 10 min. 95°C – 15 s 
60°C – 5 s 
72°C – 10 s 
95°C – 1 s 
65°C – 15 s 
95°C – ∞ 
2.2.4. Protein methods 
2.2.4.1. LDH test 
The viability of treated biopsies was tested via their supernatants using lactate dehydrogenase 
(LDH) -ELISA (Roche) according to manufacturer’s protocol. Lactate dehydrogenase (LDH) is a 
soluble, cytosolic enzyme which is released by every dying cell whose membranes lose their 
integrity during the process of apoptosis or necrosis. This way, LDH concentration in cell or 
tissue culture supernatants can be used as a marker for cell death. The cytotoxicity detection kit 
(LDH) from Roche serves to measure a colorimetric change happening when LDH reduces NAD+. 
Here, the supernatants of all treated biopsies were tested and measured in a plate reader. DMEM 
culture media was the negative control and biopsies treated with 2% TritonX served as positive 
controls. Samples with LDH values higher than 200 at 37° after 15 mins were excluded from the 
study. 
   
38 MATERIAL AND METHODS 
2.2.4.2. Immunohistochemistry 
Immunohistochemical stainings were performed based on the EnVision™ technique by Dako 
according to their protocol.  
Class I HDACs were detected in ileal (n=29) and colonic (n=23) biopsy tissue from 
patients with Crohn’s disease (ileum n=12, colon n=13) or ulcerative colitis (ileum n=10, colon 
n=7) and from healthy controls (ileum n=7, colon n=3). 
Dewaxing, antigen retrieval and endogenous blocking, was performed according to standard 
protocols. Descending alcohol concentrations, a 30 min steam treatment in target retrieval 
solution was used at pH 6 (S1699, 1:10; Dako) for HDAC2 and HDAC3 and at pH 9 for HDAC1 
and HDAC8. Furthermore, an endogenous peroxidase blocking solution (S2023, Dako), was 
applied Primary antibodies were used in the following dilutions at 4 °C overnight: 1:500 
(HDAC1), 1:10.000 (HDAC2), 1:250 (HDAC3), and 1:10 (HDAC8), all in antibody diluent (S2022, 
Dako). After washing with TBST, a horse reddish peroxidase (HRP) conjugated secondary 
antibody was applied for 30 min at room temperature. Detection of the secondary antibody was 
accomplished using the kit DAB solution. Counterstaining of cell nucleii was done using 
hematoxylin Gill II 25 % for 7 seconds. 
Ex vivo biopsy tissue integrity after cultivation was evaluated via a hematoxylin and 
eosin staining of biopsy sections. Tissue slides were 7 µm thick and used for standard staining 
procedures with hematoxylin for 7 mins and eosin for 3 mins. 
2.2.4.3. Protein quantification 
To measure the amount of hBD2 protein in CaCo2/TC7 cell lysates, an enzyme-linked 
immunosorbent assay (Human Beta-Defensin2 (hBD2) ELISA Kit; Phoenix Pharmaceuticals, 
USA) was performed according to the manufacturer’s protocol. For this, cells were pelleted at 
4°C and washed twice with ice cold PBS. Pellets were shock-frozen in liquid nitrogen until final 
usage. Lysis of cells was achieved by adding 30-50 µl of whole protein lysis buffer containing a 
protein inhibitor cocktail (PIC) to the pellet, incubating for 30 mins on ice under occasional 
vortexing. After that, lysed cells were centrifuged at 4 °C/10000g for 25 mins. Protein 
concentration was determined out of the supernatants using the Bradford method (Stebe-Frick 
et al., 2018). 
2.2.4.4. Western blotting 
Western blotting of intracellular proteins to determine the relative amounts of class I HDACs in 
human intestinal tissue of patients with IBD and healthy controls and to investigate the level of 
acetylation at histone level after usage of HDACi in CaCo2/TC7 cells was done with and by the 
Lab of Dr. Dr. Sascha Venturelli, Tübingen. For the description of the method, also see (Venturelli 
et al., 2013). Cellular proteins were separated on 10% SDS-polyacrylamide gels (for the 
detection of HDAC1, HDAC2, HDAC3, HDAC8 and vinculin as control) or 12% SDS-
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polyacrylamide gels (for the detection of H3, acetylated H3 and vinculin) under reducing 
conditions and then transferred to polyvinylidene difluoride membranes (Hybond-P, Amersham 
Biosciences, Piscataway, NJ, USA). Membranes were blocked for 1 h in Tris-buffered saline (TBS, 
150 mmol/l NaCl, 13 mmol/l Tris, pH 7.5) containing 5% non-fat dry milk powder. Next, the 
membranes were incubated with anti-vinculin (1∶5,000, Sigma-Aldrich, Germany), anti-
HDAC1(1:500, Abcam plc, Cambridge, UK), anti-HDAC2 (1:10,000, Abcam plc), anti-HDAC3 
(1:1000, Abcam plc), anti-HDAC8 (1:200, Santa Cruz Biotechnology, Dallas, USA), anti-H3 
(1:10,000, Active Motif, La Hulpe, Belgium) anti-acetyl-histone H3 (1∶8,000, Millipore, USA) 
overnight at 4°C, then washed three times with TBS-T (TBS containing Tween 20) and incubated 
with peroxidase-conjugated anti-rabbit (1∶8,000, Bio Rad, USA) or anti-mouse (1∶8,000, Bio 
Rad) for 45 min. Membranes were washed three times in TBS-T and further detection was 
performed by the ECL Western blotting detection system on Hyperfilm-ECL (Amersham 
Biosciences). Densitometrical analysis of obtained bands was done with a ChemiDoc™ MP 
Imager (BioRad) using associated Software Version 5.1. To obtain images, membranes were 
scanned using a Lexmark CX510de office scanner. 
2.2.5. Microscopy 
Examination of stained tissue slides was carried out with an BX63 microscope. Picture 
acquisition was done using a DP80 camera and the imaging software cellSens Dimension.  
Semi-quantitative analysis of HDAC1 protein expression on immunohistochemically 
stained ileal tissue was analyzed blinded. The approximate number of positively stained cells in 
either the crypt or the villus areas of was estimated separately (in %) by four different 
individuals. 
2.2.6. Statistical methods 
Statistical evaluation was done using the GraphPad Prism software. To examine the power of 
observed differences between groups, several statistical tests were performed. Testing of 
differences between two groups was done using non-parametric tests. Not normally distributed 
data was subjected to a Mann-Whitney test. Unpaired t-tests were conducted when data showed 
a Gaussian distribution. Fold changes, normalized to control treatment, were analyzed by 
Wilcoxon signed rank tests or Mann-Whitney tests as indicated in the corresponding figure 
legends. Shown are mean values + sem unless indicated otherwise. 
P-values showing the statistical significance were displayed by asterisks: 
p>0.05 = ns; p≤0.05 = *; p≤0.01 = **; p≤0.001 = ***; p<0.0001 = **** 
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3 Results 
 Differential expression of class I histone deacetylases 
in the gastrointestinal tract 
The current understanding of IBD pathology includes genetic susceptibilities (Schreiber et al., 
2005; Halfvarson et al., 2006; Jostins et al., 2012; McGovern et al., 2015) as well as 
environmental influences driving intestinal inflammation into a chronically activated status. 
Such environmental influences can be of microbiological nature or be derived from an 
individuals life style, hygene standards, dietary habits, or antibiotics use (Legaki and Gazouli, 
2016). The emerging field of epigenetics could dissect the likely present interactions between 
environment and genome in the context of IBD and would allow a better understanding of 
disease pathology (Fogel et al., 2017; Legaki and Gazouli, 2016; Scarpa and Stylianou, 2012; 
Ventham et al., 2013). While previously a link between intestinal homeostasis, gut inflammation 
and HDAC function has been established, so far mainly animal studies have been done to 
investigate a potential role in IBD like settings (Felice et al., 2014; Glauben and Siegmund, 2011). 
HDACs are increasingly recognized as key factors in regulating tissue homeostasis via epigenetic 
control of gene expression (Alenghat et al., 2013; Turgeon et al., 2013). In the context of chronic 
intestinal inflammation, a role of HDAC activity has been suggested in murine models of colitis 
(Glauben et al., 2006; Turgeon et al., 2014). The current body of knowledge points out an 
important role for class I HDACs. However, so far not much is known about their expression 
status in IBD patients. Therefore, the following strategic analysis of class I HDAC expression in 
active as well as inactive IBD allows for some first insights into the overall deacetylation capacity 
of the intestinal tissue in IBD based on their inflammatory status, as well as in comparison to and 
within overall healthy tissue. 
3.1.1. Class I HDACs in the ileum and colon of healthy controls and 
patients with inflammatory bowel diseases 
Class I HDACs, being comprised of HDAC1, 2, 3 and 8, have been investigated. For this, mRNA 
expression levels were determined via quantitative real-time PCR in ileal and colonic samples of 
healthy controls (n=24) as well as patients with active and inactive IBD including ileal CD (L1 
n=28), ileocolonic CD (L3 n=32), colonic CD (L2 n=22), and ulcerative colitis (UC) (n= 45). 
Furthermore, western blotting was used to analyze protein levels. Immunohistochemistry 
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served to gain insight into the location and distribution of specific HDACs in intestinal tissue 
(Figure 4). 
 
 
Figure 4: Experimental setup for the investigation of Class I HDAC expression in IBD 
Ileal and colonic biopsies were collected from healthy individuals and patients with either a manifestation 
of CD or UC constituting the IBD cohort from which RT-PCR analysis was conducted. Several biopsies out 
of this cohort were processed to isolate whole protein to run western blot analyses. Additional biopsies 
were collected and subjected to immunohistochemical stainings. 
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3.1.1.1. mRNA analyses 
First, the overall expression levels of HDAC1, 2, 3 and 8 were analyzed in ileal and colonic tissue 
of healthy individuals. A direct comparison of these levels can be seen in Figure 5. HDAC2 seems 
to be the most abundant class I HDAC in terms of mRNA expression levels in both ileum and 
colon with around 45.000 to 70.000 transcripts. HDAC8 shows the lowest abundancy in both 
tissues. 
Clear mRNA expression differences between inflamed and non-inflamed patient samples as well 
as in comparison to healthy controls became apparent. The strongest effects on the mRNA level 
were seen for HDAC2 in ileal tissue of CD and for HDAC1 and 2 in colonic tissue of CD as well as 
UC where they were significantly further reduced during inflammation (Figure 6). HDAC3 and 
HDAC8 were only reduced in UC specimens, in the case of HDAC3 this seemed to be only the case 
in inflamed samples. HDAC8, however, is diminished independently from inflammation in UC 
patient samples (Figure 6). Taken together, class I HDACs seem to be differentially expressed in 
IBD patients, although only reduced statuses were observed on the mRNA level. 
 
Figure 5: Class I HDAC expression in healthy human intestinal tissue 
Class I HDAC mRNA expression in human ileal (n=25) and colonic (n=24) tissue of healthy controls 
determined by quantitative RT-PCR. Shown are absolute transcript levels. 
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Figure 6: Differential expression of Class I HDAC mRNA in inflammatory bowel diseases 
Ileal and colonic biopsies from patients biopsies (n=60 for ileal (L1 n=28; L3 n=32) and n=100 for colonic 
tissue (L2 n=22; L3 n=33; UC=45, inflamed n=18, UC uninflamed n=27) and controls (n=25 for ileal tissue 
and n=24 for colonic tissue) were analyzed for Class I HDACs 1 (a), 2 (b), 3.(c) and 8 (d) mRNA expression 
via RT-PCR. Shown are relative transcript levels. * p<0.05, ** p≤0.01, *** p≤0.001, **** p<0.0001 evaluated by 
Mann-Whitney u test. 
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3.1.1.2. Protein analyses 
Statement on collaborative efforts for this chapter 
Western blotting of intracellular proteins to determine the relative amounts of class I HDACs in 
human intestinal tissue of patients with IBD and healthy controls and to investigate the level of 
acetylation at histone level after usage of HDACi in CaCo2/TC7 cells was done in cooperation 
with and by the Lab of Dr. Dr. Sascha Venturelli, Tübingen. Patient samples from the Stuttgart 
IBD cohort were processed by Sabrina Stebe-Frick. Results of the Western blots were discussed 
and interpreted with the support of Dr. Dr. Sascha Venturelli. Final densitometrical analysis, 
evaluation and figure preparation was done by Sabrina Stebe-Frick. 
Western Blotting 
For western blot experiments intestinal biopsies from patients from the IBD cohort had to be 
used that had not been included in the mRNA analysis. The specimens regarded here have been 
sampled from further patients that had not been included in the “mRNA cohort”. 
For western blot analysis of the ileum, five ileal specimens of both healthy controls and 
uninflamed L3 CD patients were analyzed and evaluated densitometrically. Western blots of 
HDAC1 and 2 from ileal tissue lysates revealed generally very low levels of HDAC1 in the ileum 
of controls. In L3 patients without acute inflammation a tendency towards increased protein 
levels of HDAC 1 and 2 was observed (Figure 7). This is in contrast to the mRNA data where 
HDAC1 displayed no differences in the ileum of L3 patients. Similarly, HDAC2 mRNA levels were 
decreased in L3 patient ileum but protein seems to be augmented. HDAC3 protein showed no 
difference which is in line with the mRNA data (Figure 7, cf. Figure 6). Unfortunately, western 
blots for the detection of HDAC8 protein were unsuccessful up to date due to technical reasons 
and a limited amount of protein from the same patients. 
*
 
Figure 7: HDAC1, 2 and 3 protein levels in ileal tissue of CD patients 
Western blots and corresponding densitometrical analyses of ileal tissue homogenate from healthy controls 
(n=5) and uninflamed L3 patients (n=5). Each lane on the western blots represents one patient. * p<0.05 
evaluated by Mann-Whitney u test. 
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The single sample lanes of the western blots showed some interindividual variations in protein 
levels, especially for HDAC1 in L3 and HDAC2 in controls and L3 patients. This observation is in 
line with the growing knowledge on seemingly substantial inter- and even intraindividual 
variations in epigenotypes (Flanagan et al., 2006; Fraga et al., 2005; Petronis et al., 2003). 
Western blots of HDAC1 and 2 from colonic tissue showed no difference between 
controls and uninflamed IBD patients, neither in L3 nor UC patients (Figure 8). However, a slight 
tendency towards a reduction for HDAC1 and an increase for HDAC2 in UC patients could be 
observed. Furthermore, the investigated UC patient samples seemed to have a diminished 
protein expression of HDAC3 (Figure 8). A fifth UC patient sample has also been tested for 
HDAC1 and 2 but had to be applied to another blot due to technical reasons and has therefore 
not been included in the densitometrical analysis. It is of note, however, that no HDAC1 had been 
detectable in that fifth sample and a similar band for HDAC2 was observed in that fifth patient 
sample as compared to the other four, showing a consistent trend. 
*
 
Figure 8: HDAC1, 2 and 3 protein levels in colonic tissue of CD and UC patients 
Western blots and corresponding densitometrical analyses of colonic tissue homogenate from healthy 
controls (n=5, uninflamed L3 patients (n=5 for HDAC1 and 2; n=4 for HDAC3), and uninflamed UC patients 
(n= 4 for HDAC1 and 2; n=5 for HDAC3). Each lane on the western blots represents one patient. * p<0.05 
evaluated by Mann-Whitney u test. 
 
The tendencial reduction of HDAC1 and HDAC3 in UC colon is in line with the observed mRNA 
expressional changes. The slight increase of HDAC2 stands in contrast to the mRNA data (cf. 
Figure 6). HDAC1 mRNA in L3 patients’ colonic tissue was unchanged- so was the protein level. 
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HDAC2 mRNA was unaltered in L3 patients and so was the protein level; HDAC3 mRNA is 
unchanged and so was the protein level (Figure 8, cf. Figure 6). 
Drawing an interindividual comparison from the colonic specimens, distinct differences 
in HDAC1 protein levels became apparent within the control group as well as among L3 samples. 
UC colonic tissue seemed to contain a consistently low amount of HDAC1. HDAC2 showed 
relatively consistent interindividual levels. In the case of HDAC3, protein levels of controls and 
L3 patient tissue displayed slightly bigger interindividual variation than UC specimens. All in all, 
western blot analyses revealed interesting tendencial differences in class I HDAC protein levels 
between IBD patients and healthy controls as well as in part remarkable interindividual 
variations.  
Immunohistochemistry 
To gain further insight into the expression patterns of class I HDACs in intestinal tissue of IBD 
patients, additional immunohistochemical analyses were performed on ileal as well as colonic 
mucosal biopsies from healthy controls, uninflamed L3 and uninflamed UC patients. These 
specimens had to be collected from new patients. Herein, HDAC1 protein was found 
predominantly in epithelial cells of the small intestine, here with a stronger intensity than in the 
lamina propria compartment (Figure 9). Interestingly, ileal CD patients showed more HDAC1-
positive epithelial cells in the villus compartment as compared to controls (Figure 9c and d 
(arrows)) where many areas of unstained villus epithelium could be found.  
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Figure 9: Expression of HDAC1 protein in ileal tissue 
a-d Representative immunohistochemical staining of HDAC1 with an HDAC1-specific antibody on 
sections through ileal biopsies of controls (a, b) and patients with L3 Crohn’s disease (c, d). b higher 
magnification of the boxed area in a. Scale bars a, c = 200 µm, b, d = 100 µm. 
 
This finding was analyzed quantitatively and blinded by 4 independent individuals and is 
depicted in Figure 10Fehler! Verweisquelle konnte nicht gefunden werden.. The higher 
number in HDAC1 positive cells in L3 ileal specimen is in line with the findings for this HDAC 
from the western blot analysis, where it was tendencially increased in CD patients as well (cf. 
Figure 7). 
 
Figure 10: Increased number of HDAC1 positive 
cells in the villus area of CD ileal tissue 
Blinded quantitative analysis by 4 independent 
individuals of 7 control biopsies, 3 L1 (2 uninflamed 
samples, 1 inflamed sample), and 8 L3 biopsies (2 
inflamed, 6 uninflamed) stained with an HDAC1-
spedific antibody. * p<0.05 evaluated by Mann-
Whitney u test. 
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As shown in Figure 11, in the large intestine HDAC1 could be found predominantly in the nuclei 
of epithelial cells with a much stronger staining intensity there than in the lamina propria 
compartment. 
 
 
Figure 11: Expression of HDAC1 protein in human colonic tissue 
a-d Representative immunohistochemical staining of HDAC1 with an HDAC1-specific antibody on 
sections through colonic biopsies of controls (a, b), patients with L3 Crohn’s disease (c, d) and patients 
with ulcerative colitis (UC) (e, f). b, d, f Higher magnification of the boxed areas in a, c and e. Scale bars a, 
c, e = 200 µm, b, d, f = 100 µm. 
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Interestingly, HDAC2 immunohistochemical staining was found to be equally strong in epithelial 
and lamina propria cells in the ileal tissue of both healthy controls and L3 CD patients (Figure 
12). Furthermore, the staining seemed to be restricted to the nuclei. 
  
 
 
Figure 12: Expression of HDAC2 protein in ileal tissue 
a-d Representative immunohistochemical staining of HDAC2 with an HDAC2-specific antibody on 
sections through ileal biopsies of controls (a, b) and patients with L3 Crohn’s disease (c, d). b and d higher 
magnification of the boxed areas in a and b. Scale bars a, c = 200 µm, b, d = 100 µm. 
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Very similar results were observed for HDAC2 protein expression in colonic specimens of 
controls, L3 and UC patients without acute inflammation (Figure 13). In this tissue, the staining 
was also equally strong in the epithelial cells as in the lamina propria and seemed to be 
restricted to the nuclei. 
 
 
Figure 13: Expression of HDAC2 protein in colonic tissue 
a-d Representative immunohistochemical staining of HDAC2 with an HDAC2-specific antibody on 
sections through colonic biopsies of controls (a, b), patients with L3 Crohn’s disease (c, d) and patients 
with ulcerative colitis (UC) (e, f). b, d, f Higher magnification of the boxed areas in a, c and e. Scale bars a, 
c, e = 200 µm, b, d, f = 100 µm. 
 
HDAC3 staining in ileal biopsies was also equally strong in epithelial and lamina propria cells, 
however, apical villi epithelial cells appeared to bear stronger cytoplasmic staining (Figure 14 
arrows) as compared to the more basal villi areas (Figure 14 arrowheads). Thereby an 
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interesting pattern was observed, with the villi showing some sort of graded staining in the 
cytoplasmatic compartment. Overall, no differences in staining intensity between healthy 
controls and L3 patients was found (Figure 14). 
 
 
Figure 14: Expression of HDAC3 protein in ileal tissue 
a-d Representative immunohistochemical staining of HDAC3 with an HDAC3-specific antibody on 
sections through ileal biopsies of controls (a, b) and patients with L3 Crohn’s disease (c, d). b and d 
higher magnification of the boxed areas in a and b. Scale bars a, c = 200 µm, b, d = 100 µm. 
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Comparable results were found for HDAC3 staining in colonic biopsies where equally strong 
intensities were observed in epithelial and lamina propria cells (Figure 15). Again, there seemed 
to be a prevalent cytoplasmatic staining in the “villus” compartment since the cytoplasm in the 
colonic crypts was less intensely stained. Taken together, there was no difference in staining 
intensity between patients and controls. 
 
 
Figure 15: Expression of HDAC3 protein in colonic tissue 
a-d Representative immunohistochemical staining of HDAC3 with an HDAC3-specific antibody on 
sections through colonic biopsies of controls (a, b), patients with L3 Crohn’s disease (c, d) and patients 
with ulcerative colitis (UC) (e, f). b, d, f Higher magnification of the boxed areas in a, c and e. Scale bars a, 
c, e = 200 µm, b, d, f = 100 µm. 
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HDAC8 showed an equal pattern and staining intensity in ileal epithelial and lamina propria cells 
among biopsies from healthy controls (Figure 16a and b). L3 patients showed a trend towards a 
generally weaker HDAC8 staining in ileal epithelium and also less HDAC8-positive cells were 
found in the lamina propria of ileal biopsies from patients with L3 CD (Figure 16c and d). 
 
 
Figure 16: Expression of HDAC8 protein in ileal tissue 
a-d Representative immunohistochemical staining of HDAC8 with an HDAC8-specific antibody on 
sections through ileal biopsies of controls (a, b) and patients with L3 Crohn’s disease (c, d). b and d 
higher magnification of the boxed areas in a and b. Scale bars a, c = 200 µm, b, d = 100 µm. 
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HDAC8 staining in colonic biopsies of healthy controls also showed equal patterns and intensity 
in epithelial and lamina propria cells (Figure 17a and b). In tissue from L3 patients, HDAC8 
staining seemed weaker and was partly absent in epithelial cells; in the lamina propria there 
were less HDAC8 positive cells observed (Figure 17c and d). A similar result was found for UC 
tissue, especially in the crypts, where the epithelium was particularly faintly stained whereas the 
villi epithelial cells were more distinctly positive for HDAC8 (Figure 17e and f). 
 
 
Figure 17: Expression of HDAC8 protein in colonic tissue 
a-d Representative immunohistochemical staining of HDAC8 with an HDAC8-specific antibody on 
sections through colonic biopsies of controls (a, b), patients with L3 Crohn’s disease (c, d) and patients 
with ulcerative colitis (UC) (e, f). b, d, f Higher magnification of the boxed areas in a, c and e. Scale bars a, 
c, e = 200 µm, b, d, f = 100 µm. 
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Overall, quite distinctive staining patterns could be detected for the different class I HDACs in 
intestinal tissue sections from IBD patients and healthy individuals even though no major 
differences could be determined between diseased and healthy tissue via 
immunohistochemistry. Staining was found in the nuclei with exception for HDAC3 which 
showed some cytoplasmic staining especially in the villus or more apical areas of the mucosa. 
This localization of class I HDACs to the nuclei is in line with the literature (Karagiannis and 
Ververis, 2012; Khochbin et al., 2001). In general, the distribution patterns of the single HDACs 
seemed to be quite similar for both ileal and colonic mucosal tissue. Of note, HDAC1 showed 
increased protein staining in the villi of CD patients and seemed to be quite restricted to the 
epithelium. Whereas the other class I HDACs, especially HDAC2 and 3 could be equally found in 
epithelial and lamina propria cells.  
Comparing the findings for mRNA levels and protein from those first western blot 
experiments, in uninflamed L3 ileum, a possible slightly negative correspondence for HDAC1 
and an even stronger negative one for HDAC2 mRNA and protein became apparent. HDAC1 and 
2 protein seems to be increased whereas mRNA is unchanged, or even reduced as for HDAC2. 
HDAC3 protein seems to correspond positively to the amount of its mRNA- no changes in mRNA 
or protein level could be detected. In L3 colon, HDAC1 shows reduced mRNA but protein is 
rather unchanged. HDAC2 and 3 in L3 are possibly corresponding positively. In the uninflamed 
colon of UC patients, HDAC1 and 3 might correspond positively, whereas HDAC2 mRNA and 
protein levels are rather opposed to each other. In general, these findings show there seem to be 
rather minor changes in HDAC protein levels with a tendency towards stabilization, despite 
reduced mRNA levels in IBD intestinal tissue, especially in UC. It has to be kept in mind that 
mRNA data and protein results came from separate biopsies of different patients and can 
therefore be affected by possible interindividual epigenetic variabilities. Despite this limitation, 
a valid rationale for these investigations was still given, since these are the first-time systematic 
results on differential HDAC expression in human tissue samples of IBD patients. They 
contribute to opening up promising new research avenues regarding epigenetic involvement 
into the disease pathology and potentially pinpoint new targets for therapeutic intervention. 
  
  
57 RESULTS 
Parts of the thesis have previously been published in: 
Stebe-Frick, S., Ostaff, M.J., Stange, E.F., Malek, N.P., and Wehkamp, J. (2018). Histone deacetylase-
mediated regulation of the antimicrobial peptide hBD2 differs in intestinal cell lines and cultured 
tissue. Sci. Rep. 8, 12886. 
Herein, S.S.-F. and M.J.O. contributed equally. S.S.-F. performed the experiments; S.S.-F. and M.J.O. 
analyzed the data and interpreted the results. M.J.O. drafted the project. S.S.-F., M.J.O. and J.W. 
designed the study and wrote the manuscript. E.F.S. and N.P.M. were involved in discussion and 
finalization of the manuscript. 
 HDACs in the regulation of human β-defensin 2 
HBD2 is an inducible innate antimicrobial molecule present in epithelia (Harder et al., 2000; 
Schröder and Harder, 1999), but also in immune cells (Duits et al., 2002; Wah et al., 2006; Yin et 
al., 2010). Microbial and/or inflammatory stimuli lead to its upregulation and it has a crucial role 
in defending the host against infections. Interestingly, hBD2 has been found to be upregulated in 
the epithelium of the colon in response to probiotic bacteria (Möndel et al., 2009; Wehkamp et 
al., 2004a), which has been suggested to be one of the mechanisms via which probiotics bolster 
gut barrier function. It might also be why they show efficiency in remission maintenance in 
ulcerative colitis (UC) (Mack, 2011). The colonic subgroup of Crohn’s disease have been 
associated with an attenuated induction of epithelial hBD2 (Wehkamp et al., 2003, 2008). A 
lower inducibility of this important defense molecule might partly explain why these patients 
are prone to chronic inflammation. It might furthermore be one reason why, different from UC 
patients, CD patients do not seem to benefit from treatment with probiotics during remission 
(Mack, 2011). While genetic studies are still unsatisfactory in explaining the changes in colonic 
defensin expression, several potential hints on an involvement of epigenetics in human beta-
defensin regulation have been gained in non IBD related studies. One epigenetic regulatory 
mechanism might be implemented by HDACs. An influence of oral microbiota on the epigenetic 
regulation of hBD2 in connection with changes in class I HDACs 1 and 2 expression has been 
observed in gingival epithelial cells (Yin and Chung, 2011). Furthermore, Kallsen and colleagues 
demonstrated an involvement of HDAC1 in the transcriptional control of hBD1 in human lung 
epithelial cells (Kallsen et al. 2012). In addition to these findings, in vitro experiments could also 
show that food derived compounds with inhibitory effects on histone deacetylation processes 
can induce hBD2 expression in intestinal epithelial cell lines (Schwab et al. 2008). Furthermore, 
a recent study from Fischer et al. - that has been conducted simultaneously to this study - used 
colonic epithelial cell culture as well as primary cell derived organoids to demonstrate a role of 
HDACs in hBD2 regulation. Their data also showed that HDACi can augment hBD2 expression in 
response to E.coli K12 (Fischer et al., 2016). Taken together, these studies point towards an 
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importance of HDAC function in the regulation of hBDs and thereby antimicrobial defense. 
Consequently, they could also be involved in the hBD related defects observed in colonic IBD. As 
mentioned above, HDAC inhibitor use has been proposed as an IBD intervention (Felice et al., 
2014; Fischer et al., 2016; Glauben and Siegmund, 2011), hence, further detailed studies on the 
exact role of HDACs in human gut barrier function are needed. Therefore, herein the role of 
HDACs in regulating hBD2 inducibility has been investigated using ex vivo cultured colonic 
biopsies serving as a more in vivo like approach (Stebe-Frick et al., 2018). 
3.2.1. Human colonic biopsy culture 
Up to now, most studies on the effect of HDACi on hBD2 inducibility and transcriptional 
regulation have been carried out in mono-layered cell lines in vitro (Fischer et al., 2016; Schwab 
et al., 2008). A peril of using cancerous epithelial cell lines is, however, that HDACs are likely 
overexpressed and otherwise deregulated in cancers (Ishihama et al., 2007; Marks et al., 2001; 
Wilson et al., 2006; Yang et al., 2014). This could potentially translate into diverging responses 
that likely differ from the reactivity in healthy non-tumorous tissue (Stebe-Frick et al., 2018). A 
human colonic tissue culture has been established allowing the integration of the ‘multicellular-
tissue-context’ into the study. This biopsy culture can survive in a culture medium nearly 
identical to the one which has also been used for the CaCo2/TC7 assays described in the 
following chapter to achieve optimal comparability. Stimulation with the probiotic bacterium 
EcN and concurrent treatment with the HDAC inhibitors SAHA, MS-275 and SB was done exactly 
as in the in vitro setting of this study at hand. 
The colonic biopsy culture has been established based on a setting that has been utilized 
recently by our working group to study small intestinal innate immune regulation (Courth et al., 
2015). After collection during routine colonoscopy, tissue samples from healthy individuals as 
well as IBD patients’ colonic mucosa were washed thoroughly with ice-cold PBS containing 10% 
antibiotics to remove remaining bacteria. Specimens were then submitted to treatment for a 
total of 20 hrs at 37 °C with 5% CO2; thereof 20 hrs with different compounds of HDACi 
(suberoylanilide hydroxamid acid (SAHA), Pyridin-3-ylmethyl N-[[4-[(2-
aminophenyl)carbamoyl]phenyl]methyl] carbamate (MS-275), or sodium-butyrate (SB)). For 
MS-275, 5 µM not 3 µM were used as in the in vitro experiments (cf. 3.2.2 Cell culture functional 
studies on hBD2 inducibility). After 2 hrs of preincubation with the HDACi, start of stimulation 
with heat-inactivated EcN was started and carried out for the following 18 hrs in parallel to the 
HDACi. After that, samples were transferred into RNAlater until RNA isolation took place. 
Obtained RNA underwent a RNA quality check via Agilent; specimens with degraded RNA were 
rejected. Furthermore, LDH assays were conducted to investigate the viability of the tissue. No 
negative effects were observed on the LDH level neither by EcN nor the different inhibitors, 
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specimen with high LDH values (compared to a TritonX-treated positive control) were excluded 
from the study. As shown by histochemical analyses using HE staining, the tissue was affected 
but still intact after 20 hrs of cultivation (Figure 18). 
 
Figure 18: Colonic biopsy before and after cultivation 
Hematoxylin and eosin (HE) staining of an uncultured (0h) and medium cultured (20 hrs) healthy control 
biopsy. Scale bars 100 µm. Figure adapted from Stebe-Frick et al., 2018. 
 
3.2.1.1. Effect of HDAC inhibition on hBD2 expression levels in healthy 
individuals and IBD patients 
EcN, which is efficiently used to maintain the remission in UC patients (Kruis, 2004), is a potent 
inducer of hBD2 in colonic CaCo2-cells (Möndel et al., 2009). Therefore, this probiotic strain was 
tested for its potential to induce hBD2 in ex vivo-stimulated colonic biopsies of healthy controls 
as well as IBD patients. Treatment of ex vivo colonic biopsies with probiotic EcN strongly 
induced hBD2, especially in healthy controls and patients with UC (Figure 19). The basal hBD2 
induction levels observed under medium-treatment have been defined as one to allow control in 
comparison to this condition rather than to ‘naïve’, untreated samples (in addition, relative 
expression levels of hBD2 of all tested patient groups are depicted in Appendix Figure 1). The 
observed results are in line with (Lewis et al., 2016) who could also show that EHEC infection of 
a colonic biopsy model induced hBD2 expression, dependent on flagellin. Fold changes in EcN-
stimulated hBD2 expression in the colon of patients with inactive ileal or colonic CD (Figure 19, 
L1 or L3 respectively), however, were lower and not significant indicating a disturbance in hBD2 
inducibility in response to EcN (Stebe-Frick et al., 2018). 
It was aimed at gaining insight into, whether a combinatatorial use of HDACi together 
with the therapeutic EcN might be a potential strategy to strengthen protective immune 
responses. For this, HDAC function was blocked in ex vivo cultured tissue using either SAHA, MS-
275, or SB (Figure 19). Interestingly, SAHA and SB abolished hBD2 expression in all samples, 
regardless of disease type. However, the inhibition of mainly only HDACs 1 and 3 with MS-275 
did not suffice to prevent hBD2 induction. Overall, these observations impressively demonstrate 
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that EcN-mediated induction of hBD2 in a tissue compound is strongly dependent on HDAC 
function (Stebe-Frick et al., 2018). 
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Figure 19: E. coli Nissle stimulates but HDACi hinders hBD2 expression in ex vivo cultured human 
colonic biopsies 
HBD2 mRNA in cultured human colonic biopsies of (a) controls (C, n=13), (b) L1 (n=15) or (c) uninflamed 
L3 (n=14) CD patients, or (d) uninflamed UC patients (n=14) in response to 18 hrs of EcN stimulation with 
or without HDACi with SAHA (5 µM), MS-275 (5 µM), or SB (3 mM) shown in the right panels of each graph 
respectively. Shown are relative fold changes compared to medium treatment alone according to 10 ng 
total RNA normalized to βactin expression. * p≤0.05, ** p≤0.01, *** p≤0.001, **** p<0.0001 evaluated by 
Mann-Whitney u test. Figure adapted from Stebe-Frick et al., 2018. 
 
Tissue integrity of the biopsies was again assessed via HE staining showing no differences 
between medium, EcN, or treatments with HDACi after 20 hrs of cultivation (Figure 20).  
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Figure 20: Colonic biopsies before and after cultivation with EcN and HDACi 
HE staining of a 20 hrs medium plus EcN cultured biopsy (top left), EcN plus SAHA (bottom left), EcN plus 
MS-275 (top right), and EcN plus SB cultured biopsy (bottom right). Scale bars 100 µm.  
 
3.2.1.2. IL8 expression in ex vivo biopsies 
Furthermore it was investigated whether IL8 expression, as an inflammatory response, was 
affected in the same way as hBD2 by HDACi. It was observed that cultivation with medium alone 
cuased an induction of IL8. The different treatments, however, mostly did not augment this 
induction (Figure 21) (Stebe-Frick et al., 2018). Most notably, HDACi did not abolish IL8 
expression as compared with hBD2, pointing towards more distinctive epigenetic regulatory 
mechanisms for IL8 and hBD2 on the level of HDAC function (Stebe-Frick et al., 2018). 
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Figure 21: Inhibition of histone deacetylases (HDACs) does not abolish IL8 expression in ex vivo 
biopsies 
IL8 mRNA expression in cultured colonic biopsies from healthy controls (a), L1 (b) , L3 (c) , and UC (d) 
patients in response to 18 hrs of EcN stimulation, alone or together with either SAHA (5 µM), MS-275 (5 
µM), or SB (3 mM). Inhibitor treatment started 2 hrs prior to the stimulation with EcN, which took then place 
in parallel to the HDAC inhibition for another 18 hrs. Shown are relative fold changes compared to medium 
treatment alone according to 10 ng total RNA normalized to βactin expression. Figure adapted from Stebe-
Frick et al., 2018. 
 
3.2.1.3. hBD1 expression in ex vivo biopsies 
To get an insight into whether a constitutively expressed defensin, such as human β-defensin 1, 
is affected by the treatment with EcN with or without HDACi, the expression of this defensin has 
also been measured. Comparable observations as with IL8 were made for the expression of 
hBD1- no significantly changes were induced by neither EcN alone nor the simultaneous 
treatment with HDAC inhibitors (Figure 22) (Stebe-Frick et al., 2018). 
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Figure 22: Effect of histone deacetylase (HDAC) inhibition on human β-defensin 1 (hBD1) expression in 
ex vivo biopsies 
hBD1 mRNA expression in cultured colonic biopsies from healthy controls (a), L1 (b) , L3 (c) , and UC (d) 
patients in response to 18 hrs of EcN stimulation, alone or together with either SAHA (5 µM), MS-275 (5 
µM), or SB (3 mM). Inhibitor treatment started 2 hrs prior to the stimulation with EcN, which took then place 
in parallel to the HDAC inhibition for another 18 hrs. Shown are relative fold changes compared to medium 
treatment alone according to 10 ng total RNA normalized to βactin expression. Figure adapted from Stebe-
Frick et al., 2018. 
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3.2.2. Cell culture functional studies on hBD2 inducibility  
Due to the limited number of biopsies that could be obtained per patient, closer functional 
investigations regarding the underlying mechanisms on how HDACi impacts the expression of 
hBD2 could not be conducted ex vivo. For this reason, all functional analyses had to be 
performed in vitro - using the human colonic epithelial CaCo2 subclone TC7 cells (CaCo2/TC7) to 
study the role of different hBD2 stimuli (heat-inactivated EcN, LPS and IL1β) without and with 
simultaneous inhibition of HDAC function by the aforementioned compounds SAHA, MS-275, or 
SB (Figure 23) (Stebe-Frick et al., 2018). Mono-layered CaCo2/TC7 cells were chosen for this 
endeavor since it had been shown before, that EcN is a good inducer of hBD2 in this cell line 
(Möndel et al., 2009). 
3.2.2.1. Induction of hBD2 by different stimuli – The effect of HDAC inhibition 
Cells were challenged with the stimulants for 18 hrs, which led to the induction of high basal 
levels of hBD2 as shown in Figure 23a (Stebe-Frick et al., 2018). The use of the inhibitors alone 
did not affect hBD2 expression within 20 hrs (Figure 23b). Very low transcript numbers of hBD2 
per 10 ng total RNA (40 transcripts max) can be considered as negavtive. Strikingly, when HDAC 
function was inhibited simultaneously, a strong enhancement of the hBD2 transcription levels 
has been detected as shown in Figure 23a (Figure 23c-e) (Stebe-Frick et al., 2018); especially in 
the case of the pan-HDAC-inhibitor SAHA (Figure 23c). Employing the more specific MS-275, 
mainly inhibting HDACs 1 and 3 at the here used concentration (Beckers et al., 2007; Hu et al., 
2003; Khan et al., 2008; Tatamiya et al., 2004) (Figure 23d), caused a comparably strong effect in 
combination with EcN (Figure 24) (Stebe-Frick et al., 2018). When combined with IL1β and LPS 
the trend was still significant but less marked (Stebe-Frick et al., 2018). The short chain fatty 
acid derivate butyrate - which occurs naturally in the human intestine and also has known HDAC 
inhibitory function - augmented hBD2 induction as well albeit to a lesser extent (Figure 23e) 
(Stebe-Frick et al., 2018). HBD2 intracellular protein levels mirrored the observed response on 
the mRNA level (Figure 25) (Stebe-Frick et al., 2018). 
Summarizing, these findings also point out an importance for HDACs in the 
transcriptional regulation of hBD2 in intestinal epithelial cells. Seemingly, they level up hBD2 
inducibility in the monolayer cellular setting. However, this is in stark contrast to the findings 
from the ex vivo experiments with colonic tissue samples where HDACi has an opposing effect. 
These differences could be due to either the tumorous nature of the CaCo2 cells or due to more 
complex tissue context of the biopsies (Stebe-Frick et al., 2018). Nevertheless, the observation 
from the in vitro approach is in line with a recent report showing similar effects, also in 
CaCo2/TC7 cells and additionally in human colonic organoids under the use of the inhibitors 
TSA and SAHA (Fischer et al., 2016). 
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Furthermore, the comparable hBD2 enhancing effects of SAHA and MS-275 when cells are 
stimulated with EcN show that, in this case, HDAC1 and 3 seem to be the mainly involved HDACs 
in the repression of hBD2 gene expression keeping it at a basal induction level when they can 
exert their normal function. 
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(2 µM) or SB (3 mM) each for 20hrs. Shown are relative copy numbers of hBD2 per 10 ng total RNA 
normalized to βactin expression. c-e shows the fold change in hBD2 induction compared to each 
stimulation alone when co-treated with either SAHA (5 µM) (c), MS-275 (2 µM) (d), or SB (3 mM) (e). Here, 
inhibitor treatment started 2 hrs prior to the stimulations, which took then place in parallel to HDAC 
inhibition for another 18 hrs. Shown are results of at least three independent experiments carried out in 
biological triplicates. * p≤0.05, ** p≤0.01, *** p≤0.001, **** p<0.0001 evaluated by Mann-Whitney u test. 
Figure from Stebe-Frick et al., 2018. 
 
Figure 23: In vitro induction of human 
β-defensin 2 (hBD2) is strongly 
enhanced by histone deacetylase  
inhibition (HDACi)  
Effect of HDACi on the induction of 
human β-defensin 2 (hBD2) in 
CaCo2/TC7 cells in response to the 
probiotic strain E. coli Nissle 1917 
(EcN), interleukin 1β (IL-1β) and 
lipopolysaccharide (LPS). HBD2 mRNA 
expression after (a) treatment with EcN 
(3 × 108 CFU/ml), IL1β (10 ng/ml) or LPS 
(1 µg/ml) each for 18 hrs or (b) with 
HDAC inhibitors SAHA (5 µM), MS-275 
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Figure 24: Comparison of the effects of SAHA and MS-275 on hBD2 expression 
Inhibition of all HDACs by SAHA and only inhibiting HDAC1 and 3 via MS-275 leads to a comparable 
enhancement of hBD2 when it is stimulated by EcN (left). If hBD2 is induced by IL1β (middle) or LPS (right), 
however, inhibition of HDAC1 and 3 does not lead to the same level of augmentation as the pan-HDACi via 
SAHA. ** p≤0.01, **** p<0.0001 evaluated by Mann-Whitney u test.  
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Figure 25: Intracellular hBD2 protein after stimulation with EcN, IL1β, or LPS and HDACi 
HBD2 peptide levels from CaCo2/TC7 cell lysates as determined by ELISA. Treatment was carried out 
exactly as for mRNA analyses. Results represent three independent experiments measured as technical 
triplicates. * p≤0.05, *** p≤0.001, **** p<0.0001 evaluated by Mann-Whitney u test. Figure from Stebe-Frick et 
al., 2018. 
 
3.2.2.2. IL8 expression under HDAC inhibition 
The influence of HDACi on the inflammatory response in CaCo2/TC7 cells was examined via 
measuring the expression of interleukin 8 (IL8) (Figure 26). The basal induction IL8 levels 
evoked by the the application of the stimulants alone, are displayed in Figure 26a. These levels 
are comparable to what has been seen for hBD2. Interestingly, inhibitor treatment alone induced 
the pro-inflammatory cytokine IL8 (Figure 26b). In slight contrast to the study from Fischer et al 
(Fischer et al., 2016), HDAC inhibition in parallel with the stimulation had a synergistic effect on 
IL8 induction as well and also strongly increased the basal transcription level of this pro-
inflammatory gene (Figure 26c-e) (Stebe-Frick et al., 2018). Interestingly, these findings are 
different from those observed in ex vivo biopsies within this study at hand, where HDACi did not 
further enhance IL8 expression in response to medium treatment alone or stimulation with EcN. 
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started 2 hrs prior to the stimulations, which took then place in parallel to HDAC inhibition for another 18 
hrs. Shown are results of at least three independent experiments carried out in biological triplicates. * 
p≤0.05, ** p≤0.01, *** p≤0.001, **** p<0.0001 evaluated by Mann-Whitney u test. Figure from Stebe-Frick et 
al., 2018. 
 
3.2.2.3. hBD1 expression under HDAC inhibition 
Contrasting, human β-defensin 1 (hBD1), which is constitutively expressed in intestinal 
epithelial cells, was neither significantly affected by HDAC inhibition nor by the stimulants 
(Figure 27). However, a significant trend towards an enhanced hBD1 mRNA expression could be 
observed for MS-275 and SB (Figure 27b and c), especially when acting together with the 
stimulants (Stebe-Frick et al., 2018). 
Figure 26: In vitro induction of IL8 is 
also strongly enhanced by histone 
deacetylase inhibition 
Expression of IL8 mRNA after (a) 
treatment with EcN (3 × 108 CFU/ml), 
IL1β (10 ng/ml) or LPS (1 µg/ml) each 
for 18 hrs, or (b) with HDAC inhibitors 
SAHA (5 µM), MS-275 (2 µM) or SB 
(3 mM) each for 20hrs. Shown are 
relative copy numbers of hBD2 per 10 
ng total RNA normalized to βactin 
expression. c-e shows the fold change 
in IL8 induction compared to each 
stimulation alone when co-treated with 
either SAHA (5 µM) (c), MS-275 (2 µM), 
(d) or SB (3 mM) (e). Inhibitor treatment 
   
68 RESULTS 
*
*
*
*
*
*
*
*
 
Figure 27: The effect of histone deacetylase (HDAC) inhibition on human β-defensin 1 (hBD1) 
expression in vitro 
Fold changes in relative hBD1 mRNA expression after (a) treatment with HDAC inhibitor SAHA (5 µM), (b) 
MS-275 (2 µM) or (c) SB (3 mM) each for 20hrs together with or without the EcN (3 × 108 CFU/ml), IL1β 
(10 ng/ml) or LPS (1 µg/ml) each for 18 hrs. Expression of hBD1 according to 10 ng total RNA normalized 
to βactin expression. Inhibitor treatment started 2 hrs prior to the stimulations, which took then place in 
parallel to HDAC inhibition for another 18 hrs. Shown are results of at least three independent experiments 
carried out in biological triplicates. * p<0.05, ** p<0.01 evaluated by Mann-Whitney u test. Figure from 
Stebe-Frick et al., 2018. 
 
  
69 RESULTS 
3.2.2.4. Viability of CaCo2 cells after HDAC inhibition 
Scrutinizing the viability of CaCo2 cells after the treatments, first the proliferation marker Ki67 
(Scholzen and Gerdes, 2000) has been checked by measuring its mRNA expression (Figure 28). 
HDACi did not affect Ki67 expression. The stimulants EcN, IL1β, and LPS lead to a slight but not 
significant reduction of Ki67 indicating a decrease of the growth fraction of the regarded CaCo2 
population (Scholzen and Gerdes, 2000). 
 
 
Figure 28: Expression of the proliferation marker Ki67 in treated CaCo2 cells 
Shown are results of at least two independent experiments carried out in biological triplicates. 
 
Furthermore, the metabolic activity of the cells has been assessed via MTT assays to infer on cell 
survival and proliferation (Figure 29). The left part of the figure shows that neither the 
stimulants alone, nor together with the HDACi had a severe effect on the cellular capability to 
reduce MTT. The right side of the graph shows the metabolic activity under the additional 
treatment with the NF-κB inhibitor Helenalin (relevant for the investigations described in the 
following chapter: 3.2.3 The role of NF-κB and AP1 transcription factors in the HDAC inhibition-
dependent enhancement of hBD2 induction) which took place for 1h right at the beginning of the 
20 hrs and was then removed to avoid cytotoxic effects. Helenalin reduced metabolic activity 
only by about 20% relative to untreated cells which is still in an acceptable range. 
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Figure 29: Metabolic activity of CaCo2 cells after treatment 
CaCo2 metabolic activity as determined by the MTT reducing capacity of the differentially treated cells. 
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3.2.3. The role of NF-κB and AP1 transcription factors in the HDAC 
inhibition-dependent enhancement of hBD2 induction 
In 2004, it has been shown that hBD2 induction via EcN is dependent on at least two NF-κB 
binding sites present in the promoter region of hBD2 (Wehkamp et al., 2004a). There are also 
NF-kB binding sites in the IL8 promoter (Hoffmann et al., 2002). The use of HDAC inhibition 
generally leads to a more relaxed chromatin structure by blocking their deacetylation function at 
histone proteins which then promotes transcription (Xu et al., 2007). But besides histones, 
HDACs have a large number of non-histone protein substrates such as transcription factors (Seto 
and Yoshida, 2014). Several reports implicated a role for HDACs in the epigenetic control of NF-
κB signaling and its transactivation function. It has been shown, e.g. that HDAC1 and 2 interact 
with the p65 subunit exerting a corepressor function (Ashburner et al., 2001) and that HDAC3 
deacetylates p65 and thereby facilitates the nuclear export of RelA which reduces NF-κB 
regulated gene expression (Chen et al., 2001; Huang et al., 2010). Inhibiting HDACs might 
therefore reduce the repressive effect they might have on NFkB. This could then lead to a 
fortified NF-kB-dependent gene expression (Stebe-Frick et al., 2018). So, based on these studies, 
it was aimed to test whether the pronouncing effects of HDACi on hBD2 induction might indeed 
depend on NF-κB function (Stebe-Frick et al., 2018). 
3.2.3.1. Pharmacological inhibition of NF-κB 
To verify the dependency on NF-κB, simultaneously to blocking HDAC function, NF-κB was 
inhibited by Helenalin (Figure 30). This compound hinders DNA binding of p65 via alkylation of 
the latter (Lyß et al., 1998). Therefore, Helenalin was expected to avert the enhancement of 
hBD2 expression under HDACi. Indeed, enhancement of hBD2 induction mediated by SAHA in 
response to all three tested stimulants was abolished (Figure 30a) (Stebe-Frick et al., 2018). In 
the case of the MS-275, simultaneous inhibition of NF-κB rather caused an attenuating effect 
when stimulation of hBD2 occurred via activation of TLRs (EcN, LPS) (Figure 30b, left and right 
panel) (Stebe-Frick et al., 2018). When IL1β was used to induce hBD2, the MS-275-mediated 
reinforcement of its expression was not blocked by NF-κB inhibition (Figure 30b, middle panel) 
(Stebe-Frick et al., 2018). For SB, the observed effect resembled the one with SAHA – blocking 
NF-κB in EcN- or LPS-stimulated cells caused an abolishment of the HDACi-mediated 
enhancement (Figure 30c, left and right panel) (Stebe-Frick et al., 2018). For IL1β, this trend 
demontrated to be weaker but still present (Figure 30c, middle panel) Overall, these findings 
show that the potentiation in hBD2 expression under pan-HDACi is mediated via NF-κB. This 
does not seem to be the case when the HDAC1 and 3 inhibitor MS-275 is used upon IL1β-
stimulated cells. Here, signaling pathways and molecules other than NF-κB seem to be of 
importance (Stebe-Frick et al., 2018). 
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Figure 30: Pan-HDAC inhibition enhancement of hBD2 expression is dependent on NF-κB 
a-c show the abolishment of the enhancing effect of HDAC inhibition through Helenalin in CaCo2/TC7 
cells. HBD2 mRNA induction in response to EcN (3 × 108 CFU/ml), IL1β (10 ng/ml) or LPS (1 µg/ml) alone, 
together with SAHA (5µM) (a), MS-275 (2 µM) (b), or SB (3 mM) (c), and after pretreatment for 1 h with the 
NFkB inhibitor Helenalin (20 µM). Represented are the results of four independent experiments carried out 
in biological triplicates. Shown are relative copy numbers of hBD2 per 10 ng total RNA normalized to 
βactin expression. * p<0.05 evaluated by Mann-Whitney u test. Figure from Stebe-Frick et al., 2018. 
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3.2.3.2. Reportergene studies 
To further elucidate the importance of NF-κB, CaCo2/TC7 cells were transfected with different 
hBD2 promoter constructs – with either a wildtype construct (hBD2-2338-luc) or with 
constructs that bear mutations in either the proximal (positions -205 to -186) or the distal NF-
κB binding sites (positions -596 to -572), but the activator protein-1 (AP1) binding site 
(positions −127 to −121). All were either mutated alone or in different combinations (Figure 
31). After treatment with either one of the stimulants EcN, IL1β, or LPS together with SAHA, 
hBD2 promoter activation was analyzed (Figure 31) (Stebe-Frick et al., 2018). 
hBD2 promoter constructs 
The wildtype construct (hBD2-2338-luc) displayed an about 13 fold activation of the hBD2 
promoter when stimulated with EcN alone compared to untreated cells. Strikingly, together with 
HDACi this activation was enhanced up to approximately 43 fold (Figure 31 topmost row, EcN 
panel) (Stebe-Frick et al., 2018). This was similar for LPS but not for IL1β (Figure 31 topmost 
row, IL1β and LPS panel, respectively). Mutation of the proximal NF-κB binding site (NF-κB-
mut1-luc) hindered EcN- as well as LPS-induced hBD2 reportergene activation, which confirmed 
a previous finding made by our group (Wehkamp et al., 2004a) and also dampened the 
EcN+SAHA-mediated enhancement, leaving over only an about ~4 fold activation (Figure 31 
second row, EcN panel) (Stebe-Frick et al., 2018). Interestingly, the malfunction of the proximal 
binding site also abolished the IL1β induced promoter activation, indicating that the initial 
induction of the hBD2 gene via IL1β signaling is strongly dependent on this NF-κB binding site 
but in this case not the enhanced expression of hBD2 as has been observed for the intrinsic gene 
expression in CaCo2 cells (cf. Chapter 3.2.2.1 Induction of hBD2 by different stimuli – The effect 
of HDAC inhibition). So, the augmentation of IL1β-induced hBD2 is likely mediated via additional 
NF-κB binding sites that are missing from the constructs used here since blocking total NF-κB 
function with Helenalin had been capable of abolishing the SAHA-enhanced hBD2 expression. 
Mutation of the distal binding site (hBD2-mut2-luc) did, however, not show an effect on the 
inducibility of the promoter construct for neither one of the three stimulants (Figure 31 third 
row) (Stebe-Frick et al., 2018). The binding site for AP1 (AP1-mut-luc) seems to also play a role 
not only for the basal induction of the hBD2 promoter but also for the capacity of reinforcing the 
amplitude of its activation, leading to an elevation from ~5 fold to ~14 fold (Figure 31 fifth row, 
EcN panel) (Stebe-Frick et al., 2018). The observation was comparable for LPS as well as for IL1β 
where the lack of this AP1 site led to a diminished activation of the reportergene. Overall, the 
effect is minor compared to NF-κB but significant. Together, these findings substantiate the NF-
κB involvement as well as demonstrating an involvement of AP1 in the HDACi-mediated 
augmentation of hBD2 induction on the promoter level (Stebe-Frick et al., 2018). 
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Figure 31: The proximal NF-κB binding site in the hBD2 promoter and an AP1 binding site are essential for 
the enhancing effect of HDACi on hBD2 expression 
The left panel shows a diagram of the used hBD2 promoter constructs (bp −2338 to −1 linked to the luciferase 
gene). Two NF-κB binding sites and one AP1 binding site are marked relative to the hBD-2 transcription start. 
Constructs with mutated binding sites were used as indicated. Transfection of CaCo2/TC7 cells took place 
with either the wild-type (hBD2-2338-luc) or the mutated hBD2 promoter constructs together with a Renilla 
luciferase plasmid as internal standard. 24 hrs post transfection, cells were treated with either EcN (3 × 108 
CFU/ml), IL1β (10 ng/ml), or LPS (1 µg/ml) for 18 hrs, with SAHA (5µM) for 20 hrs or a simultaneous 
combination of a stimulant and SAHA (18 and 20 hrs, respectively). Promoter activation was measured 
subsequently and is displayed as luciferase activity normalized to Renilla activity. Shown are the results of at 
least 3 independently conducted experiments carried out in biological triplicates. * p<0.05 evaluated by 
Wilcoxon signed rank test. Parts of this figure have been published before (Stebe-Frick et al., 2018). 
 
NF-κB and AP1 constructs 
In addition to the hBD2 promoter constructs, CaCo2/TC7 cells were transfected with two 
general luciferase reporter plasmids with either tandemly repeated NF-κB or AP1 binding sites 
to test their reaction to stimulation with EcN under pan-HDACi by SAHA (Figure 32). This has 
been done to answer the question on how isolated NF-κB or AP1 binding sites contribute to a 
promoter activation under the respective conditions and to allow drawing inferences about 
more general effects of pan-HDACi on these transcription factors. Of note, in contrast to the 
hBD2 promoter constructs, the reporter genes under the control of tandem NF-κB or AP1 
binding sites showed an initial level of activation in CaCo2 cells indicating a certain “basal” level 
of activity by these transcription factors. This level has been set as one. Treatment with EcN 
alone slightly activated NF-κB but not AP1 binding sites. Both types of binding sites were 
activated by SAHA alone, whereas this was more distinctive for AP1. Most interestingly, EcN and 
SAHA acted synergistically on the NF-κB binding sites leading to an about doubled reportergene 
activation as compared to either EcN or SAHA treatment alone (Figure 32). 
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Figure 32: NF-κB binding sites are synergistically 
activated by EcN and HDACi 
Tandemly repeated NF-κB-binding sites are slightly 
activated by EcN (3 × 108 CFU/ml) or SAHA (5µM) 
alone but together act synergistically (upper panel). 
AP1 binding sites are not activated by EcN 
treatment alone but strongly respond when HDACs 
are inhibited via SAHA (lower panel). Shown are 
fold changes in reportergene activation as results 
of 3 independently conducted experiments carried 
out in biological triplicates. 
 
From this point of view, it can be concluded that in CaCo2/TC7 cells, EcN alone does not activate 
AP1 transcription factors or rather that AP1 binding sites alone are not sufficient to reach gene 
activation via EcN. However, administration of the pan-HDACi SAHA leads to a strong activation 
of AP1 sites and an enhanced expression of NF-κB-controlled genes supporting the hypothesis of 
hBD2 mRNA expression being indirectly repressively controlled by HDACs via NF-κB. Therefore, 
the pronouncing effects of HDACi on hBD2 induction might indeed depend on NF-κB function 
and activity. 
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3.2.4. Investigations on the discrepancy between the ex vivo and in 
vitro hBD2 transcriptional response to HDAC inhibition 
As has been mentioned before, most studies on the effect of HDAC inhibition on hBD2 
inducibility have been conducted in mono-layered in vitro cell culture approaches (Fischer et al., 
2016; Lan et al., 2011; Schwab et al., 2008). Since HDACs are often overexpressed and 
deregulated in many cancers (Ishihama et al., 2007; Marks et al., 2001; Wilson et al., 2006; Yang 
et al., 2014), tumorous epithelial cell lines could, however, show differential responses as 
compared to non-cancerous complex tissue. A human colonic biopsy culture has been 
established as described in chapter 3.2.1 (Human colonic biopsy culture), which is able to 
survive in a culture medium almost identical to the one used for the CaCo2/TC7 assays as 
depicted in chapter 3.2.2 (Cell culture functional studies on hBD2 inducibility). This has been 
done to add the tissue context and potential crosstalks between different cell types to the 
picture. Stimulation with the probiotic EcN and treatment with the HDAC inhibitors SAHA, MS-
275 and SB was conducted in the same way in both settings with only one exception (Stebe-Frick 
et al., 2018). The MS-275 concentration was 5 µM in the ex vivo experiments as compared to 2 
µM in vitro which has been adopted from the literature (Tatamiya et al., 2004). This has been 
done since first results from the biopsies showed that MS-275 was not capable of hindering 
hBD2 expression after EcN stimulation whereas SAHA and SB could. Therefore, an initial check 
on whether maybe MS-275 was not able of diffusing as well into the tissue compound as it could 
diffuse into the mono-layered CaCo2/TC7 cells. The higher concentration also did not abolish 
hBD2 expression in ex vivo biopsies but due to the advanced status of the experiments with 
valuable patient samples, it has been decided to abide to the higher concentration for the 
ongoing ex vivo experiments. 
As has been delineated in the previous chapters, the findings from the ex vivo and in vitro 
experiments showed that HDACi has an opposing effect on hBD2 induction levels- in cultured 
biopsies HDACi mostly prevents whilst in CaCo2/TC7 cells it strongly reinforces hBD2 mRNA 
expression (cf. Figure 19 versus Figure 23) (Stebe-Frick et al., 2018). 
 
3.2.4.1. hBD2 response to IL1β in colonic epithelial HCT116 cells under HDAC 
inhibition 
Since these differences from ex vivo and in vitro observations could be due to either the 
tumorous nature of the CaCo2 cells or due to the more complex tissue context of the biopsies, at 
first the effect of HDACi has been studied in an additional colorectal carcinoma cell line with an 
epithelial morphology. For this, HCT116 cells were treated with the same stimulants that have 
been used in the CaCo2 cells- EcN, IL1β or LPS (Figure 33). Likely due to a lack of detectable or at 
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least only a very low amount of TLR4 receptor expression in this cell line (Zhao et al., 2007; 
Doan et al., 2009), there was no induction of hBD2 in response to the TLR4 ligand LPS. However, 
LPS was able to induce the expression of a small amount of IL8 mRNA, possibly owed to a still 
present but very low level of TLR4 receptor expression (Doan et al., 2009). Interestingly, there 
was no TLR5-dependent induction of hBD2 in HCT116 cells following stimulation with EcN 
(Figure 33a) but IL8 was readily induced (Figure 33b). HCT116 cells seem to express TLR5 
receptor at rather low levels (Zhao et al., 2007). Furthermore, the responsiveness to flagellin in 
cancer cells lines might be differentially modulated due to the presence different single 
nucleotide polymorphisms (SNPs) that have been found in the TLR5 receptor gene in colorectal 
cancers (Klimosch et al., 2013). This might the reason for an only very weak hBD2 response to 
EcN in these cells.  
*
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Figure 33: Induction of hBD2 and IL8 in HCT116 colonic epithelial cells following stimulation with EcN, 
IL1β, or LPS 
Effect of HDACi on the induction of (a) human β-defensin 2 (hBD2) or (b) interleukin 8 (IL8) in HCT116 
cells in response to the probiotic strain EcN (3 × 108 CFU/ml), IL1β (10 ng/ml), or LPS (1 µg/ml) for 18 hrs. * 
p<0.05 evaluated by Mann-Whitney u test. Parts of this figure have previously been published (Stebe-Frick 
et al., 2018). 
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However, HCTs strongly responded to IL1β stimulation with hBD2 induction (Figure 33). Since 
for IL1β-mediated hBD2 induction, this is the first report on an enhancement effect of HDACi in 
intestinal epithelial cells in vitro, the aim was to confirm the results for IL1β from 
CaCo2/TC7cells in HCT116 cells. HDACi alone did not affect hBD2 induction in HCT116 cells but 
had an elevating effect on basal IL8 expression (Appendix Figure 4). The enhancing effect on 
hBD2 expression by HDACi could also be observed (Figure 34a) (Stebe-Frick et al., 2018).  
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Figure 34: IL1β mediated hBD2 induction is enhanced by HDACi in colonic carcinoma HCT116 cells 
a Induction level of hBD2 mRNA in HCT116 cells by IL1β (10 ng/ml) after 18 hrs of stimulation. Fold 
change in hBD2 (a) or IL8 (b) induction are shown for IL1β stimulation alone compared to when co-
treated with either SAHA (5 µM), MS-275 (2 µM), or SB (3 mM). Inhibitor treatment and stimulation were 
done exactly as for CaCo2/TC7 cells. Depicted are results of at least three independent experiments 
carried out in biological triplicates. * p<0.05, ** p<0.01, evaluated by Mann-Whitney u test. Figure from 
Stebe-Frick et al., 2018. 
 
In contrast to the CaCo2/TC7 cells, however, IL1β induced IL8 expression was not further 
enhanced when HDAC inhibitors were used (Figure 34b) indicating a possibly cell line specific 
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inflammatory response that differs in respect to IL8 between CaCo2/TC7 and HCT116 cells 
(Stebe-Frick et al., 2018). 
3.2.4.2. hBD2 expression under HDAC inhibition in primary gingival epithelial 
cells 
To gain insight into whether the observed enhancement effect of HDACi on hBD2 induction in 
the two cell lines CaCo2/TC7 and HCT116 was due to their cancerous nature or rather the 
mono-layered status of the in vitro system, in a first pilot experiment, the effect of HDACi was 
also tested in the non-tumorous human primary gingival epithelial cell line hgep. For this, hgep 
cells were cultivated until they nearly reached a mono-layered confluency. Thereafter, 
differentiation was induced to obtain mature gingival epithelial cells. Two timepoints were 
chosen where differentiation had taken place for either 48 or 72 hrs to see whether different 
timespans might play a role. Cells were then subjected to either stimulation with IL1β alone or 
together with SAHA or MS-275 at the same timepoints and in the same manner as in CaCo2/TC7 
and HCT116 cells.  
 
 
Figure 35: IL1β-mediated hBD2 induction is enhanced by HDACi in human primary gingival epithelial 
cells 
Induction level of hBD2 mRNA in hgep cells by IL1β (10 ng/ml) after 18 hrs of stimulation. Relative 
transcript numbers (normalized to βactin) for hBD2 induction are shown for IL1β stimulation alone 
compared to when co-treated with either SAHA (5 µM) or MS-275 (2 µM) for a total of 20hrs starting. 
Inhibitor treatment and stimulation were done exactly as for CaCo2/TC7 or HCT116 cells. Depicted are 
preliminary results of a first experiment. 
 
 
Interestingly, hgeps showed the same reaction patterns for hBD2 like CaCo2/TC7 or HCT116 
cells. Inhibition of HDACs via SAHA or MS-275 also enhanced hBD2 mRNA expression, 
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irrespective of whether the duration of differentiation had been 48 or 72 hrs (Figure 35). This 
result, together with the findings from CaCo2/TC7 and HCT116 cells, points towards the 
conjecture, that rather the mono-layered and cell-typologically more homogeneous (as 
compared to the tissue compound of colonic mucosal biopsies) than the tumorous character of 
the in vitro cell lines is responsible for the mode of impact of the epigenetical intervention on 
hBD2 expression via HDACi. 
3.2.4.3. Effect of HDAC inhibition on hBD2 induction in colonic tumor 
biopsies 
To be able to shine further light on the hypothesis that the more complex, inhomogeneous 
nature of the colonic biopsies is the demarcating factor for the differing effect of HDACi on the 
level of hBD2 induction ex vivo versus in vitro, not only its mRNA expression of biopsies from 
non-cancerous healthy controls or IBD patients has been examined (see chapter 3.2.1 Human 
colonic biopsy culture), but also of biopsies obtained from colorectal tumors (n=4) (Figure 36). 
*
0.0571
 
 
Figure 36: Inhibition of histone deacetylases HDACs hinders hBD2 induction in human colorectal 
tumor biopsies 
HBD2 mRNA expression in cultured human colonic biopsies of four colorectal tumor specimens in 
response to EcN, alone or together with either SAHA (5 µM), MS-275 (2 µM), or SB (3 mM). Inhibitor 
treatment started 2 hrs prior to the stimulation with EcN, which took then place in parallel to HDAC 
inhibition for another 18 hrs. * p≤0.05 evaluated by Mann-Whitney u test. This figure has partly been 
published in Stebe-Frick et al., 2018. 
 
Remarkably, in these tumorous biopsies HDACi via SAHA or SB averted hBD2 induction 
stimulated by EcN whereas blocking mainly HDAC1 and 3 through the inhibitor MS-275 did not 
suffice to do so (Figure 36), mirroring the situation in the non-tumorous tissue samples (cf. 
Figure 19). These results furthermore strengthen the hypothesis, that the more sophisticated 
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tissue compound of biopsies possibly creates an opposing epigenetic effect of HDACi on hBD2 
inducibility as compared to the mono-layered, homogeneous epithelial cell lines.  
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4 Discussion 
This study is an important contribution to the existing body of knowledge on the role of HDACs 
in the epigenetic control of AMP expression, focussed on that of hBD2. In this study, emphasis 
has been put on the therapeutically relevant probiotic E. coli Nissle 1917 (EcN) as hBD2-
inducing factor in addition to the pro-inflammatory stimulant IL1β and the bacteria-derived 
factor LPS. It could be shown and confirmed that in vitro HDAC inhibition (HDACi) generates an 
NF-κB-dependent enhancement on EcN- and LPS-induced hBD2 expression, whereas for IL1β-
induced hBD2 an augmentation of expression seems to be depending on additional transducing 
factors and conditions when only a subset of HDACs are inhibited. In the case of IL1β, the 
enhancing effect of HDACi could be evinced in a second intestinal epithelial cell line. In parallel, 
an ex vivo human colonic biopsy culture has been established as an effort to mimic the in vivo 
situation and allow a comparison to the in vitro results since it is of substantial interest to learn 
how a more complex, non-tumorous, human tissue compound reacts to HDACi. Strikingly, in this 
context, an opposing impact of HDACi on EcN-stimulated hBD2 expression was observed. 
Inhibiting HDAC function using pan-HDAC inhibitors hindered hBD2 expression instead of 
enhancing it. These contrary findings were further investigated using ex vivo treated human 
colorectal cancer tissue showing the same response as non-cancerous intestinal biopsies. 
Furthermore, first insights into the reactivity of primary gingival epithelial cells towards HDACi 
upon IL1β-stimulation were collected. Interestingly, this homogeneous, non-malignant cell line 
showed a comparable response towards IL1β as did the cancerous intestinal cell lines. Together, 
these investigations point towards a tissue context dependency of the effect of HDACi on hBD2 
expression. In addition to these investigations, light has been shed on the expressional pattern of 
class I HDAC enzymes in respect to IBD via mRNA and prtoein analyses. This first systematic 
analysis is potentially opening new venues of targeted treatment. 
This chapter first describes the possible means of HDAC-mediated epigenetic regulation 
of the antimicrobial hBD2. Furthermore, especially the involvement of NF-κB in the 
enhancement mechanism via HDACi is elucidated. The divergent effects between the in vitro and 
ex vivo approaches are discussed, and the limitiations of colonic tissue culture are addressed. 
Finally, the results of the HDAC expressional analysis in IBD patients are put into the literary 
context and discussed in the light of the use of HDAC inhibitors as possible therapeutics.  
 hBD2 expression is modulated by HDAC function  
Within recent years, several studies have pointed towards the importance of HDAC function in 
the regulation of AMPs like the inducible hBD2 and thereby antimicrobial defense in different 
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tissues (Kallsen et al., 2012; Schwab et al., 2008; Yin and Chung, 2011). They could consequently 
be involved in the human β defensin-related defects observed in IBD. Complementing and 
extending previous investigations, this work also shows a TLR-dependent upregulation of hBD2 
after HDACi in vitro (see Figure 23) (Fischer et al., 2016; Schlee et al., 2007, 2008; Stebe-Frick et 
al., 2018; Wehkamp et al., 2004a; Yin and Chung, 2011). Furthermore, the same effect has been 
observed using the pro-inflammatory cytokine IL1β as inducer of hBD2 where pan-HDACi as 
well as the more specific inhibitor MS-275, inhibiting only HDAC1 and 3, strongly enhanced 
hBD2 mRNA and intracellular peptide in CaCo-2 cells(see Figure 23 and Figure 25). Expression 
of hBD2 mRNA showed the same trends in HCT cells in response to IL1β and HDACi. These 
results, together with those of others, hint towards a consistency of the observed enhancing 
effect for several inducers tested in different in vitro systems, including several cell lines and 
even cultured human colonic organoids (Fischer et al., 2016; Stebe-Frick et al., 2018; Yin and 
Chung, 2011). This present work is, however, the first one to demonstrate that, under the given 
conditions, pan-HDACi has the opposite effect in ex vivo treated healthy control, IBD, and 
cancerous intestinal biopsies where it seems to hinder hBD2 induction (see Figure 19 and Figure 
36) (Stebe-Frick et al., 2018). In an effort to illuminate the possible reasons for this disparity, the 
manifold ways in which HDACs are possibly impacting on hBD2 expression need to be taken into 
consideration. 
4.1.1. NF-κB dependency of the in vitro enhancement effect of HDACi 
on hBD2 inducibility 
Since the hBD2 promoter bears at least two binding sites for NF-κB transcription factors 
(Wehkamp et al., 2004a), the epigenetic control of NF-κB via HDAC-mediated mechanisms is 
likely a crucial working point in hBD2 transcriptional regulation. 
Overall, remarkable progress has been made within the last two decades in 
understanding the complex regulation of NF-κB activation. Chromatin organization together 
with nucleosome remodelling has been shown to be a crucial regulatory layer in the highly 
complex orchestration of NF-κB-dependent inflammatory gene expression (Saccani et al., 2001; 
Natoli et al., 2005; Ramirez-Carrozzi et al., 2006; Natoli, 2009). Two distinct types of NF-κB-
regulated genes have been described based upon the kinetics of their activation following a 
stimulus – the “fast” ones with constitutively and immediately accessible (CIA) promoters and 
the “slow” ones, that have promoters with a regulated and late accessibility (RLA) (Saccani et al., 
2001). While both fast and slow genes bear high-affinity binding sites for NF-κB transcription 
factors, they are encompassed by different chromatin landscapes leading to a differential 
accessibility for NF-κB and the transcriptional machinery (Saccani et al., 2001). Chromatin 
surrounding readily accessible fast genes is, for example, characterized by histone marks that 
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correlate positively with transcription such as acetylated histones H3 and H4 or trimethylated 
lysine 4 on histone 3 (H3K4me3) (Henikoff and Shilatifard, 2011; Krogan et al., 2003; Natoli, 
2009; Saccani et al., 2001; Yang and Seto, 2003). On the other hand, slow genes are rather 
shielded due to hypoacetylated and more condensed chromatin that is often also negative for 
H3K4me3 as long as cells rest in an unstimulated state. Upon stimulation, chromatin 
modifications undergo changes leading to easier accessible gene regulatory elements, e.g. NF-κB 
sites (Henikoff and Shilatifard, 2011; Natoli, 2009; Saccani et al., 2001). Furthermore, 
nucleosomes are being moved with the help of chromatin remodeling complexes such as the 
Swi/Snf or the Mi2/Nurd complex (Becker and Hörz, 2002; Ramirez-Carrozzi et al., 2006; Scarpa 
and Stylianou, 2012; Skiniotis et al., 2007), the latter’s catalytic core comprises HDAC1 and 
HDAC2 (Yang and Seto, 2008). Together, the necessity of these events to take place leads to a 
delayed transcriptional start of slow genes (Saccani et al., 2001). Unfortunately, so far direct 
experimental evidence on the kinetics of NF-κB recruitment to hBD2 gene regulatory sequences 
is sparse. A hint that a change in histone modification at the hBD2 promoter is happening in 
CaCo2 cells under HDACi and upon E.coli K12 stimulation has been demonstrated recently with 
the detection of increased phosphorylation of serine 10 of H3 (Fischer et al., 2016) -a histone 
mark that is known to facilitate NF-κB access to DNA possibly by alleviating recruitment of 
chromatin-remodeling complexes at a subset of innate immune genes (Cheung et al., 2000; 
Saccani et al., 2002). At this point, it is worth mentioning that Saccani and colleagues could 
furthermore show that the IL6 promoter is activated at different velocities via NF-κB in mouse 
macrophages (rather slowly) in response to LPS as compared to in fibroblasts where NF-κB is 
recruited very fast (Natoli et al., 2005; Saccani et al., 2001, 2004). So the possibility exists that 
hBD2 transcriptional activation also does not exhibit the same kinetics in different tissues or cell 
types, e.g. in keratinocytes of the skin and intestinal epithelial cells. All in all, it would be 
worthwhile to investigate further, whether the NF-κB-dependent hBD2 promoter is indeed late 
accessible in the tissue or cells of interest to be able to further dissect or even better – predict 
what specific effect a certain HDACi might have there and at which rate. 
By impacting on the overall cellular acetylation status, HDACs influence on this complex, 
dynamic and multilayered organization of chromatin (Heintzman et al., 2007; Seto and Yoshida, 
2014; Yang and Seto, 2003), and furthermore on the posttranslational modification (PTM) of NF-
κB itself, e.g. via class I HDAC activity on RelA. Many stimulus- and possibly cell-type specific 
PTMs have been shown to influence on the duration and strength of NF-κB nucelar activity 
(Huang et al., 2010). Chen et al demonstrated for example how acetylation of RelA at specific 
lysines differentially impacts on its DNA-binding capacity, the ability to assemble with inhibitory 
κB (IκB) molecules, delaying or facilitating its nuclear export, or affecting the completeness of its 
transcriptional activity (Chen et al., 2002). It has been shown that HDAC3, likely by deacetylating 
RelA at lysines 218 and 221, accelerates its nuclear export and abrogates NF-κB-dependent gene 
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expression (Chen et al., 2001; Huang et al., 2010). Interestingly, deacetylation of lysines 122 and 
123 by HDAC3 unmasks the positive charge of those lysines which seem to be essential for the 
binding of RelA to a κB-enhancer (Kiernan et al., 2003). This is an example where deacetylation 
actually leads to increased rather than repressed transcription, adding another twist to the 
complexity of posttranslational regulation of NF-κB. Furthermore, HDAC1 together with HDAC2 
have been shown to associate with the RelA subunit acting as corepressors (Ashburner et al., 
2001). Recently, acetylated ReLA at lysine 310 has been reported to be increasingly recruited to 
the hBD2 promoter under HDACi (Fischer et al., 2016).  
Effect of NF-κB-inhibition 
Our results from the experiments with the NF-κB-inhibitor Helenalin in CaCo2 cells nicely reflect 
that prevention of NF-κB binding to DNA largely abolished SAHA- and SB-induced enhanced 
hBD2 expression, indicating that the “unleashed” activity of NF-κB transcription factors due to 
elevated acetylation under HDACi could be hindered via NF-κB-inhibition. Therefore, that 
“unleashed” activity is likely causative for the enhancing effect on hBD2 expression observed in 
vitro. However, not only the effect of HDACi on NF-κB modifications but also on histone 
acetylation possibly occurring at the hBD2 promotor after stimulation has to be taken into 
account. Considering all the above mentioned spots where HDACs influence on deacetylating 
histones in relevant nucleosomes and NF-κB itself, perturbing HDAC function with the use of 
inhibitors, especially with pan-inhibitors like SAHA or SB, can easily derange the order in 
inflammatory and innate immunity gene regulation by NF-κB on several levels. This also holds 
true for hBD2. 
Interestingly, inhibiting only HDAC1 and HDAC3 by using MS-275 revealed that some 
level of hBD2-enhancement was still possible under simultaneous NF-κB inhibition (Figure 30b, 
left and right panel, EcN and LPS stimulation respectively), suggesting further HDACs to be 
substantially involved in a putative chromatin remodeling process at the hBD2 promoter which 
are blocked in the case of pan-HDACi (Stebe-Frick et al., 2018). The promoter might be left 
rendered accessible to further transcription factors, which are in turn possibly negatively 
regulated by other HDACs than HDAC1 or 3, accounting for the left-over enhanced hBD2 
expression. Shedding some light on HDAC1 and 3 involvement at modifying histone acetylation 
signatures especially of nucleosomes surrounding the hBD2 promoter would be interesting. 
For IL1β- induced hBD2, the MS-275-mediated enhancement has neither been 
sufficiently blocked nor attenuated by NF-κB inhibition (Figure 30b, middle panel) suggesting 
other signaling pathways and transcription factors to be involved in IL1β-mediated hBD2 
induction (Stebe-Frick et al., 2018). Besides AP1 (Wehkamp et al., 2004a), further factors and 
signaling proteins like p38 mitogen-activated protein kinase (p38 MAPK), or c-Jun N-terminal 
kinase (JNK) could play a role (Jang et al., 2004). In addition, putative feedback loops involving 
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upregulated cytokines such as IL8 or the IL1β-responsive IL6 could be taking part in modulating 
signal transducers and activators of transcription (STAT) signaling-induced hBD2 transcription 
(Albanesi et al., 2007; Kanda and Watanabe, 2008; Vitkus et al., 1998). HDACs together with 
histone transferases (HATs) have been shown to regulate STAT signaling in multiple, 
sophisticated ways (Icardi et al., 2012a; Zhuang, 2013). A few years ago, Icardi et al reported 
that the SIN3 transcription regulator homolog A (Sin3a) co-repressor complex containing 
HDAC1 and 2, deacetylates STAT3 and thereby negatively regulates STAT3-dependent gene 
expression (Icardi et al., 2012b). But also possibly positive effects of HDAC activity on STAT 
function have been demonstrated, e.g. that in mouse macrophages binding of STAT1 to DNA is 
compromised when STAT1 is hyperacetylated (Guo et al., 2007), or that HDACi can lead to 
increased expression of suppressors of cytokine signaling (SOCS-)1 and 3 and thereby to 
downregulated STAT3 signaling in colorectal cancer cells (Xiong et al., 2012). Furthermore, NF-
κB-STAT signaling crosstalk could be affected by the use of HDACi. Acetylated STAT1 has been 
shown to interact with RelA decreasing its DNA binding and nuclear localization (Krämer et al., 
2006). 
Those and many more findings on non-histone (de-)acetylation processes indicate how 
tightly, multilayered, and dynamic not only cytokine expression but also expression of the 
antimicrobial hBD2 are regulated and modulated. So, in general, there are very likely multiple 
signaling pathways that might be affected and modulated simultaneously by HDACi and thereby 
their interplay among each other. This possibly leads to a differential impact on hBD2 
expressional control depending on the stimulatory context and furthermore the 
microenvironment of each cell especially in a tissue compound or organ. This microenvironment 
is probably additionally affected by the overall epigenetic state a certain individual is in. The 
development or discovery of HDAC isotype specific inhibitors is therefore very important, to 
lower possible undesirable side effects and to be able to interfere more specifically in certain 
disease aspects related to HDAC function or are at least mendable by altering it. 
Of notice, comparing the enhancing effect of the specific inhibitor MS-275 on hBD2 to 
that of the pan-inhibitor SAHA when stimulating CaCo2 cells with EcN shows that the selective 
inhibition, at least in this setup, is similar. When hBD2 is stimulated via IL1β or LPS the 
enhancing capacities of the two inhibitors are significantly different. Here SAHA has a stronger 
effect. According to those results, HDACs 1 and 3 play a major role in negatively regulating TLR5-
dependent hBD2 induction, whereas other HDACs seem to have greater importance when cells 
are stimulated via LPS or IL1β (cf. Figure 24) (Stebe-Frick et al., 2018). 
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Role of different transcription factor binding sites in the hBD2 promoter region 
The role of NF-κB but also the AP1 binding site controlling hBD2 expression could be further 
confirmed inhibiting total HDAC function using SAHA on CaCo2 cells transfected with hBD2 
promoter constructs (see Figure 31). The proximal NF-κB binding site in the hBD2 promotor 
region has proven to be the one essential for a great deal of the enhancing effect of SAHA on EcN- 
or LPS-induced reportergene activity. When the AP1 site was non-functional but the proximal 
NF-κB site still was, the enhancement of hBD2 was also clearly diminished. This suggests a 
cooperative function of those two regulatory elements where the proximal NF-κB site needs the 
AP1 site to be activatable for full enhancing effect on hBD2, while AP1 alone is not sufficient. 
Since those two transcription factor binding sites are in a similar manner necessary and 
responsible for the plain or basal inducibility of hBD2, as has been demonstrated before 
(Wehkamp et al., 2004a), it can be assumed that the HDACi effect in this experimental setting 
can be ascribed to changes in epigenetic regulation of signaling pathways and transcription 
factors. This assumption is furthermore strengthened by the finding that transiently transfected 
plasmids do not seem to be packed efficiently into nucleosomes (Smith and Hager, 1997), 
making the regulatory layer of chromatin modification unlikely to play a role in the above 
mentioned observation. Strikingly, mutation of the proximal binding site also hindered the IL1β-
induced promoter activation, indicating that the initial induction of the hBD2 gene via IL1β 
signaling is strongly dependent on this NF-κB binding site, and AP1 also plays a similar part, but 
in this case not the augmentation of hBD2 as has been observed for the intrinsic gene expression 
in CaCo2 cells (cf. Chapter 3.2.2.1 Induction of hBD2 by different stimuli – The effect of HDAC 
inhibition). In the CaCo2 stimulation experiments, the observed enhancement of IL1β-induced 
hBD2 is likely mediated by additional NF-κB binding sites, which are not included in the 
constructs utilized here, since blocking total NF-κB function with Helenalin was capable of 
abolishing the SAHA-enhanced IL1β-induced hBD2 expression (see Figure 30). 
More general inferences on the pan-HDACi effect on these transcription factors could be 
drawn from the use of plasmids with either tandemly repeated NF-κB or AP1 binding sites 
reacting to stimulation with EcN under SAHA application (see Figure 32). EcN alone did not 
activate AP1 binding sites but slightly elevated NF-κB controlled reportergene expression. SAHA 
alone could activate NF-κB sites, but even more so AP1 sites. AP1 has been shown to be as well 
negatively regulated by deacetylation processes (Yang et al., 2017). Seemingly, the sole use of 
HDACi might have relieved some sort of repression from AP1 transcription factors exerted by 
HDACs. Most interestingly, a synergistic effect of EcN and SAHA treatment could be observed on 
the reportergene activity mediated by NF-κB site tandem repeats, additionally supporting the 
hypothesis of hBD2 mRNA expression to be indirectly repressively regulated by HDACs via NF-
κB transcription factors.  
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Summarizing, the means via which HDACs can influence on the transcriptional regulation 
of hBD2 are via a combination of chromatin accessibility together with the impact they can exert 
on transcription factors themselves, such as NF-κB, AP1, or STATs, and other signaling 
molecules.  
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4.1.2. Divergent effects in tissue versus monolayered cells 
The data regarding hBD2 presented here show a striking divergence in the direction of the effect 
of HDACi on hBD2 inducibility when investigating different experimental setups, namely 
homogeneous monolayered cancerous cell lines as opposed to the more complex tissue 
compound of colonic mucosal biopsies (Stebe-Frick et al., 2018). This finding is unprecedented 
and highlights the importance of more in vivo like experimental approaches. 
Enhanced hBD2 induction in vitro 
While in vitro in CaCo-2 intestinal epithelial cells, hBD2 mRNA and peptide are enhanced when 
induced via bacterial or pro-inflammatory stimuli and HDACs are inhibited in parallel, the 
complete opposite effect has been observed in ex vivo biopsies where pan-HDACi with SAHA or 
SB abolished hBD2 mRNA expression. In quest of an explanation, a second intestinal epithelial 
cell line, HCT116 cells, has been examined. It displayed the same answer in hBD2 expression in 
response to IL1β and HDACi as did CaCo2 cells. Neither EcN nor LPS lead to a significant 
induction of hBD2 in HCT116 cells. Therefore and since this is the first report on an enhancing 
effect of HDACi on IL1β-induced hBD2 in vitro, HCT116 cells served as a second intestinal 
epithelial cell line to confirm the CaCo2 results concerning IL1β. The non-tumorous human 
primary gingival epithelial cell line hgep was tested in a pilot experiment and showed the same 
answer to HDACi+IL1β treatment as did the two cancerous cell lines suggesting that tumorous 
cell lines and primary cell culture seem to show the same reaction in this respect (cf. Figure 33-
Figure 35) (Stebe-Frick et al., 2018). Inhibiting HDAC function in rather homogeneous cell line in 
vitro systems seems to release a potentially repressive effect of HDACs on hBD2 expression, 
leading to an enhancement. So, this appears consistent for multiple inducers. A very similar 
effect has also been observed in cultured human organoids derived from colonic epithelial cells 
(Fischer et al., 2016). The means via which a repression by HDACs could possibly be established, 
have been discussed in the previous chapters. 
Of note, HDACi alone did not induce hBD2 in neither CaCo2 nor HCT116 cells but had an 
elevating effect on basal IL8 expression, a finding that needs to be kept in mind when talking 
about the use of HDACi as anti-inflammatory therapeutic. Furthermore in this context, in 
contrast to a previous report (Fischer et al., 2016), the results presented herein clearly show an 
upregulation of the pro-inflammatory IL8 in response to stimulation under HDACi (Stebe-Frick 
et al., 2018) (also see Chapter 4.3 HDACi-mediated enhancement of hBD2 as therapeutic option 
in IBD). The study at hand does therefore not support the proposition of HDACi as a 
pharmacological mean to reinforce antimicrobial defense without risking an increase in the 
inflammatory response in parallel. This discrepancy in respect to IL8 could, however, be due to 
the different study designs used. Fischer et al pretreated with HDACi for 16 hrs before 
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stimulating with E.coli K12 for only one or two hours, while in this study, HDACi started 2 hrs 
prior to the addition of the different stimulants for another simultaneous treatment for 18 hrs. 
Consequently, it would be of interest to further investigate the pharmacokinetics of HDACi in 
respect to antimicrobial and cytokine regulation in epithelial cells. The concentrations and 
timepoints used in this study are drawn from the literature stating reasonable durations for and 
concentrations of HDACi (Boffa et al., 1978; Butler et al., 2002; Leoni et al., 2002; Oger et al., 
2010; Tatamiya et al., 2004; Wilson et al., 2006), and fitted to known kinetics of hBD2 (Möndel et 
al., 2009; Schlee et al., 2008; Wehkamp et al., 2004a). 
In contrast to the observation in CaCo2 cells, where stimulus-induced IL8 transcription 
was further increased by the use of HDACi, IL1β-induced IL8 expression was not enhanced in 
HCT116 cells (Figure 34b) indicating a potential cell line specific inflammatory response-
additionally potentially under a different epigenetic control. This assumption is underlined by 
the observed primary inducibility of IL8 by IL1β stimulation which lead to a much higher IL8 
level (about 100 000 transcripts/10ng RNA normalized to βactin) in HCT cells than in CaCo2 
cells (about 1300 transcripts/10ng RNA normalized to βactin). The differing epigenetic statuses, 
owed to the cancerous nature of the cell lines (Ahmed et al., 2013), could be accountable for both 
the difference in the initial IL8 response towards IL1β and also for the absent enhancing 
capacity of the applied HDACi. 
At this point, it is worth noting that in HCT116, the response to EcN with hBD2 was very 
low but a substantial induction of IL8 was possible. So, TLR5-dependent induction of hBD2 in 
HCT116 cells following stimulation with EcN (see Figure 33a) seems to be impaired. HCT116 
cells have been shown to express TLR5 receptor at rather low levels (Zhao et al., 2007). 
Furthermore, the responsiveness to flagellin in cancer cells lines might be differentially 
modulated due to the presence of different SNPs that have been found in the TLR5 receptor gene 
in colorectal cancers (Klimosch et al., 2013). This might explain why only a very weak hBD2 
response could be observed downstream to EcN stimulation in these cells while IL8 could be 
induced to some extent. Likely due to a lack of detectable or at least only a very low amount of 
TLR4 receptor expression in this cell line (Zhao et al., 2007; Doan et al., 2009), there was no 
induction of hBD2 in response to the TLR4 ligand LPS. However, LPS was able to induce the 
expression of a small amount of IL8 mRNA, possibly owed to a still present but very low level of 
TLR4 receptor expression which possibly was sufficient to activate the IL8 promotor (Doan et 
al., 2009). 
Repressed expression of hBD2 ex vivo 
Analyzing the role of HDACs in hBD2 regulation in human intestinal tissue, however, unraveled a 
completely opposite effect, at least when all HDACs were inhibited collectively. Under the use of 
SAHA or SB on ex vivo cultured colonic biopsies, the upregulation of hBD2 mRNA by the 
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probiotic EcN was completely prevented and expression levels returned to. The more selective 
inhibitor MS-275, that only blocks HDACs1 and 3 also did not cause an enhancement, as has 
been observed in CaCo2 cells in vitro, but still allowed for hBD2 induction by EcN baseline 
(Stebe-Frick et al., 2018). At this stage, it can be concluded, that SAHA and SB both had a clear 
effect on the tissue response, whereas in the case of MS-275 a possible insufficient functionality 
could not be completely excluded as the reason for the lacking or differing effect. Technical 
issues such as a limited uptake of the compound by and/or reduced diffusibility within the tissue 
have been tried to be ruled out. Firstly, by an initial check to clarify whether MS-275 was 
potentially not able of diffusing as well into the tissue as it could diffuse into the mono-layered 
CaCo2/TC7 cells. Therefore the MS-275 concentration used in the ex vivo experiments was 
increased to 5 µM as compared to 2 µM in vitro which has been adopted from the literature 
(Tatamiya et al., 2004). The higher concentration also was not able to abolish hBD2 expression 
in ex vivo biopsies. Due to the advanced progress of the experiments with the valuable patient 
samples, it has been decided to abide to the higher concentration for the ongoing ex vivo 
experiments. And secondly, by conducting a western blot analysis to attest that HDAC proteins 
have been inhibited efficiently, in one feasibility test, the acetylation status of histone 3 has been 
checked after the 20 h treatment with EcN and SAHA, MS-275 and SB in the biopsies of one 
patient. A marked increase in histone 3 acetylation could be observed in response to all HDACi 
used, indicating that at least enough of each of the inhibitors has diffused into the cells to cause 
an effect on chromatin modification (see Appendix Figure 3). However, no direct inferences on 
the actual effect at the transcription factor level can be drawn from these results, as to which 
extend the applied concentrations and durations of HDACi have an impact on e.g. the acetylation 
status of NF-κB, AP1, or STATs. Those and others are known targets of HDAC1 and 3 and could 
thereby still affect hBD2 regulation at the deployed concentration of MS-275(Ashburner et al., 
2001; Chen et al., 2001; Huang et al., 2010). In this regard, a limited mode of action of MS-275 
within the tissue cannot be ruled out. Furthermore, due to the limited amount of the specimens, 
it was unfortunately not possible to conduct these additional experiments for each patient 
included in the study. This data still allows to hypothesize that the specific inhibition of HDACs 1 
and 3 cannot hinder hBD2 in ex vivo stimulated human intestinal epithelial tissue from neither 
healthy individuals, nor ones with IBD, nor ones colorectal cancer (which are further discussed 
below). 
At this point, it cannot be excluded that, further ex vivo testing of time- and dose-
responses towards HDACi might deliver a different picture of the effect on the transcriptional 
profile, including that of hBD2, of the ex vivo cultured biopsies. Maybe even one resembling the 
effects observed in vitro. Unfortunately, investigating pharmacokinetics in ex vivo tissue culture 
has not been feasible due to the limited amount of patient specimens. Nevertheless, the 
described profound effect clearly demonstrates that pan-HDACi of all class I isoforms might 
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potentially hinder hBD2 expression under certain circumstances and thereby impair 
antimicrobial defense. This needs to be taken into serious consideration when evaluating HDAC 
inhibitors, also more selective ones, as a therapeutic (also see Chapter 4.3 HDACi-mediated 
enhancement of hBD2 as therapeutic option in IBD), since the abolishment of hBD2 has equally 
been observed in IBD patient samples (cf. Figure 19). 
In the quest of exploring the underlying mechanisms of the divergent findings from the 
in vitro and ex vivo approaches, it has been important to further consider the possibility, that the 
reason for this could be lying in the cancerous nature of the intestinal cell lines (as mentioned in 
the previous chapter) as opposed to the non-malignant tissue samples. Therefore, biopsies from 
colorectal tumors have been examined under the same ex vivo conditions. Strikingly, here pan-
HDACi also seemed to disable hBD2 induction, whereas MS-275 again still allows for hBD2 
transcription to take place (see Figure 36). This result supports the assumption that the 
discrepancy between in vitro and ex vivo effects are unlikely to be caused by the altered HDAC 
function in cancers (Ahmed et al., 2013; Ropero and Esteller, 2007). The findings from the 
primary cell culture experiments with differentiated gingival epithelial cells complement this 
assumption and strengthen the hypothesis, that the more sophisticated tissue compound of 
biopsies possibly creates an opposing epigenetic effect of HDACi on hBD2 inducibility as 
compared to the mono-layered, homogeneous epithelial cell lines. This could be due to possibly 
still feasible paracrine crosstalks within the tissue, for example, with lamina propria cells. 
Consequently, further investigation is needed, e.g. in dissecting the effect of HDACi on hBD2 in 
single cells from ex vivo treated biopsies via single cell sequencing as well as in co-cultures of 
intestinal epithelial and stromal cells such as fibroblasts (Viney et al., 2009). Such co-cultures, 
also with immune cells like intestinal intraepithelial lymphocytes (IELs) (Beagley et al., 1995; 
Nozaki et al., 2016), bear the potential of investigating the exact molecular mechanisms of the 
HDAC-dependent gene regulation in cells embedded in a more diverse cellular 
microenvironment. As for now, future epigenetic considerations of cell culture systems need to 
be carefully evaluated in the light of these divergent findings from tissue culture. 
Last but not least, the expression of IL8 in ex vivo treated intestinal biopsies appeared to 
not be significantly affected by any of the HDAC inhibitors in neither of the patient groups tested. 
As opposed to the results from the CaCo2 cells, HDACi did not further enhance IL8 expression in 
response to medium treatment alone or stimulation with EcN. Strikingly however, HDACi also 
did not abolish IL8 expression as compared with hBD2, pointing towards more distinctive 
epigenetic regulatory mechanisms for IL8 and hBD2 on the level of HDAC function (Stebe-Frick 
et al., 2018). 
Taken together, the remarkable divergence from the ex vivo culture and the cell culture 
experiments presented in this study and the findings from others prompt the speculation that 
the role of HDACs in hBD2 transcriptional regulation likely is more complex and context-
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dependent than so far anticipated, not only in terms of the microenvironment of the cells but 
also in terms of stimulus type and duration. Fischer and colleagues reported a very similar result 
in cultured organoids derived from human colonic epithelial cells (Fischer et al., 2016) as has 
been observed in classical cell culture. This furthermore suggests the involvement of other non-
epithelial mucosal cells, potentially infiltrated immune cells as well as IELs that could modulate 
and possibly reverse the HDACi effect on the epithelium. Up until now however, the exact 
mechanisms underlying the gap between cell-/organoid- and ex vivo tissue culture remain 
elusive(Stebe-Frick et al., 2018). 
Brief evaluation of the in vitro and ex vivo approach used in this study 
This study at hand is the first to show that HDACi seems to have a different potential in affecting 
hBD2 and also IL8 expression depending on the experimental system used. Therefore, it 
highlights the importance of more in vivo like experimental approaches employing human 
patient material. At this point it is important to be said, that using mice for the study of the role 
of HDAC function in the regulation of antimicrobials is a necessary endorsement that allows 
proof of concept conclusions and to receive in vivo insights. However, mice are not humans, 
physiologically differing in respect to defensins (Cunliffe and Mahida, 2004) or the immune 
system in general (Mestas and Hughes, 2004). This has to be kept in mind when working with 
mouse systems, even though HDACs are generally well conserved among mammals (Gregoretti 
et al., 2004). 
In vitro investigations such as those that have been undertaken here, are indispensable 
for studying the mechanistics of the observed effects, since high throughput experiments as 
would for example be necessary for pharmacokinetic studies are mostly unfeasible with patient 
tissue material. It has become obvious though, that the establishment of more sophisticated in 
vitro culture systems such as co-cultures of different cellular components of the intestinal 
epithelium like epithelial cells, fibroblasts and even lymphocytes, would possibly reveal much 
needed insights whilst incorporating more aspects than homogeneous cell culture. The ex vivo 
culture of epithelial biopsy tissue employed in this study definitely offers the advantage of 
evaluating the impact of HDACi treatment on the probiotic response in tissue in the context of 
the surrounding multicellular microenvironment. 
Tissue culture limitations 
However, like each experimental system, tissue culture as well bears some limitations. Given the 
procedure of obtaining colonic biopsies and the fact, that they are samples that have been torn 
out of a greater context, it is important to keep in mind, that by this, they are likely primed 
towards a pro-inflammatory status. This is reflected by the substantial expression of IL8 in 
medium-treated samples (cf. Appendix Figure 2). Therefore, in this setup, additional auto- and 
paracrine effects of pro-inflammatory mediators on the inducibility of hBD2 cannot be ruled out 
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and have to be taken into consideration when evaluating the microenvironment of the cells in ex 
vivo tissue. Those effects would however already be present in the medium-control samples. 
Therefore, those samples have been used as references focusing on fold changes compared to 
the already basally hBD2-induced medium control samples.  
Besides this, biopsies from different patients also are not as homogeneous in terms of 
their background concerning genetics, lifestyle of the individual patient, and also the epigenetic 
status. Therefore, quite a large number of samples was needed to receive a representative 
population profile. A positive aspect of ex vivo culture is, that biopsies also contribute primary 
defects present in IBD patients (Courth et al., 2015; Stebe-Frick et al., 2018). 
Furthermore, histological stainings of biopsies treated for 20 hrs using hematoxylin and 
eosin (cf. Figure 18 and Figure 20) revealed the tissue to be partially affected to the extend that 
disintegrated laminae propriae and epithelial linings could be observed equally throughout all 
the culturing conditions. This is due to the short viability of the tissue ex vivo. However, overall 
the tissue was still relatively intact after 20 hrs of incubation. In general, cellular viability 
seemed to still be in quite a good condition since most of the determined LDH values of the 
biopsies were in low-end to intermediate levels (data not shown) which allows to reckon on 
reasonable testing conditions. Furthermore, e.g. Aldhous and colleagues also have successfully 
ex vivo-treated and investigated colonic biopsies over a period of even 24 hrs which exceeds the 
duration employed herein by another 4 hrs (Aldhous et al., 2009). 
As has been elaborated above, unfortunately only one time point and concentration per HDACi 
could be tested as well as one stimulant (EcN) due to the limited number of samples per patient. 
Up till now, this leaves blanks as to whether the stimulation and inhibition might be able to elicit 
a different effect at earlier timepoints, but still gave an important and unexpected insight which 
ultimately underlines the importance of reconciliation of the use of HDACi as therapeutic 
treatment especially for IBD, if it possibly has this dampening effect on the expression of at least 
one AMP shown to be important for the barrier function of the intestinal lining (Ostaff et al., 
2013; Wehkamp et al., 2002, 2005a). 
Reflections on the inducibility of hBD2 in ex vivo cultured biopsies  
Generally speaking, the study of hBD2 has been of particular interest in the context of IBD, 
especially UC and colonic CD (Jäger et al., 2013). Those two forms of IBD display different 
potentials in upregulating hBD2, which seems to be readily inducible in actively inflamed UC, 
however in CD patients hBD2 induction attenuated which might renders the epithelium more 
prone to be infected by resident microbiota (Nuding et al., 2007; Wehkamp et al., 2003). This 
variation has been found in several IBD cohorts investigated by different groups (Fahlgren et al., 
2003; Wehkamp et al., 2002; Zilbauer et al., 2010) even though the mechanisms remain unclear. 
Gene copy number variations of the beta defensin cluster bearing reduced gene copies of hBD2 
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have been suggested as the underlying cause in German and US American patients (Fellermann 
et al., 2006). However, this association could not be confirmed in another cohort (Aldhous et al., 
2009). Our herein presented data on hBD2 induction in ex vivo cultured biopsies could indeed 
help in further elucidating those differences in the two IBD entities. This work on biopsies from 
IBD patients is the first to show that the probiotic strain EcN alone is capable of inducing hBD2 
in ex vivo colonic mucosa and that there are clear differences in the inducibility between healthy 
individuals and L1 CD patients, but also in comparison to L3 (Stebe-Frick et al., 2018). This 
nicely adds to previous work from our group were it has been shown, that oral intake of EcN 
leads to an increase in hBD2 levels in stool samples of healthy individuals (Möndel et al., 2009). 
In line with the above mentioned investigations describing distinct hBD2 expression levels 
in CD and UC, it could also be demonstrated that on the level of fold changed induction, Crohn´s 
disease (L1 and L3) patient mucosa indeed seems compromised in inducing hBD2 using ex vivo 
EcN-treated biopsies. This is especially marked in the group of L1 patient samples. However, this 
finding only became apparent, when comparing the fold change in induction of hBD2 under EcN 
stimulation to the respective unstimulated, only medium-treated control biopsies. It is of note, 
that when looking at the relative expression levels of L3 patient biopsies (as depicted in 
Appendix Figure 1) it became apparent that those samples show a higher median starting point 
than the other groups tested and then end up at the same level as the UC samples. The reason for 
the higher median basal induction in the L3 medium-treated group is so far unclear, but can be 
credited to the samples of 5 out of the 14 patients tested. Four out of those 5 L3 “high starters” 
also show the highest end levels in hBD2 expression under EcN stimulation (labelled with red 
shapes in Appendix Figure 1). There were however no explicit reasons to exclude those 
particular L3 patients from the cohort. Doing so, would have leveled the L3 median relative 
hBD2 expression under both treatment conditions into the range of the L1 group. Of note, an 
exclusion of the indicated UC “high starters” with high end levels after EcN stimulation from the 
UC group in parallel to hypothetically excluding the L3 “high starters” would not change the 
picture (Appendix Figure 1, sample values marked in blue). Apriori, it is however rather 
necessary to include further L3 colonic samples to decipher whether these few “high inducers” 
truly are exceptions and do separate completely from the rest of the L3 group. Furthermore, it is 
a stand-alone interesting finding, that L1 disease-unaffected colonic samples also seem to be 
compromised in inducing hBD2 on the relative expression level in an ex vivo setup with 
probiotic bacteria as the hBD2 stimulant.  
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 Changes in class I HDAC expression levels in patients 
with IBD 
To this date, not much is known about the expression status of HDACs in IBD patients which 
have been shown to be involved in chronic intestinal inflammation (Glauben et al., 2006; 
Turgeon et al., 2014). Especially class I HDACs seem to play a role. Therefore, expression of class 
I HDACs has been strategically analyzed in ileal and colonic mucosa from active as well as 
inactive IBD. 
4.2.1. Diverse findings from mRNA and protein analyses 
The results of these analyses provide first insights into the overall deacetylation capacity of the 
intestinal tissue in IBD based on the inflammatory status, as well as in comparison to and within 
overall healthy tissue. Data from the RT PCR analysis of mRNA expression levels showed that 
overall if there were changes in the expression levels of IBD patients as compared to healthy 
controls, they were always diminished (cf. Figure 6). No increased levels could be detected. In 
ileal tissue only HDAC2 was reduced in both L1 and L3 CD, independent from the inflammatory 
status (only ileal or ileal and colonic affliction respectively). In the colonic samples of CD (L2 and 
L3 patients examined, L2 being only affected in the colon by the disease) reductions have been 
observed in HDAC1 and HDAC2 levels. In UC samples of the colon, however, all 4 class I HDACs 
seemed to be affected- HDAC8 independently of the inflammation status, HDACs 1,2, and 3 were 
even further reduced during inflammation. At this point, it is worth mentioning that Tsaprouni 
et al could demonstrate that histone 4 acetylation is slightly increased in the uninflamed ileal 
tissue of CD patients, but was markedly elevated in inflamed specimens. This was also shown in 
the inflamed mucosa of a murine model of colitis (Tsaprouni et al., 2011). These results hint 
towards a reduced HDAC function in CD ileal tissue, especially during inflammation. 
Interestingly however, the findings from the western blot experiments display a 
diverting picture - at least in some aspects (cf. Figure 7 and Figure 8). For instance, HDAC2 
protein seems to not be reduced in L3 specimens but instead rather markedly increased 
compared to healthy controls. A tendencial increase in protein levels has also been found for 
HDAC1 in the ileum of L3 but not so for the mRNA level. Colonic specimens, for example showed 
a trend towards reduced HDAC1 protein levels in UC, which is in line with the corresponding 
mRNA data, but HDAC2 protein in UC seemed tendentially increased not decreased as was 
HDAC2 mRNA. HDAC3 protein on the other hand again rather corresponded to its mRNA. L3 
tissue from the colon showed no changes in HDAC1 or 2 protein, thereby did not correspond to 
their mRNA. Before going into discussing possible underlying causes, it needs to be remarked 
that different, meaning new biopsies not identical to those used for RT PCR, had to be used for 
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western blotting. Therefore, a direct deducibility for conclusions regarding mRNA and protein 
correlations is not given. Although small, considering the IBD samples investigated via western 
blot as an at least to some extend comparable patient cohort still allows to speculate about 
potential coherences. Unfortunately, overall not much is known so far about the expressional 
regulation of neither HDAC mRNA nor its translation into protein. Several reports point towards 
feedback mechanisms involving HDACs themselves. For HDAC1, for example, it has been shown 
in hepatocellular carcinoma cells that HDACi by Trichostatin A leads to HDAC1 upregulation 
(Gray and Ekström, 1998). Schuettengruber and colleagues could thereafter demonstrate that 
transcriptional regulation of the mouse HDAC1 is autoregulated and involves specificity protein 
1 (SP1) and nuclear transcription factor Y (NF-Y) transcription factors, which can recruit HDAC1 
to its own promotor leading to HDAC1-mediated HDAC1 transcriptional repression 
(Schuettengruber et al., 2003). HDAC1 has furthermore been shown to also negatively regulate 
the expression of HDAC2 and 3 in mouse embryonic stem cells (Lagger et al., 2002). At the level 
of alternative splicing, HDAC3 mRNA has been shown to be regulated by diverse stimuli and 
pathways, even more so in differing ways between murine and human cells (Gray et al., 2003). 
HDAC2 seems to furthermore be repressively regulated by the adenomatosis polyposis coli 
(APC) tumor suppressor in a Wnt pathway-dependent manner in colorectal cancer cells (Zhu et 
al., 2004). A large number of microRNAs (miRNAs) has been predicted via in silico analyses to 
interact and thereby potentially post-transcriptionally regulate HDAC mRNA (Felice et al., 2014). 
A link to IBD could be found in miRNA expression profiles of IBD biopsies where for example 
miR-192, predicted to target HDAC2, has been reported to be reduced in active UC (Wu et al., 
2008). All the above-mentioned findings display a complex multilayered and potentially species- 
and/or cell-type-specific regulation of HDAC transcription where distinct IBD regardings still 
remain due. It becomes clear, that there is unlikely an easy answer to the question whether the 
downregulated class I HDAC mRNA levels in intestinal IBD tissue presented herein are cause of 
changes in corresponding protein levels and/or whether the manifold ways of post-
translationally modulating HDAC function and stability (Segré and Chiocca, 2011; Sengupta and 
Seto, 2004) are rather feeding back on mRNA expression rates. Furthermore, a possible 
inflammation dependency of HDAC expression but also activity needs to be considered since 
HDAC1 mRNA as well as protein have been found to be increased in response to tumor necrosis 
factor α (TNFα) in rheumatoid arthritis synovial fibroblasts (Kawabata et al., 2010). To be able 
to draw more precise conclusions, not only mRNA and protein from the very same biopsy need 
to be examined, but furthermore, a larger cohort than could be used for western blotting here, 
would be needed. This is also true since there are partly substantial interindividual variations 
that have been found in protein levels, especially for ileal HDAC1 in L3 and HDAC2 in controls 
and L3 patients. This finding is in line with the growing knowledge on seemingly substantial 
inter- and even intraindividual variations in epigenotypes (Flanagan et al., 2006; Fraga et al., 
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2005; Petronis et al., 2003). Nevertheless, the findings presented here concerning mRNA and 
protein levels in IBD patients as well as healthy individuals deliver some important first 
systematic insights and definitely show changes in mRNA expression of members of the class I 
HDAC family in this inflammatory condition. Those are valuable findings for the discussion on 
HDACi as a therapeutic intervention in IBD. The herein presented data might suggest that, while 
mRNA expression differences exist, a possible inflammation mediated change in HDAC protein 
levels could be minor due to for example possible compensatory mechanisms in stabilizing 
protein. 
4.2.2. Insights into tissue distribution of HDACs in IBD 
In general, immunohistochemical stainings are well recognized for the investigation of the 
cellular distribution of the protein of interest, less for quantitative analyses (Cregger et al., 
2006). Staining intensity can vary due to technical reasons (de Matos et al 2010), therefore, in 
this study, IHC was mainly used to describe the spatial distribution of the investigated HDAC 
proteins. Only the different amount in HDAC1 positive cells in ileal tissue of CD patients could be 
semi quantitatively assessed, not considering staining intensity, and has been evaluated in 
percentage terms by four independent individuals (cf. Figure 10). This particular finding is 
interesting, since it shows a trend towards an increased number of HDAC1 positive cells in the 
mucosa, and more specifically, in the villus epithelial linings of CD patients as compared to 
healthy controls. This indicates, that HDAC1 protein levels are higher in villus epithelial cells of 
ileal CD, not only delivering important spatial information of HDAC1 expression, but also 
underpinning the finding from the western blot depicted in Figure 7a. Since, of course, those are 
only a snapshots in time, it remains elusive, whether this elevation of HDAC1 protein is 
sustained over a longer period of time, whether it is causative for or rather an effect of the 
disease, or to which extend and at which specific point of disease progression it is relevant. It 
seems however likely to be of importance, as HDAC1 and also 2 have been shown to impact on 
the inflammatory response in rat intestinal epithelial cells (Gonneaud et al., 2014) and the 
general intestinal homeostasis in mice (Turgeon et al., 2013, 2014). The negative feedback 
autoregulatory mechanism described for HDAC1 (Schuettengruber et al., 2003) could potentially 
be underlying to an oscillation in the amount of epithelial HDAC1 protein level and thereby be 
involved in the interindividual differences seen in the western blot (see Figure 7 and Figure 8). 
Furthermore, an increase in HDAC1 expression could possibly cause a decrease in HDAC2 in 
affected cells as well as the other way around - potentially transiently auto-downregulated 
HDAC1 could have the effect that HDAC2 is upregulated. Such an interdependent expression of 
HDAC1 and 2 has been demonstrated in several mouse cell types and knockdown or knockout 
studies (Jurkin et al., 2011; Lagger et al., 2002, 2002; Senese et al., 2007). Future experiments 
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could comprise attempts to knockdown HDAC1, but also other HDACs, via small interfering RNA 
(siRNA) molecules or using gene-editing tools such as the CRISPR/Cas9 system in human 
intestinal organoids (Driehuis and Clevers, 2017) to get additional mechanistic information 
about the complex expressional regulation of those epigenetic players in the human gut. 
The cellular distributions of class I HDACs found in this study of intestinal tissue confirm 
the described mainly nuclear localization of those proteins (Karagiannis and Ververis, 2012; 
Khochbin et al., 2001; The Human Protein Atlas, 2018; Thul et al., 2017; Uhlen et al., 2010); with 
the exception of HDAC3, which was herein also found to display cytoplasmatic occurrence in 
both ileal and colonic mucosa, irrespective of disease status. Cytoplasmatic staining was 
especially seen in the epithelial cells (see Figure 14 and Figure 15). For HDAC8, slight differences 
between IBD patients and healthy individuals could be observed. Patients with CD and UC 
displayed weaker HDAC8 staining in the mucosa, but no differences in spatial staining patterns 
could be seen. The differences in HDAC8 staining intensity were, however, unquantifiable and to 
this point remain solely an observation. Furthermore, the general staining patterns of the single 
HDACs appeared to be quite alike in ileal and colonic tissue. 
  
   
100 DISCUSSION 
 HDACi-mediated enhancement of hBD2 as 
therapeutic option in IBD 
In this study, class I HDAC mRNA expression levels have been shown to be reduced in IBD 
intestinal specimens. Furthermore, distinctions in protein levels could also be made out in a 
small patient cohort. The chicken-and-egg problem concerning HDAC levels remains unresolved 
at this stage, however, this is so far the first systematic approach on differential HDAC 
expression in human intestinal tissue samples of IBD patients and therefore a valuable 
contribution in the evaluation of HDACi as a therapeutic option in IBD. Furthermore, the in vitro 
and ex vivo results on the effect of HDACi on hBD2 expression obtained herein deliver relevant 
new aspects demanding consideration in the quest of strengthening the intestinal antimicrobial 
barrier while at the same time suppressing an overshooting inflammatory response via the use 
of HDACi. 
A link between intestinal inflammation, gut homeostasis and HDAC function has been 
established and HDACi are widely discussed as potential anti-inflammatory agents (Edwards 
and Pender, 2011; Felice et al., 2014; Glauben and Siegmund, 2011; Scarpa and Stylianou, 2012; 
Ventham et al., 2013). In vivo animal studies have demonstrated the efficacy of HDACi in murine 
colitis models (Glauben et al., 2006; Turgeon et al., 2014) and have helped in deciphering HDAC 
roles in intestinal tissue homeostasis via epigenetic control of gene expression (Alenghat et al., 
2013; Gonneaud et al., 2016; Turgeon et al., 2013). Several in vitro investigations have shown 
general anti-inflammatory effects of HDACi (Chen et al., 2012; Glauben et al., 2006; Leoni et al., 
2002; Segain, 2000). HDACi led to a dose-dependent suppression of cytokine production and 
induction of apoptosis in vitro, where lower doses were needed to affect cytokines. In vivo, 
HDACi reduced the severity of dextran sulfate sodium (DSS)-induced colitis and the expression 
of colonic pro-inflammatory cytokines. Interestingly, HDACi-induced local hyperacetylation only 
occurred in parallel with DSS treatment and only at the site of inflammation, namely in the colon, 
suggesting a need of cell activation in the presence of an HDACi to result in an increase in 
histone acetylation (Glauben et al., 2006). Turgeon and colleagues could demonstrate recently, 
that an intestinal epithelial cell-specific double knockout of HDAC1 and HDAC2 increased DSS 
colitis severity and led to higher inflammatory gene expression. However, HDAC2 depletion 
alone seemed to protect against DSS colitis, did not lead to chronic intestinal inflammation per 
se and resulted in an upregulation of colonic antimicrobials (Turgeon et al., 2013). A loss of 
HDAC1 only on the other side disturbed intestinal architecture and increased susceptibility to 
DSS (Gonneaud et al., 2016). Additionally, it has been found that butyrate administration on 
colonic biopsies, lamina propria mononuclear cells (LPMC), and human peripheral blood 
mononuclear cells (PBMC) of CD patients led to reduced TNFα expression under LPS stimulation 
(Segain, 2000). Furthermore, PBMCs secrete less TNFα, IL-1-beta, IL-12, and IFNγ after 
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stimulation with LPS upon simultaneous inhibition with SAHA, but levels of IL8 were not 
affected (Leoni et al., 2002). HDAC3 has also been identified as an important governor of 
intestinal homeostasis and the barrier function (Alenghat et al., 2013; Navabi et al., 2017). 
Alenghat and her coworkers investigated the effects of an intestinal epithelial cell-specific 
deletion of HDAC3 in mice and found it to be crucial for the integration of commensal-bacteria-
derived signals by the epithelium, modulating host cellular responses for the establishment of a 
homeostatic coexistence of the epithelium and its inhabitant microbiota. Absence of HDAC3 in 
conventionally housed mice caused Paneth cell loss, spontaneous inflammation and increased 
susceptibility to intestinal damage. This phenotype was widely lost and barrier function, 
dysregulated gene expression and homeostasis were largely restored in HDAC3 deficient mice 
re-derived into germ-free conditions (Alenghat et al., 2013). Another study attributes further 
protective features to HDAC3, where it has been demonstrated that a lack of HDAC3 in mice 
intestinal epithelial cells were rendered more susceptible to an infection by Citrobacter 
rodentium due to a defective communication between intestinal epithelial cells and resident 
lymphocytes via IL18 and IFNγ. This suggests HDAC3 as an epigenetic effector important in 
regulating host defense (Navabi et al., 2017). On the contrary, HDAC3 has also been marked 
essential for the activation of about half of the inflammatory gene expression program in LPS-
stimulated mouse macrophages indicating (Chen et al., 2012). 
Therefore, when looking at the available literature it becomes obvious that there is no 
one-size-fits-all answer to the question on whether and how to employ HDACi as an effective 
anti-inflammatory therapeutic. The current body of knowledge highlights that HDACs seem to 
hold anti- as well as pro-inflammatory properties. This became especially apparent in a study, 
where HDAC1 was found to repress but also activate different subsets of inflammatory genes in 
response to IL1β in rat intestinal epithelial cells (Gonneaud et al., 2014). 
The findings in this study at hand are of note for this discussion, since HDACi use alone 
already had an elevating effect on basal pro-inflammatory IL8 expression in colonic epithelial 
cells, whereas the antimicrobial defense molecule hBD2 was elevated only after primary 
stimulation of the cells with hBD2 inducing molecules or bacteria. In addition to this, stimulus-
induced IL8 expression in CaCo2 cells was even further elevated after treatment with HDACi 
(Stebe-Frick et al., 2018). Therefore, this contrasting finding to a previous report from Fischer 
and colleagues (Fischer et al., 2016) does not support an unconditional proposition of HDACi as 
a way to bolster antimicrobial defense without risking an increase in the inflammatory response 
in parallel (Stebe-Frick et al., 2018). Not only in vitro, but also the results of the ex vivo 
investigations conducted in this study here advise caution, since increased IL8 levels could not 
be reduced nor abolished by HDACi use. Whether this is a technical artefact of the tissue culture 
remains to be clarified. At this point, it could however be physiologically relevant and therefore 
be important in an inflamed state of the mucosa of an IBD patient potentially treated with an 
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HDACi. In parallel, hBD2 could not only not be enhanced ex vivo but was even abolished by pan-
HDACi. 
Hence, further detailed investigations are needed to sort out the different targets and 
mechanisms of action of HDACs, deciphering their manifold cell-, tissue- and organ-specific 
functions, factoring in the stimulus-dependent activation of inflammatory programs that have 
been shown to influence the downstream response modulation by HDACs (Huang et al., 2010; 
Natoli, 2009). Considering the fact that HDACs regulate the acetylation status not only of 
histones but of thousands of different proteins explains their involvement in diverse cellular 
processes (Choudhary et al., 2009). Furthermore, impacting on transcriptional programs via 
HDACi likely leads to secondary effects that might even overwrite the direct effects caused by 
the inhibition (Chen et al., 2012). One of these secondary transcriptional effects might be exerted 
by hBD2 itself if it should prove possible to elevate its expression by combining HDACi with the 
therapeutic EcN in vivo. As do other antimicrobials, hBD2 also possesses immunomodulatory 
properties (Lai and Gallo, 2009; Niyonsaba et al., 2005, 2007). Overly abundant hBD2 expression 
levels are thought to be a driver in psoriasis as it has been demonstrated that hBD2 triggers the 
activation of dendritic cells by breaking self-DNA tolerance (Lande et al., 2015). On the contrary, 
in cells originating from a different organ, the lung, hBD2 displayed anti-inflammatory 
properties by reducing pro-inflammatory cytokines under LPS-stimulation (Donnarumma et al., 
2007). 
Nonetheless, as discussed above, HDACi bear intriguing promises to be effective as anti-
inflammatory agents or adjuvants in IBD therapy. It is therefore worth to continue studies on the 
specific effects of single HDAC isoforms and combinations thereof acting as HDAC complexes on 
cytokine and antimicrobial peptide expression. With more precisely targeted HDACi and a better 
understanding of their pharmacokinetics within the different cell and tissue types undesired 
side effects could potentially be significantly reduced. 
 Arising conclusion and outlook 
The data obtained and presented in this study deliver new knowledge about the expression 
status of class I HDACs in a large cohort of IBD patients, revealing reductions on the mRNA levels 
of several HDACs together with a more diverse expression pattern on the protein level. 
Furthermore, this study strengthens the link between HDAC-mediated epigenetic control of the 
transactivating function of the transcription factor NF-κB, a controller of hBD2. 
Induction of the antimicrobial hBD2 in response to the therapeutically relevant probiotic 
EcN, the pro-inflammatory stimulant IL1β, and the bacteria-derived factor LPS has been shown 
to be strongly augmentable in a NF-κB-dependent manner by the use of HDACi in colonic 
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epithelial cells in vitro. The effect could also be found for the likewise NF-κB-dependent pro-
inflammatory cytokine IL8. The establishment of an ex vivo human colonic biopsy culture as an 
effort to closer mimic an in vivo situation and to test the effect of HDACi in a complex, non-
tumorous, human tissue compound, however, revealed contrasting results – pan-HDACi seemed 
to impede hBD2 expression while IL8 was not downregulated. Respective observations from a 
second transformed colonic epithelial cell line, colorectal tumor biopsies, but also from a non-
transformed primary epithelial cell line, suggest not the cancerous nature of the in vitro cell lines 
to be the underlying cause of these opposing effects between the in vitro and ex vivo approaches. 
Rather the complex, multicellular composition of the biopsies might be leading to a tissue-
specific transcriptional repression by HDACs creating a different outcome of inhibiting HDACs 
within the tissue. Hence, these results argue for a cellular context-dependent modulation of the 
epigenetic regulation of hBD2 expression by HDACs. 
To expediently evaluate the controversially discussed issue of the use for HDACi as a safe 
and effective therapeutic for inflammatory conditions, such as IBD, and/or infectious diseases, 
further research is required. With future studies, a more detailed understanding of the potential 
functional consequences of more selective HDACi in specific inflammatory disease contexts and 
in specific organs must be achieved. Potential experiments could utilize parallel treatment with 
HDACi and different isolated innate immune stimulants but also with e.g. supernatants from 
peripheral lymphocytes from patients. Stronger focus could be laid on ex vivo cultures of 
additional tissues other than colonic epithelia, co-cultures of intestinal epithelial with stromal 
cells such as fibroblasts together with intestinal intraepithelial lymphocytes, as well as animal 
studies. Understanding the complex and dynamic mechanisms by which HDACs synergize or 
interfere with different stimulants, immune mediators and signaling pathways to control 
antimicrobial and cytokine expression, will be decisive in translating the knowledge on these 
epigenetic factors into potential therapy development. 
Overall, this work at hand corroborates the growing understanding of epigenetics as the 
conjoining integrative mechanism between genome and environment, bridging the way to 
answering many yet elusive questions in the pathogenesis of IBD. 
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Appendix Figure 1: E. coli Nissle stimulates hBD2 expression in ex vivo cultured human colonic 
biopsies 
HBD2 mRNA in cultured human colonic biopsies of controls (C, n=13), L1 (n=15) or uninflamed L3 (n=14) 
CD patients, or uninflamed UC patients (n=14) in response to 18 hrs of EcN stimulation alone or together 
with either SAHA (5 µM), MS-275 (5 µM), or SB (3 mM). Inhibitor treatment started 2 hrs prior to the 
stimulation with EcN, which took then place in parallel to the HDAC inhibition for another 18 hrs. Shown is 
relative hBD2 mRNA expression according to 10 ng total RNA normalized to βactin expression. Horizontal 
bars denote median values. Red and blue shapes mark each one value of two separate biopsies taken 
from the same patient but treated either with or without EcN. ** p≤0.01, *** p≤0.001, ns not significant, 
evaluated by Mann-Whitney u test. 
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Appendix Figure 2: IL8 expression levels in ex vivo cultured intestinal biopsies 
IL8 mRNA in cultured human colonic biopsies of (a) controls (n=13), (b) L1 (n=15) or (c) uninflamed L3 
(n=14) CD patients, or (d) uninflamed UC patients (n=14) in response to medium treatment only, 18 hrs of 
EcN stimulation with or without HDACi with SAHA (5 µM), MS-275 (5 µM), or SB (3 mM) shown in the right 
panels of each graph respectively. Shown are relative expression levels according to 10 ng total RNA 
normalized to βactin expression. * p≤0.05 evaluated by Mann-Whitney u test. 
 
 
 
Appendix Figure 3: Histone H3 acetylation status in ex vivo biopsies of one patient tested after 
treatment with HDACi 
Western blot analysis of colonic tissue homogenate from a healthy control patient. Each lane on the 
western blot represents one biopsy of the same patient stimulated with EcN (3 × 108 CFU/ml) with or 
without HDACi with SAHA (5 µM), MS-275 (5 µM), or SB (3 mM). Inhibitor treatment started 2 hrs prior to the 
stimulation with EcN, which took then place in parallel to HDAC inhibition for another 18 hrs. 
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Appendix Figure 4: Expression of hBD2 and IL8 in HCT116 colonic epithelial cells following HDACi  
Effect of HDACi on the induction of (a) human β-defensin 2 (hBD2) or (b) interleukin 8 (IL8) in HCT116 cells 
in response to either SAHA (5 µM), MS-275 (2 µM), or SB (3 mM) for 20 hrs. * p<0.05 evaluated by Mann-
Whitney u test. 
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